 
 
 Protocol I6T-MC-AMBG(a)  
 
 
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel -Arm, Placebo -Controlled 
Maintenance Study of Mirikizumab in Patients with Moderately to Severely Active  Ulcerative 
Colitis . 
LUCENT 2  
  
 NCT0 3524092 
 
Approval Date: 12- Sep-2019 
 
 
I 6 T -M C -A M B G( a) Cli ni c al Pr ot o c ol P a g e 1
L Y 3 0 7 4 8 2 8 Pr ot o c ol I 6 T -M C -A M B G ( a) 
A P h a s e 3, M ulti c e nt er, R a n d o mi z e d, D o u bl e -Bli n d, 
P ar all el -Ar m, Pl a c e b o -C o ntr oll e d M ai nt e n a n c e St u d y  of 
Miri ki z u m a b i n P ati e nt s wit h M o d er at el y  t o S e v er el y  A cti v e 
Ul c er ati v e C oliti s 
L U C E N T 2
E U D R A C T A: 2 0 1 7 -0 0 3 2 3 8 -9 6 
C o nfi d e nti al I nf or m ati o n 
T h e i nf or m ati o n c o nt ai n e d i n t hi s d o c u m e nt i s c o nfi d e nti al a n d i s i nt e n d e d f or t h e u s e of 
cli ni c al i n v e sti g at or s.  It i s t h e pr o p ert y of Eli Lill y a n d C o m p a n y or it s s u b si di ari e s a n d 
s h o ul d n ot b e c o pi e d b y or di stri b ut e d t o p er s o n s n ot i n v ol v e d i n t h e cli ni c al i n v e sti g ati o n of 
miri ki z u m a b ( L Y 3 0 7 4 8 2 8 ), u nl e s s s u c h p er s o n s ar e b o u n d b y a c o nfi d e nti alit y a gr e e m e nt 
wit h Eli Lill y a n dC o m p a n y or it s s u b si di ari e s. 
N ot e t o R e g ul at or y A ut h oriti e s:   T hi s d o c u m e nt m a y c o nt ai n pr ot e ct e d p er s o n al d at a 
a n d/ or c o m m er ci all y c o nfi d e nti al i nf or m ati o n e x e m pt fr o m p u bli c di s cl o s ur e.  Eli Lill y a n d 
C o m p a n y r e q u e st s c o n s ult ati o n r e g ar di n g r el e a s e/r e d a cti o n pri or t o a n y p u bli c r el e a s e.  I n 
t h e U nit e d St at e s, t hi s d o c u m e nt i s s u bj e ct t o Fr e e d o m of I nf or m ati o n A ct ( F OI A) 
E x e m pti o n 4 a n d m a y n ot b e r e pr o d u c e d or ot h er wi s e di s s e mi n at e d wit h o ut t h e writt e n 
a p pr o v al of Eli Lill y a n d C o m p a n y or it s s u b si di ari e s. 
Miri ki z u m a b ( L Y 3 0 7 4 8 2 8 )
Eli Lill y a n d C o m p a n y 
I n di a n a p oli s, I n di a n a U S A 4 6 2 8 5 
Pr ot o c ol El e ctr o ni c all y Si g n e d a n d A p pr o v e d b y Lill y :  1 3 -M ar -2 0 1 8 
A m e n d m e nt ( a) El e ctr o ni c all y Si g n e d a n d A p pr o v e d b y Lill y o n d at e pr o vi d e d b el o w. 
A p pr o v al D at e: 1 2- S e p- 2 0 1 9 G M T 
I6T-MC-AMBG(a) Clinical Protocol Page 2
LY3074828Table of Contents
Secti on Page
Protocol  I6T-MC-AMBG (a) A Phase 3, Multicenter, Randomized, 
Doubl e-Blind, Parallel -Arm, Placebo -Controlled Maintenance Study  
of Mirikizumab in Pat ients with Moderately  to Severely  Active 
Ulcerat ive Co litis LUCENT 2 ............................................................................................. 1
Table of Contents ........................................................................................................................ 2
1. Synopsis ............................................................................................................................. 9
2. Schedule of Act ivities....................................................................................................... 18
3. Introduction ...................................................................................................................... 30
3.1. Study  Rati onale ............................................................................................................ 30
3.2. Backgro und.................................................................................................................. 30
3.2.1. Disease State and Treatm ent Goals ....................................................................... 30
3.2.2. Current ly Available Treatments and Unmet Need ................................................. 30
3.2.3. Interl eukin- 23 as a Therapeut ic Target in Ulcerat ive Colit is.................................31
3.2.4. Preclinical and Clinical Studies of Mirikizumab ................................................... 32
3.2.5. Other IL -23 Targeted Therapies in Humans .......................................................... 33
3.3. Benefit/Risk Assessment .............................................................................................. 33
4. Object ives and Endpo ints.................................................................................................. 35
5. Study  Design ..................................................................................................................... 41
5.1. Overall Design ............................................................................................................. 41
5.2. Number of Participants .................................................................................................45
5.3. End of Study  Definit ion............................................................................................... 45
5.4. Scientific Rationale for Study  Design ........................................................................... 45
5.5. Justification for Dose ................................................................................................... 46
6. Study  Popul ation............................................................................................................... 49
6.1. Inclusio n Cri teria.......................................................................................................... 49
6.2. Exclu sion Criteria........................................................................................................ 52
6.3. Lifest yle Restrict ions.................................................................................................... 54
6.4. Screen Failures ............................................................................................................. 54
7. Treatment s........................................................................................................................ 55
7.1. Treatments Administered ............................................................................................. 55
7.1.1. Packaging and Labeling ....................................................................................... 58
7.2. Method of Treatment Assignment ................................................................................ 58
7.2.1. Selection and Timing o f Doses ............................................................................. 58
7.3. Blinding ....................................................................................................................... 58
I6T-MC-AMBG(a) Clinical Protocol Page 3
LY30748287.4. Dosage Modification .................................................................................................... 59
7.5. Preparati on/Handling/Storage/Accountabilit y............................................................... 59
7.6. Treatment Compliance .................................................................................................60
7.7. Concomitant Therapy ................................................................................................... 60
7.8. Treatment after the End of the Study ............................................................................ 61
7.8.1. Study  Extensio ns.................................................................................................. 61
7.8.2. Treatment after Study  Com pletion........................................................................ 62
7.8.3. Speci al Treatm ent Consi derat ions........................................................................ 62
7.8.3.1. Prem edicat ion for Infusio ns............................................................................ 62
7.8.3.2. Management of Hypersensit ivity, Infusio n-Related 
Events, Infusio n Site Reactions and Injection Site 
React ions........................................................................................................ 62
8. Discontinuati on Cri teria .................................................................................................... 64
8.1. Discontinuati on from Study  Treatm ent......................................................................... 64
8.1.1. Perm anent Discont inuat ion from Study Treatment ............................................... 64
8.1.2. Temporary  Interrupti on (Wi thhol ding) of Study  Treatm ent.................................. 66
8.1.3. Discontinuati on of  Inadvertent ly Enrolled Patients ............................................... 67
8.2. Discontinuati on from the Study .................................................................................... 67
8.3. Lost to Follow -Up........................................................................................................ 67
9. Study  Assessments and Procedures ................................................................................... 68
9.1. Efficacy Assessments ................................................................................................... 69
9.1.1. Primary Efficacy  Assessments ............................................................................. 69
9.1.1.1. Primary Endpo int........................................................................................... 69
9.1.1.2. Mayo Score .................................................................................................... 69
9.1.1.3. Endoscopy ...................................................................................................... 71
9.1.1.4. Endoscopic Biopsies ....................................................................................... 72
9.1.2. Secondary  Efficacy  Assessments .......................................................................... 72
9.1.2.1. Major Secondary  Endpo ints............................................................................ 72
9.1.2.1.1. Histopathol ogy Scoring Instrum ents......................................................... 72
9.1.2.1.2. Patient Reported Outcome Instruments ..................................................... 72
9.1.2.2. Other Secondary  Endpo ints............................................................................ 73
9.1.2.2.1. Physician Reported Instrument .................................................................. 73
9.1.2.2.2. PRO Instruments Used to Assess Secondary  
Endpoints .................................................................................................. 73
9.1.3. Exploratory  Endpo ints.......................................................................................... 73
9.1.3.1. Inflammatory  Biomarkers ............................................................................... 73
9.1.3.2. Extraintestinal Manifestations ......................................................................... 73
9.1.3.3. PRO Instruments Used to Assess Exploratory  Endpoints ................................ 74
I 6 T -M C -A M B G( a) Cli ni c al Pr ot o c ol P a g e 4
L Y 3 0 7 4 8 2 8 9. 1. 4. A p pr o priate ness of Assess me nts .......................................................................... 7 4 
9. 2. A d verse E ve nts ............................................................................................................ 7 4 
9. 2. 1. S eri o us A d verse E ve nts ........................................................................................ 7 5 
9. 2. 1. 1. S us pecte d U ne x pecte d Seri o us A d verse React i o ns .......................................... 7 6 
9. 2. 2. A d verse E ve nts of S pecial I nterest ....................................................................... 7 6 
9. 2. 3. C o m plai nt Ha n dli n g ............................................................................................. 7 7 
9. 3. Treat me nt of O ver d ose ................................................................................................ . 7 7 
9. 4. Saf et y........................................................................................................................... 7 7 
9. 4. 1. Vi t al  Si g ns........................................................................................................... 7 7 
9. 4. 2. Electr ocar di o gra ms .............................................................................................. 7 8 
9. 4. 3. L a b orat or y  Tests .................................................................................................. 7 8 
9. 4. 3. 1. Pre g na nc y Testi n g .......................................................................................... 7 8 
9. 4. 4. I m m u n o ge nicit y Assess me nts .............................................................................. 7 9 
9. 4. 5. Ot her Tests ........................................................................................................... 7 9 
9. 4. 5. 1. P h ysical E xa mi nat i o n..................................................................................... 7 9 
9. 4. 5. 2. T u berc ul osis ................................................................................................... 7 9 
9. 4. 5. 3. He pati ti s B ...................................................................................................... 8 0 
9. 4. 5. 4. He p ati ti s C ...................................................................................................... 8 1 
9. 4. 5. 5. De pressi o n a n d S ui ci dali t y ............................................................................. 8 1 
9. 4. 5. 6. St o ol  Testi n g .................................................................................................. 8 2 
9. 4. 6. S af et y M o ni t ori n g ................................................................................................ 8 2 
9. 4. 6. 1. He pati c Safet y M o ni t ori n g .............................................................................. 8 2 
9. 5. P har mac o ki net ics ......................................................................................................... 8 3 
9. 6. P har mac o d y na mics ...................................................................................................... 8 3 
9. 9. Me dical Res o urce Utilizat i o n a n d Healt h Ec o n o mics ................................................... 8 4 
1 0. Stati st ical C o nsi derati o ns .................................................................................................. 8 5 
1 0. 1. S a m ple Si ze Deter mi nat i o n.......................................................................................... 8 5 
1 0. 2. P o p ul at i o ns f o r A nal yses .............................................................................................. 8 5 
1 0 . 3. Stati st ical A nal yses ...................................................................................................... 8 6 
1 0. 3. 1. Ge neral Statist ical C o nsi derat i o ns ........................................................................ 8 6 
1 0. 3. 1. 1. Missi n g Data I m p utati o n: ............................................................................... 8 8 
1 0. 3. 1. 2. M ul ti plici t y  C o ntr ol ........................................................................................ 8 8 
1 0. 3. 2. Treat me nt Gr o u p C o m para bilit y........................................................................... 8 8 
1 0. 3. 2. 1. P ati e nt Dis p osi ti o n .......................................................................................... 8 8 
1 0. 3. 2. 2. P ati e nt C haracteri st ics .................................................................................... 8 9 C CI 
C CI 
I6T-MC-AMBG(a) Clinical Protocol Page 5
LY307482810.3.2.3. Concomitant Therapy ..................................................................................... 89
10.3.3. Efficacy Analyses ................................................................................................ 89
10.3.3.1. Primary Analyses ........................................................................................... 89
10.3.3 .2. Secondary  Analyses ........................................................................................ 90
10.3.3.3. Exploratory  Analyses ..................................................................................... 90
10.3.4. Safety Analyses .................................................................................................... 90
10.3.5. Pharmacokinet ic/Pharmacodynamic Analyses ...................................................... 90
10.3.6. Evaluat ion of Immunogenicit y............................................................................. 91
10.3.7. Other Analyses ..................................................................................................... 91
10.3.7.1. Subgroup Analyses ......................................................................................... 91
10.3.8 .Interim Analyses .................................................................................................. 92
11. References ........................................................................................................................ 93
12. Appendices ....................................................................................................................... 99
I6T-MC-AMBG(a) Clinical Protocol Page 6
LY3074828List of Tables
Table Page
Table AMBG.2.1. Schedule of Act ivities –Responders from Induction Study ....................... 19
Table AMBG.2.2. Schedule of Act ivities –Nonresponders fro m Inducti on Study .................. 25
Table AMBG.4.1. Object ives and Endpo ints.......................................................................... 35
Table AMBG.7.1. Treatment Regimens:  Induction Clinical Responders ............................... 56
Table AMBG.7.2. Treatment Regimens:  Induction Clinical Nonresponders .......................... 57
Table AMBG.9.1. Endpoint Definit ions in Study  AMBG ...................................................... 69
Table AMBG.10.1. Analysis Populat ions in Study  AMBG ................................................ 86
Table AMBG.10.2. Analysis Cohorts in Study  AMBG ...................................................... 86
I6T-MC-AMBG(a) Clinical Protocol Page 7
LY3074828List of Figures
Figure Page
Figure AMBG.5.1. Illustrati on of  study  design for Clini cal
           Protocol I6T -MC-AMBG. ................................................................... 44
I6T-MC-AMBG(a) Clinical Protocol Page 8
LY3074828List of Appendices
Appendix Page
Appendix 1. Abbreviat ions and Definit ions...................................................................... 100
Appendix 2. Clinical Laboratory  Tests ............................................................................. 105
Appendix 3. Study  Governance Considerat ions................................................................ 108
Appe ndix 4. Hepati c Moni toring Tests for Treatment -Emergent Abnormalit y.................. 113
Appendix 5. Risk Factors for Latent Tuberculosis Infect ion............................................. 115
Appendix 6. Mayo Scoring Sy stem  for the Assessment of Ulcerative Colit is Activity......117
Appendix 7. Patient-Reported Outcome Instruments ........................................................ 119
Appendix 8. Prohibited Medications ................................................................................ 123
Appendix 9. Permi tted Medicat ions with Dose Stabilizat ion............................................ 126
Appendix 10. Addit ional Informat ion on Sy stemic Drug Administration React ions........... 128
Appendix 11. Addit ional Informat ion on the Columbia Suicide Severit y Rating Scale, 
and Quick Inventory  of Depressive Symptom atology (Self Report) ............. 130
Appendix 12. Protocol  Amendment I6T -MC-AMBG(a) Summary A Phase 3, 
Multicenter, Randomized, Double -Blind, Parallel -Arm, Placebo -
Controlled Main tenance Study  of Mirikizumab in Pati ents wi th 
Moderately to Severely Act ive Ulcerative Colit is
LUCENT 2 .................................................................................................. 132
I6T-MC-AMBG(a) Clinical Protocol Page 9
LY30748281.Synopsis
Title of Study:
A Phase 3, Mult icenter, Randomized, Double -Blind, Parallel -Arm, Placebo -Controlled 
Maintenance Study  of Mirikizumab in Pat ients with Moderately  to Severely  Active Ulcerat ive 
Colit is.
Rationale:
Mirkizumab (LY3074828) is a humanized immunoglobulin G4 (IgG4) monoclonal ant ibody  that 
binds to the p19 subunit of interleukin -23 (IL -23), a cytokine that has been implicated in mucosal 
inflammat ion in ulcerat ive co litis (UC).  Study I6T-MC-AMBG (AMBG) is a Phase 3 clinical 
studythat is designed to evaluate the safet y and efficacy o f mirikizumab in maintaining 
remission at Week 40 in patients who completed the12-week induct ion study I6T-MC-AMAN 
(AMAN).
Objective(s)/Endpoints:
Objectives Endpoints
Primarya
 To test the hypothesis that mirikizumab is superior 
to placebo in achieving clinical remission at 
Week 40 (Week 52 of continuous therapy) among 
patients induced into clinical response with 
mirikizumab in Study AMAN  The proportion of patients in clinical r emission at 
Week 40, defined as:
oStool frequency (SF) subscore = 0, or SF = 1 
with a ≥1-point decrease from induction 
baseline, and
oRectal bleeding (RB) subscore = 0, and
oEndoscopic subscore (ES) = 0 or 1 (excluding 
friability ).
Major Secondarya,b
 To evaluate the efficacy of mirikizumab compared 
to placebo in maintaining clinical remission at Week 
40 (Week 52 of continuous therapy) among patients 
induced into clinical remission with mirikizumab  The proportion of patients who were in clinical 
remiss ion at Week 40 among patients in clinical 
remission at Week 12 in Study AMAN (i.e. 
durable clinical remission). Clinical remission is 
defined as:
oSF subscore = 0 or SF = 1 with a ≥1-point 
decrease from induction baseline, and
oRB subscore = 0, and
oES subsco re = 0 or 1 (excluding friability)
 To evaluate the efficacy of mirikizumab compared 
to placebo on endoscopic remission at Week 40
among patients induced into clinical response with 
mirikizumab The proportion of patients in endoscopic 
remission at Week 40, defined as:
oES = 0 or 1 (excluding friability)
 To evaluate the efficacy of mirikizumab compared 
to placebo in achieving corticosteroid-free remission 
without surgery among patients i nduced into 
clinical response with mirikizumab and receiving 
corticosteroids at induc tion baseline Corticosteroid-free remission without surgery at 
Week 40, defined as:
oClinical remission at Week 40, and 
oSymptomatic remission at Week 28, and 
oNo corticosteroid use for ≥12 weeks prior to 
Week 40 
I6T-MC-AMBG(a) Clinical Protocol Page 10
LY3074828 To evaluate the efficacy of mirikizumab compared 
to placebo on histologic remission at Week 40
among patients induced into clinical response with 
mirikizumab Proportio n of patients in histologic remission at 
Week 40, as defined in the SAP 
 To evaluate the efficacy of mirikizumab compared 
to placebo on stable maintenance of symptomatic 
remission among patients who were induced into 
clinical response and symptomatic remission with 
mirikizumab  The proportion of patients in symptomatic 
remissio n defined as being in symptomatic 
remission for at least 7 out of 9 visits from Week 
4 to Week 36 and being in symptomatic remission 
at Week 40 among patients in symptomatic 
remission at Week 12 of Study AMAN.
 Symptomatic remission is defined as:
oSF = 0, or SF = 1 with a ≥1-point decrease 
from induction baseline and
oRB = 0
 To evaluate the efficacy of mirikizumab compared 
to placebo on bowel movement urgency 
improvement at Week 40, among patients who: (1) 
had bowel urgency symptoms at induction baseline 
and (2) were induced into clinical response with  
mirikizumab  The proportion of patients with bowel movement 
urgency improvement at Week 40 as defined in 
the study  SAP.
Other Secondary
 To evaluate the efficacy of mirikizumab compared 
to placebo in achieving clinical remission at Week 
40 among patients induced into clinical response 
with mirikizumab, in the subgroup of patients in 
whom biologic agents have failed or caused 
intolerance. Clinical remission at Week 40 in the subgroup of 
patients in whom biologic agents have failed or 
caused intolerance.  Clinical remission is defined 
as:
oSF subscore = 0 or SF = 1 with a ≥1-point 
decrease from induction baseline, and
oRB subscore = 0, and
oES = 0 or 1 (excluding friability)
 To evaluate the efficacy of mirikizumab compared 
to placebo in achieving endoscopic remission at 
Week 40 among patients induced into clinical 
response with mirikizumab, in the subgroup of 
patients in whom biologic agents have failed or 
caused intolerance. Endoscopic remission at Week 40 in the subgroup 
of patients in whom biologic agents have failed or 
caused intolerance.  Endoscopic remission is 
defined as: ES = 0 or 1 (excluding friability)
 To evaluate the efficacy of mirikizumab as 
compared to placebo in maintaining clinical 
remission at Week 40 (Week 52 of continuous 
therapy ) among patients induced into clinical 
remission with mirikizumab, in the subgroup of 
patients in whom biologic agents have failed or 
caused intol erance The proportion of patients who were in clinical 
remission at Week 40 among patients in clinical 
remission at Week 12 in Study AMAN (i.e. 
durable clinical remission) in whom biologic 
agents have failed or caused intolerance.  Clinical 
remission is de fined as:
oSF subscore = 0 or SF = 1 with a ≥1-point 
decrease from induction baseline, and
oRB subscore = 0, and
oES = 0 or 1 (excluding friability)
I6T-MC-AMBG(a) Clinical Protocol Page 11
LY3074828 To evaluate the efficacy of mirikizumab compared 
to placebo in achieving corticosteroid-free remission 
without surgery among patients induced into 
clinical remission with mirikizumab and receiving 
corticosteroids at induction baseline Corticosteroid-free r emission without surgery at 
Week 40 among induction clinical remitters, 
defined as:
oClinical remission at Week 40, and
oNo corticosteroid use for ≥12 weeks prior to 
Week 40 
 To evaluate the efficacy of mirikizumab compared 
to placebo in achieving clinical remission (using a 
more stringent ES) at Week 40  among patients 
induced into clinical response with  mirikizumab  The proportion of patients with clinical remission 
(using a more stringent ES) at Week 40, with 
clinical remission defined as:
oSF subscore = 0, or SF = 1 with a ≥1-point 
decrease from induction baseline, and
oRB subscore = 0; and
oES = 0
 To evaluate the efficacy of mirikizumab compared 
to placebo on achieving ES of 0 at Week 40among 
patients induced into clinical response with 
mirikizumab The proportion of patients achieving ES = 0
 To evaluate the efficacy of mirikizumab compared 
to placebo in achieving an endoscopic response at 
Week 40 among patients induced into clinical 
response with mirikizumab The proportion of patients in endoscopic 
response at Week 40 defined as:
oA decrease in ES of ≥1 point from induction 
baseline.
 To evaluate the treatment of mirikizumab compared 
with placebo on achieving the symptomatic 
components of clinical remission as defined by the 
modified Mayo score (MMS) at Week 40 The proportion of patients at Week 40 with SF 
subscore = 0, or SF = 1 with a ≥1-point decrease 
from induction baseline
 The proportion of patients at Week 40 with RB 
subscore =0 
 To evaluate the numerical value and change from 
baseline of the individual MMS subscores and the 
composite sym ptom subscore over time during 
maintenance between mirikizumab and placebo  The numerical value and change from induction 
baseline in each of the following items:
oSF at each post baseline visit
oRB at each post baseline visit
oES (Week 40 only)
oThe sum of the SF and RB subscores at each 
post baseline visit
 To evaluate the efficacy of mirikizumab compared 
to placebo in maintaining clinical response at 
Week 40 amo ng patients induced into clinical 
response with mirikizumab Clinical response at Week 40.  Clinical response 
is defined as:
oA decrease in the MMS of ≥2 points and 
≥30% decrease from induction baseline, and
oA decrease of ≥1 point in the RB subscore or 
an RB subscore = 0 or 1
I6T-MC-AMBG(a) Clinical Protocol Page 12
LY3074828 To evaluate the efficacy of mirikizumab compared 
to placebo in reducing corticosteroid use over the 
course of maintenance treatment among patients 
induced into clinical response with mirikizumab 
and w ho entered the maintenance study on 
corticosteroids The change and percent change in daily 
(average) corticosteroid dose (prednisone 
equivalent) from maintenance baseline to end of 
maintenance study (Week 40), among clinical 
responders to mirikizumab induction who 
entered the maintenance study on corticosteroids
 To evaluate the effect of mirikizumab compared to 
placebo in health outcome endpoints at Week 40  Change f rom inductio n baseline in:  
oIBDQ score at Week 40
oEQ-5D 5L index at Week 40
oWPAI:UC score at Week 40
oSF-36, V2 phy sical and mental component and 
domain scores at Week 40
 To evaluate the efficacy of mirikizumab compared 
to placebo in inducing combined clinical remission, 
with normalization of fecal calprotectin, and 
histologic remission The proportion of patients with all of the 
following at Week 4 0:
oIn clinical remission, defined as:
oSF subscore = 0 or SF = 1 with a ≥1-point 
decrease from induction baseline, and
oRB subscore = 0, and
oES = 0 or 1 (excluding friability)
oIn histologic remission, as defined in the SAP
oFecal calprotectin within limits of normal 
 To evaluate the effect of mirikizumab compared to 
placebo on changes in inflammatory biomarkers  Change f rom baseline at various time points in 
the following biomarkers:
oC-reactive protein 
oFecal calprotectin
 To evaluate the efficacy of mirikizumab compared 
to placebo in achieving 24 -week corticosteroid -free 
remission without surgery among patients induced 
into clinical response with mirikizumab and 
receiving corticosteroids at induction baseline Corticosteroi d-free remission without surgery at 
Week 40, defined as:
oClinical remission at Week 40, and 
oSymptomatic remission at Week 28, and 
oNo corticosteroid use for ≥24 weeks prior to 
Week 40 
 To evaluate the effect of mirikizumab compared to 
placebo on changes in Abdominal pain at Week 40 Change f rom inductio n baseline at Week 40 in the 
Abdominal pain NRS score
 To evaluate the efficacy of mirikizumab in reducing 
the proportion of patients un dergoing surgery for 
UC, colectomy, and hospitalization for UC The proportion of patients undergoing:
oSurgery  for UC (including colectomy)
oHospitalization for UC
I6T-MC-AMBG(a) Clinical Protocol Page 13
LY3074828 To evaluate the treatment of mirikizumab compared 
with placebo on achieving symptomatic remission  The proportion of patients with symptomatic 
remission at various time points, defined as:
oSF = 0, or SF = 1 with a ≥1-point decrease 
from induction baseline, and
oRB = 0
To evaluate key efficacy endpoints in biologic -failed 
and conventional -failed subgroups of patients 
(except those major secondary objectives noted 
above) Key efficacy  endpoints in the subgroup of 
patients in whom biologic agents have failed or
caused intolerance, and in whom conventional 
therapies have failed or caused intolerance
To evaluate key efficacy endpoints in the subgroups 
of patients on concomitant treatment for UC Key efficacy  endpoints in the subgroups of 
patients on concomitant me dication for UC 
(corticosteroids and immunomodulators)
 To evaluate clinical remission, clinical response and 
endoscopic remission rates with extended induction 
in patients who did not respond to mirikizumab with 
initial induction  At Week 12 (Week 24 of continuous therapy), 
oClinical remission, defined as:
oSF subscore = 0, or SF = 1 with a ≥1-
point decrease from induction baseline, 
and
oRB subscore = 0; and
oES = 0 or 1 (excluding friability)
oClinical response, defined as:
oA decrease in MMS of ≥2 points and 
≥30% decrease from induction baseline, 
and 
oA decrease of ≥1 point in the RB subscore 
from induction baseline or a RB score of 0 
or 1
oEndoscopic remission, defined as:
oES = 0 or 1 (excluding friability)
 To evaluate the e fficacy of mirikizumab compared 
to placebo on maintaining endoscopic remission at 
Week 40 among patients induced into endoscopic 
remission with mirikizumab The proportion of patients in durable endoscopic 
remission at Week 40, defined asES = 0 or 1 
(exclud ing friability )
 Evaluate the pharmacokinetics and 
pharmacokinetic/pharmacodynamic relationship of 
mirikizumab  Clearance and volume of distribution of 
mirikizumab
 Relationship between mirikizumab exposure and 
efficacy 
 To evaluate the potential development of 
anti-mirikizumab antibodies and their potential 
relatio nship with efficacy, safety, and mirikizumab 
exposure Relationship between TE -ADA and efficacy 
 Relationship between TE -ADA and safety
 Relationship between TE -ADA and mirikizumab 
pharmacokinetics
I6T-MC-AMBG(a) Clinical Protocol Page 14
LY3074828 To evaluate the efficacy of mirikizumab compared 
to placebo in UCEIS endoscopic remission at Week 
40 among patients induced into clinical response
with  mirikizumab  The proportion of patients with a UCEIS score of 
≤1 at Week 40
 To evalu ate the efficacy of mirikizumab compared
to placebo in mucosal healing at Week 40 among 
patients induced into clinical response with 
mirikizumab  The proportion of patients with mucosal healing 
at Week 40, defined as achieveing both:  
oHistologic remission, as described in the 
SAP, and
oEndoscopic remission,  defined as ES = 0 or 
1 (excluding friability)
 To evaluate the effect of mirikizumab compared to 
placebo on change in fatigue at Week 40 Change f rom inductio n baseline at Week 40 in the 
Fatigue NRS score
Abbreviations:  EQ -5D 5L = European Quality of Life 5-Dimensions 5 Level; ES = endoscopic subscore; 
IBDQ =Inflammatory Bowel Disease Questionnaire; MMS = modified Mayo Score ;NRS = numeric rating 
scale; RB = rectal bleeding; SAP = statistical analysis plan; SF = stool frequency; SF -36 = Medical Outcomes 
Study 36 -Item Short Form Health Survey; UC = ulcerative colitis; WPAI :UC = Work Productivity and Activity 
Impairment Questionnaire Ulcerative Colitis ; TE-ADA =treatment -emerge nt anti -drug antibody ; 
UCEIS =Ulcerative Colitis Endoscopic Index of Severity .
aAll primary and major secondary endpoints will be evaluated for mirikizumab versus placebo.  All primary and 
major secondary endpoint analyses will utilize the multiplicity control approach based on ‘graphical multiple 
testing procedure’ to control the overall family -wise type I error rate at a 2 -sided alpha level of 0.05.  The 
graphical multiple testing procedure described in Bretz et al. (2009) will be used.
bThe order of t esting of the major secondary endpoints will be determined from the results of the statistical 
simulations. Therefore ,the o rder of the secondary endpoints does not reflect the order of the statistical testing.
I6T-MC-AMBG(a) Clinical Protocol Page 15
LY3074828Summary of Study Design:
Study  AMBG is a Phase 3, mult icenter, randomized, double -blind, placebo -controlled, 
parallel- arm study  evaluat ing the safet y and efficacy  of 200 m g mirikizumab every  4 weeks 
(Q4W )subcutaneous (SC) in maintaining treatment response at Week 40 (that is, at Week 52 of 
continuous st udy drug treatment).
The study  popul ation includes patients with moderately to severely  active UC who com pleted 
Study  AMAN .  Study  AMAN includes patients who have an inadequate r esponse to, loss of 
response to, or are intolerant to convent ional (nonbio logic) therapy  for UC 
(“convent ional-failed ”),and those who have an inadequate response to, loss of response to, or 
are intolerant to bio logic therapy  for UC ( “biologic-failed”).
Treatment Arms and Duration:   
Patients who achieved clinical respons e with blinded mirikizumab treatment during Study  
AMAN will be rando mized 2:1 to blinded 200 m g mirikizumab Q4W SC or blinded placebo . 
Patients who responded to blinded placebo in thei r inducti on study  will remain on blinded 
placebo in Study  AMBG.  Open -label rescue therapy  with300 m g mirikizumab Q4W 
intravenous ( IV)
will be administered for 3 doses if these patients lose response.  
Patients who di d not achieve clinical response with either blinded mirikizumab or blinded 
placebo during Study  AMAN will receive open -label extended induction therapy  with300mg 
mirikizumab Q4W IV administered for 3 dos es.Patients who achieve delayed clinical response 
(defined us ing induct ion study  baseline) will then receive open -label 200 mg mirikizumab Q4W 
SC.  Induction study  nonresponders who do not achieve clinical response at Week 12 of Study  
AMBG will be discont inued.
Lead -in Period :  Visit [V
]1 (Week 0) should occur no more than 1 0days from start of 
V5 (Week 12 )of Study  AMAN .  
Treatment Period :  40weeks .  
Follow -up Period :  Up to 16 weeks .
Extension Period :  N/A. Patients who complete Study  AMBG will be eligible for 
extensio n Study I6T-MC-AMAP .  
Continued Access Period : N/A.
Number of Patients :
Enrolled: Approximately  1044.
Statistical Analysis:
Assuming that 
90% of patients complete Study AMAN (which is expect edto rando mize 
approximately  1160 pat ients), Eli Lilly and Company ( Lilly )anticipates approximately 
1044 patients will enroll in Study  AMBG. Itis expected that approximatel y 470 of these patients 
will enter Study  AMBG as clinical responders to mirikizumab and then will be rando mized 2:1 
I6T-MC-AMBG(a) Clinical Protocol Page 16 
LY3074828 to 200 mg mirikizumab SC (approximately 313 patients) and placebo (approximately 157 
patients).  Among the expected 470 mirikizumab clinical responders, approximately 180 
mirikizumab clinical remitters will be randomized to 200 mg mirikizumab SC (approximately 
120 patients) and placebo (approximately 60 patients).  This assumes that: 
 The induction study (AMAN, which has a mixed population with approximately 50% 
biologic-failed patients) is expected to have an overall clinical re mission rate of 23% and 
response rate of 60% with mirikizumab. 
 75% of induction patients receive treatm ent with mirikizumab, based on a 3:1 
randomization ratio for the induction study. 
 10% dropout rate from induction to maintenance. 
The primary endpoint, clinical remission at W eek 40, will be assessed on patients who achieved 
clinical response to mirikizumab induction treatment.  Assu ming mirikizumab and placebo 
clinical remission rates of 47% and 27%, respec tively, this study based on the 470 mirikizumab 
induction responders is expected to have >95% power to dem onstrate that mirikizumab is 
superior to placebo by using a chi-square test with a 2-sided significance level of 0.05.  In 
addition, the sample size is expected to provi de adequate power (>80%) to demonstrate that 
mirikizumab is superior to placebo for e ndoscopic remission, histologic remission, and 
corticosteroid-free remission at Week 40, among responders to mirikizumab induction treatment 
by using a chi-square test with a 2-sided significance level of 0.05.  
Summary statistics for continuous variables may include mean, standard deviation, median, and 
minimum and maximum values.  Categorical variables will be presented as counts and 
percentages.  Unless otherwise specified, variables will be analyzed in the original scale on which they are measured.  All hypothesis tests of treatment effects will be 2-sided, unless 
otherwise stated. 
For assessments of the primary endpoint and other categorical efficacy endpoints among induced 
responders, the Cochran-Mantel-Haenszel (CMH) chi-square test will be used to compare 
mirikizumab and placebo with stratification factors:  (a) previous biologic therapy failure (yes or no), (b) baseline corticos teroid use (yes or no), (c) region (North America/Europe/Other), (d) 
induction remission status (yes/no).  The CMH ch i-square p-value and the relative risk along 
with its 95% 2-sided confidence interval will be provided. 
Treatment comparisons of continuous efficacy and health outcome variables with a single 
post-baseline time point will be made using analysis of covariance with:  (a) treatment group, 
(b) previous biologic therapy failu re (yes or no), (c) corticosteroid use (yes or no), (d) region 
(North America/Europe/Other), (e) baseline value in the model, a nd (f) induction remission 
status. 
A prespecified multiple testing scheme based on graphical approach (Bretz et al. 2009, 2011) 
will be used to test the primary and major sec ondary hypotheses at overall family wise type 1 
error rate (FWER) of 0.05.  The graphical approach is a closed testing procedure, hence, it 
strongly controls the FWER acro ss all endpoints (Alosh et al. 2014) .  Details of the specific 
graphical testing scheme (includi ng testing order, interrelationshi ps, type I error allocation for 
I6T-MC-AMBG(a) Clinical Protocol Page 17
LY3074828the major seco ndary  endpoints, and the associated propagation) will be prespecified in the 
statist ical analysis plans ( SAPs )prior to fi rst unblinding of efficacy .
The Fisher exact test will be used to perform the between- treatm ent group c omparisons for 
adverse events ( AEs), discont inuat ions, and other categorical safet y data.  The change fro m 
baseline in cont inuous vital signs, physical characterist ics, and other continuous safet y variables, 
including laboratory  variables, will be summariz ed by visit and treatm ent.  Shift tables for 
categori cal safet y analyses ( for example, “high” or “low” laboratory  resul ts) will  also be 
produced .
No m ultiplicity control  approach will be used for testing of other secondary  endpoints.
I6T-MC-AMBG(a) Clinical Protocol Page 18
LY30748282.Schedule of A ctivities
I6T-MC-AMBG(a) Clinical Protocol Page 19
LY3074828Table AMBG .2.1. Schedule of A ctivities –Responders from Induction Study
Procedure Randomized Maintenance PeriodPost-
treatment 
Follow -up
NotesVisit V1 V2 V3 V4 V5 V6 V7 V8 V9 V10 V11 N/A V997 801 802
Week 0 4 8 12 16 20 24 28 32 3640
LVETV UVLV or 
ETV
+4LV  or 
ETV
+12/16 b
Day and/or Visit 
Interval Tolerance1a29 
+/-757 
+/-785 
+/-7113 
+/-7141 
+/-7169 
+/-7197 
+/-7225 
+/-7253 
+/-7281 
+/-7N/A N/A +/-10 +/-10
Informed consent XPatients may consent between the start of V5 of 
Study AMAN and before any procedures at 
V1/Week 0 are performed.
Inclusion and exclusion 
criteriaX Can begin at Week 12 of induction and continue 
until dosing is initiated in Study AMBG.
Concomitant medication X X X X X X X X X X X X X X X
Review AEs X X X X X X X X X X X X X X X
Tobacco/nicotine use XcX X X X
IP Administration
IWRS/ Randomization X
IP SC administration X X X X X X X X X X
Rescue mirikizumab IV 
dosingXdXd:  Three Q4W IV rescue doses administered 
instead of SC dosing, if secondary loss of 
response (LOR) is confirmed.  The IV dosing 
must start no later than V8/Week 28.  The IV 
dosing visit window may shift if first rescue dose 
is given outside of SC dosing visit window.  
Rescue IV doses to be given Q4W with visit 
window tolerance of +/-3 days.
Physical Examination 
Vital signs (T, BP, and 
PR)X X X X X X X X X X X X X X X
Weight XcX X X
I6T-MC-AMBG(a) Clinical Protocol Page 20
LY3074828Procedure Randomized Maintenance PeriodPost-
treatment 
Follow -up
NotesVisit V1 V2 V3 V4 V5 V6 V7 V8 V9 V10 V11 N/A V997 801 802
Week 0 4 8 12 16 20 24 28 32 3640
LVETV UVLV or 
ETV
+4LV  or 
ETV
+12/16 b
Day and/or Visit 
Interval Tolerance1a29 
+/-757 
+/-785 
+/-7113 
+/-7141 
+/-7169 
+/-7197 
+/-7225 
+/-7253 
+/-7281 
+/-7N/A N/A +/-10 +/-10
Physical examination XcXdX X XdXd:  A targeted physical exam to be performed as 
appropriate for patients with secondary LOR.  
Evaluate for EIMs X X X X X X X X X X X X X See Section 9.1.3.2 .  
12-lead ECG XcX X
Laboratory Investigations
Urine pregnancy test X X X X X X X X X X X X X X XOnly in women of childbearing potential.  Done 
locally and prior to dosing.  
HBV DNA d Xc,dXdXdXdXdXd:  For patients who were HBsAg -, anti -HBc+, 
and HBV DNA not detected in Study AMAN.  
See Section 9.4.5.2 .
Hematology XcX X X X X X X X X X X X X X
Chemistry XcX X X X X X X X X X X X X X
Fasting lipid profile e XcX X
hsCRP e XcX X
FSH (optional in 
women to confirm 
nonchild -bearing 
potential )eXOptional, to confirm post -menopausal status in 
women ≥50 years with amenorrhea for >1 year.  
Serum and plasma for 
cytokinesXcX X X
I 6 T -M C -A M B G( a) Cli ni c al Pr ot o c ol P a g e 2 1 
L Y 3 0 7 4 8 2 8 Pr oce d ure R a n d o mize d M ai nte n a nce Peri o d P ost -
tre at me nt 
F oll o w -u p 
N otes Visit V 1 V 2 V 3  V 4  V 5 V 6 V 7  V 8  V 9 V 1 0 V 1 1 N/ A V 9 9 7 8 0 1 8 0 2 
Wee k 0 4 8 1 2 1 6 2 0 2 4 2 8 3 2 3 6 4 0 
L V E T V U V L V  or  
E T V 
+4 L V  o r 
E T V 
+12/16 b
D a y a n d/ or Visit 
I nter v al T oler a nce 1a2 9 
+/ - 7 5 7 
+/ - 7 8 5 
+/ - 7 1 1 3 
+/ - 7 1 4 1 
+/ - 7 1 6 9 
+/ - 7 1 9 7 
+/ - 7 2 2 5 
+/ - 7 2 5 3 
+/ - 7 2 8 1 
+/ - 7 N/ A N/ A +/ - 1 0 +/ - 1 0 
P K assess me nt XcX  X  X dXdX  X dXdXdX  X  X dXSer u m f or P K assess me nt  
  See Secti o n 9. 5 .  I n a d diti o n, 
patie nts wit h p ote ntial h y perse nsiti vit y or 
i nf usi o n -relate d e ve nt s h o ul d ha ve sa m ple ta ke n 
as s o o n as p ossi ble after e ve nt occ urs, at 4 a n d 
1 2 t o 1 6 wee ks after t he e ve nt. 
Xd:  Patie nts wit h c o nfir me d sec o n dar y L O R 
s h o ul d ha ve sa m ples ta ke n pri or t o I V 
miri kiz u ma b resc ue d osi n g, a n d 4 a n d 1 2 wee ks 
after resc ue i nitiati o n.  
A D A assess me nt XcX  X  X dXdX  X dXdXdX  X  X dXSee Secti o n 9. 4. 4 .  I n a d diti o n, patie nts wit h 
p ossi ble h y perse nsiti vit y or i nf usi o n -relate d 
e ve nt s h o ul d ha ve sa m ple ta ke n as s o o n as 
p ossi ble after e ve nt occ ur s, at 4 a n d 1 2 t o 16 
wee ks after t he e ve nt. 
Xd:  Patie nts wit h c o nfir me d sec o n dar y L O R 
s h o ul d ha ve sa m ples ta ke n pri or t o I V 
miri kiz u ma b resc ue d osi n g, a n d 4 a n d 1 2 wee ks 
after resc ue i nitiati o n.  
Ser u m, plas ma a n d wh ole 
bl o o d f or e x pl orat or y 
bi o mar kers XcX X X  X 
A d diti o n al P atie nt -Re p orte d Tests 
C- S S R S, Self -Har m 
S u p ple me nt F or m, a n d 
Self -Har m “ F oll o w -U p” 
F or m X
QI D S -S R 1 6 XcX X X  X C CI 
I6T-MC-AMBG(a) Clinical Protocol Page 22
LY3074828Procedure Randomized Maintenance PeriodPost-
treatment 
Follow -up
NotesVisit V1 V2 V3 V4 V5 V6 V7 V8 V9 V10 V11 N/A V997 801 802
Week 0 4 8 12 16 20 24 28 32 3640
LVETV UVLV or 
ETV
+4LV  or 
ETV
+12/16 b
Day and/or Visit 
Interval Tolerance1a29 
+/-757 
+/-785 
+/-7113 
+/-7141 
+/-7169 
+/-7197 
+/-7225 
+/-7253 
+/-7281 
+/-7N/A N/A +/-10 +/-10
Stool Samples
C. difficile testing XdX XdXd:  Collection only at time of the first LOR 
assessment. 
Additional local stool testing (e.g., ova and 
parasites) is allowed at the investigator’s 
discretio n.
Fecal calprotectin and 
exploratory fecal 
biomarkersXcXdX X XdXd:Collection at time of the first LOR 
assessment.  
Endoscopic Procedure
Endoscopy with biopsies XdX X XdXd:  At least 1 endoscopy is performed at Week 
40/ETV or if LOR is confirmed.  LOR 
confirmatio n based on endoscopy can only occur 
at a scheduled or unscheduled visit between V4 
and V8. Please refer to Section 9.1.1.3 for 
procedure clarification.
UC Activity Assessments
Patient diary device 
dispensed X
Patient diary compliance 
reviewX X X X X X X X X X X X
PGA XcXdX X XdXd:  Performed at the second of 2 LOR 
assessments which may occur at a scheduled or 
unscheduled visit, at least 7 days from first LOR 
assessment.  See Section 5.1.
I6T-MC-AMBG(a) Clinical Protocol Page 23
LY3074828Procedure Randomized Maintenance PeriodPost-
treatment 
Follow -up
NotesVisit V1 V2 V3 V4 V5 V6 V7 V8 V9 V10 V11 N/A V997 801 802
Week 0 4 8 12 16 20 24 28 32 3640
LVETV UVLV or 
ETV
+4LV  or 
ETV
+12/16 b
Day and/or Visit 
Interval Tolerance1a29 
+/-757 
+/-785 
+/-7113 
+/-7141 
+/-7169 
+/-7197 
+/-7225 
+/-7253 
+/-7281 
+/-7N/A N/A +/-10 +/-10
Review modified Mayo 
ScoreXcXdX X XdXd:  Performed at the second of 2 LOR 
assessments which may occur at a scheduled or 
unscheduled visit, at least 7 days from first LOR 
assessment.  See Section 5.1.
Patient diary device 
collectedX X
Health Outcome Assessment
IBDQ XcXdX X Xd Xd:  To be performed for patients who have LOR 
confirmed by endoscopy before rescue dosing. EQ-5D 5L XcXdX X Xd
PGRC XdX X XdXd:  To be performed for patients who have LOR 
confirmed by endoscopy before rescue dosing. 
SF-36 XcX X
WPAI:UC XcX X
I6T-MC-AMBG(a) Clinical Protocol Page 24
LY3074828Footnotes for Table AMBG .2.1
Abbreviations:  ADA = anti -drug antibody; AE = adverse event; anti-HBc+ = positive for anti -hepatitis B core antibody; BP = blood pressure; C-SSRS = 
Columbia -Suicide Severity Rating Scale; DNA = deoxyribonucleic acid; 
ECG = electrocardiogram; EIM = extraintestinal manifestation; EQ-5D-5L = European 
Quality  ofLife 5-Dimension 5 Level; ET V= early termination visit; FSH = follicle - stimulating hormone; HBsAg -= negative for hepatitis B surface antigen ; 
HBV = hepatitis B virus ; hsCRP = high -sensitivity C -reactive protein; IBDQ = Inflammato ry Bowel Disease Questionnaire; IP=investigational product; IV = 
intravenous; IWRS = interactive web -response sy stem; LOR = loss of response ; LV = last visit ; N/A = not applicable ; PGA = Physician’s Global Assessment; 
PGRC = Patient’s Global Rating of Change; PK = pharmacokinetic; PR = pulse rate; Q4W = every 4 weeks; QIDS -SR16 = Quick Inventory of Depressive 
Symptomatology—Self -Report (16 Items); SC = subcut aneous; SF-36 = Medical Outcomes Study 36 -Item Short Form Health Survey; T = temperature; 
UV=unscheduled visit; V = visit; WPAI :UC = Work Productivity and Activity Impairment Questionnaire Ulcerative Colitis .
Notes: All activities should be completed prior to any  study  drug adminis tratio n unless otherwise stated .  Last visit or ETV is last visit prior to entering long term 
extension Study AMAP or post -treatment follow -up.  Post -treatment follow -up visits should only occur if the patient is not proceedi ng to lo ng term extension 
Study AMAP or if they discontinue treatment in Study AMBG early.
aV1 (Week 0) should occur no more than 14 days from the start of theVisit 5/ Week 12 visit of Study AMAN .
bPatients who discontinue study drug with last dose administered IV will return for an LV +16 week post -treatment follow -up visit without a 12 week follow -
up.  Patients who discontinue study drug with last dose administered SC will return for an LV + 12 week post -treatment follow -up visit wit hout a 16 week 
follow -up.
cResults from Week 12 of Study AMAN will be used for Week 0 of this study .
dActivity  to be performed on a subpopulation of patients. See Notes column in table.
eThese tests will be run from the “chemistry” sample.
I6T-MC-AMBG(a) Clinical Protocol Page 25
LY3074828Table AMBG .2.2. Schedule of A ctivities –Nonresponders from Induction Stud y
ProcedureExtended 
InductionOpen -Label Maintenance PeriodPost-
treatment 
Follow -up Notes
Visit V1 V2 V3 V4aV5 V6 V7 V8 V9 V10 V11 V997 801 802
Week 0 4 8 12 16 20 24 28 32 3640
LV ETV UVLV 
+ 4LV 
+12/16c
Day and/o r Visit Interval 
Tolerance1b29 
+/-357 
+/-385 
+/-7113 
+/-7141 
+/-7169 
+/-7197 
+/-7225 
+/-7253 
+/-7281 
+/-7N/A +/-10 +/-10
Informed consent XPatients may consent between the start of V5 of 
Study AMAN and before any procedures at 
V1/Week 0 are performed. 
Inclusion and exclusion 
criteriaX Can begin at Week 12 of induction and continue 
until dosing is initiated in Study AMBG.
Concomitant medication X X X X X X X X X X X X X X X
Review AEs X X X X X X X X X X X X X X X
Tobacco/nicotine use XdX X X X
IP Administration
IWRS/Randomization X
Open -label mirikizumab 
extended IV dosingX X X
Open -label mirikizumab SC 
dosingX X X X X X X
Physical Examination 
Vital signs (T, BP, and PR) X X X X X X X X X X X X X X X
Weight XdX X X X
Physical examination XdX X
Evaluate for EIMs X X X X X X X X X X X X X See Section 9.1.3.2 .  
12-lead ECG XdX X
Laboratory Investigations
Urine pregnancy test X X X X X X X X X X X X X X XOnly in women of childbearing potential.  Done 
locally and prior to dosing.  
I 6 T -M C -A M B G( a) Cli ni c al Pr ot o c ol P a g e 2 6 
L Y 3 0 7 4 8 2 8 Pr oce d ure E xte n de d 
I n d ucti o n O pe n -L a bel M ai nte n a nce Peri o d P ost -
tre at me nt 
F oll o w -u p N otes 
Visit V 1 V 2  V 3 V 4 aV 5 V 6  V 7 V 8 V 9 V 1 0 V 1 1 V 9 9 7 8 0 1 8 0 2 
Wee k 0 4 8 1 2 1 6 2 0 2 4 2 8 3 2 3 6 4 0 
L V E T V U V L V  
+ 4 L V  
+12/16 c
Da y  a n d/ o r V isit I nter val 
T olera nce 1b2 9 
+/ - 3 5 7 
+/ - 3 8 5 
+/ - 7 1 1 3 
+/ - 7 1 4 1 
+/ - 7 1 6 9 
+/ - 7 1 9 7 
+/ - 7 2 2 5 
+/ - 7 2 5 3 
+/ - 7 2 8 1 
+/ - 7 N/ A +/ - 1 0 +/ - 1 0 
H B V D N A e Xd,e XeXeXeXeXe  F or patie nts w h o were H Bs A g -, a nti -H Bc +, 
a n d H B V D N A n ot detecte d at V 0 i n St u d y 
A M A N.  Se e Secti o n 9. 4. 5. 2 .
He mat ol o g y XdX  X  X  X  X  X  X  X  X  X  X  X  X  X 
C he mistr y XdX  X  X  X  X  X  X  X  X  X  X  X  X  X 
Fasti n g li pi d pr ofile f XdX  X 
hs C R P f XdX X  X 
F S H ( o pti o nal i n w o me n 
t o c o nfir m n o nc hil d -
beari n g p ote ntial) fXO pti o nal, t o c o nfir m p ost -me n o pa usal stat us i n 
w o me n ≥ 5 0 years wit h a me n orr hea f or > 1 year.  
Ser u m a n d plas ma f or 
c y t o ki nes XdX X X  X 
P K assess me nt XdX  X X X  X  X  X Ser u m f or P K assess me nt  
  See Secti o n 9. 5 .
I n a d diti o n, patie nts wit h p ote ntial 
h y perse nsiti vit y or i nf usi o n -relate d e ve nt s h o ul d 
ha ve sa m ple ta ke n as s o o n as p ossi ble after e ve nt 
occ urs, at 4 a n d 1 2 t o 1 6 wee ks after t he e ve nt. 
A D A assess me nt XdX  X X X  X  X  X See Secti o n 9. 4. 4 .
I n a d diti o n, patie nts wit h p ossi ble h y perse nsiti vit y 
or  i nf usi o n -r e late d e ve nt s h o ul d ha ve sa m ple 
ta ke n as s o o n as p ossi ble after e ve nt occ urs, at 4 
a n d 1 2 t o 1 6 wee ks after t he e ve nt. 
Ser u m, plas ma a n d w h ole 
bl o o d f or e x pl orat or y 
bi o mar kers XdX X X  X C CI 
I6T-MC-AMBG(a) Clinical Protocol Page 27
LY3074828ProcedureExtended 
InductionOpen -Label Maintenance PeriodPost-
treatment 
Follow -up Notes
Visit V1 V2 V3 V4aV5 V6 V7 V8 V9 V10 V11 V997 801 802
Week 0 4 8 12 16 20 24 28 32 3640
LV ETV UVLV 
+ 4LV 
+12/16c
Day and/o r Visit Interval 
Tolerance1b29 
+/-357 
+/-385 
+/-7113 
+/-7141 
+/-7169 
+/-7197 
+/-7225 
+/-7253 
+/-7281 
+/-7N/A +/-10 +/-10
Additional Patient -Reported Tests
C-SSRS, Self -Harm 
Supplement Form, and 
Self-Harm “Follow -Up” 
FormX
QIDS -SR16 XdX X X X
Stool Samples
C. difficile testing X XeXXe:  Should be performed if clinical response is 
not achieved with extended induction. 
In addition, may be performed if loss of clinical
benefit, per investigator discretion, on OL SC 
maintenance dosing.
Additional local stool testing (e.g., ova and 
parasites) is allowed at the investigator’s 
discretio n. V1 C. difficile testing does not need to 
be completed before the patient can start stu dy 
drug therapy. 
Fecal calprotectin and 
exploratory fecal 
biomarkersXdX X X
Endoscopic Procedure
Endoscopy with biopsies X X XPlease refer to Section 9.1.1.3 for procedure 
clarificatio n.
UC Activity Assessments
Patient diary device 
dispensed X
I6T-MC-AMBG(a) Clinical Protocol Page 28
LY3074828ProcedureExtended 
InductionOpen -Label Maintenance PeriodPost-
treatment 
Follow -up Notes
Visit V1 V2 V3 V4aV5 V6 V7 V8 V9 V10 V11 V997 801 802
Week 0 4 8 12 16 20 24 28 32 3640
LV ETV UVLV 
+ 4LV 
+12/16c
Day and/o r Visit Interval 
Tolerance1b29 
+/-357 
+/-385 
+/-7113 
+/-7141 
+/-7169 
+/-7197 
+/-7225 
+/-7253 
+/-7281 
+/-7N/A +/-10 +/-10
Patient diary compliance 
reviewX X X X X X X X X X X X
PGA XdX X X
Review Modified Mayo 
ScoreXdX X XIn addition, may be performed if loss of clinical 
benefit, per investigator discretion, on OL SC 
maintenance dosing
Patient diary device 
collectedX X
Health Outcome Assessments
IBDQ XdX X X
EQ-5D 5L XdX X X
PGRC X X X
SF-36 XdX X
WPAI:UC XdX X
I6T-MC-AMBG(a) Clinical Protocol Page 29
LY3074828Footnotes for Table AMBG .2.2
Abbreviations:  ADA = anti -drug antibody; AE = adverse event; anti-HBc+ = positive for anti -hepatitis B core antibody; BP = blood pressure ; C-SSRS = 
Columbia -Suicide Severity Rating Scale; EC G =electrocardiogram; EIM = extraintestinal manifestatio n; EQ-5D 5L = European Quality of Life 5 -
Dimension
5 Level; ETV= early termination visit; FSH = follicle -stimulating hormone; HBsAg -= negative for hepatitis B surface antigen ; HBV= hepatitis B virus ; 
hsCRP = high -sensitivity C -reactive protein; IBDQ = Inflammatory Bowel Disease Questionnaire; IP=investigational product; IV = intravenous; IWRS = 
interactive web -response sy stem; LV = last visit; N/A = not applicable; PGA = Physician’s Global As sessment; PGRC = Patient’s Global Rating of Change; 
PK = pharmacokinetic; PR = pulse rate; QIDS -SR16 = Quick Inventory of Depressive Symptomatology —Self -Report (16 Items); SC =subcutaneous; 
SF
-36 = Medical Outcomes Study 36 -Item Short Form Health Survey; T = temperature; UV = unscheduled visit; V =visit; WPAI :UC = Work Productivity 
and Activity Impairment Questionnaire Ulcerative Colitis .
Notes:  All activities should be completed prior to any study drug administration unless otherwise stated.  Last visit or ETV is last visit prior to entering long term
extension Study AMAP or post -treatment follow -up.  Post -treatment follow -up visits shoul d only occur if the patient is not proceeding to long term extension 
Study AMAP or if they discontinue treatment in Study AMBG early (i.e. patients who do not achieve delayed clinical response) .
aFor patients who cannot continue beyond V4 because they di d not achieve delayed clinical response, ETV activites that are performed as part of V4 do not 
need to be rep eated.Only those ETV activities that are not part of V4 should be completed during the ETV.
bV1 (Week 0) should occur no more than 14 days from the start of the Visit 5/Week 12 visit of Study AMAN .
cPatients who discontinue study drug with last dose administered IV will return for an LV +16 week post -treatment follow -up visit without a 12 week follow -
up.  Patients who discontinue study drug with last dose administered SC will return for an LV + 12 week post -treatment follow -up visit without a 16 week 
follow -up.
dResults from V5 (Week 12) of Study AMAN will be used for Week 0 of this study.
eActivity  to be performed on a subpopulation of patients . See Notes column in table.
fThese tests will be run from the “chemistry” sample
I6T-MC-AMBG(a) Clinical Protocol Page 30
LY30748283.Introduction
3.1. Study Rationale
Mirikizumab (LY3074828) is a humanized immunoglobulin G4 (IgG4) monoclonal ant ibody  
that binds to the p19 subunit of interleukin- 23 (IL -23), a cy tokine that has been implicated in 
mucosal inflammat ion.  Study I6T-MC-AMBG (AMBG ) is a Phase 3 clinical study that is 
designed to evaluate the safet y and efficacy  of mirikizumab in maintaining remissio nof 
ulcerat ive co litis (UC) at Week 40in patients who com pleted the 12- week induct ionstudy
I6T-MC-AMAN (AMAN )
.  Stud yAMAN include spatients wi th moderate to severely  active UC
who have an inadequate response to, loss of response to, or are intolerant to conventional 
(nonbio logic) therapy  for UC ( “convent ional-failed ”), and those who have an inadequate 
response to, loss of response to, or are intolerant to bio logic therapy  for UC ( “biologic-failed”).  
3.2. Background
3.2.1. Disease State and Treatment Goals 
Ulcerat ive co litis isa chronic disease of unknown etio logy that i s characteri zed by  inflammat ion 
of the rectum  and co lon.  Symptoms include diarrhea, rectal bleeding (RB) , urgency , and 
tenesmus (a feeling of inco mplete evacuation o f the rectum  after defecat ion).  Ulcerative colitis
has a rel apsing -remitt ing course, meaning that many patients have intermittent disease flares that 
are interspersed with periods of remissio n.  Treatment goals in UC include induction o f 
remission (ty pically wi thin a 6 to 12 week time frame) and ma intenance o f remissio n in the 
longer term  (assessed over 52 weeks of continuous treatment in clinical trials).  In both clinical 
practi ce and clinical trials, clinical response and clinical remissio n are assessed by  a combinat ion 
of endoscopy  (improvement in the endoscopic appearance of the mucosa and healing of ulcers) 
and pat ient-reported outcomes (PROs), including a reduction in stool frequency (SF) and a 
resol ution of RB(Levesque et al.2015).  Control of intestinal inflammat ion in UC is also 
associ ated with a reducti on in the ri sk of hospi talizati on, col ectomy and, in the l onger term , 
UC-associ ated dy splasia and colorectal cancer.
3.2.2. Currently Available Treatments and Unmet Need 
Medicat ions used for the treatment of UC include 5 -aminosalicylic acid (5 -ASA) –containing 
medicat ions (sulfasalazine, mesalazine, balsalazide, olsalazine), corticosteroids, 
immuno modulators such as azathioprine (AZA) and 6 -mercaptopurine (6 -MP), and bio logic 
medicat ions.  A si gnificant proportion of pat ients with moderately to sev erely  active UC m ay 
have an inadequate response to medicines such as 5
-ASAs or corticosteroids, be unable to 
maintain a clinical response to 5 -ASAs or AZA , or be unable to discont inue corticosteroids 
without a rel apse in disease activit y (reviewed in Digna ss et al . 2012).  Many  of these pat ients 
requi re addi tional treatm ent wi th the next line of therapy , which coul d include medical treatment 
with a biologic m edicat ion or surgical treatment with a colectomy.  Bio logics, including 
antitumor necrosis factor (TNF) antibodies (infliximab, adalimumab, golimumab) and 
vedo lizumab, an ant i-α4β7integrin ant ibody , are indi cated for the treatment of UC in pat ients 
who fail to respond to, have an inadequate response to, or are intolerant to other medicat ions 
I6T-MC-AMBG(a) Clinical Protocol Page 31
LY3074828used in the treatm ent of UC, and as a first -line treatment for UC in selected patients.  However, 
in the pivotal ACT1 and ACT2 studies of infliximab therapy  in patients wi th moderately  to 
severely  active UC ,and in the pivotal PURSUIT studies of golimumab in the same patient 
popul ation, only  approximately  50% to 65% of the pati ents achieved clinical response (as 
defined by co mplete May o score) at the induction time point (Weeks 6 to 8), wi th approximately  
50% of the patients maintaining clinical response up to Week 54(Rutgeerts et al. 2005; 
Sandborn et al. 2014a, 2014b).  In the pivotal ULTRA studies of adalimumab in the same patient 
popul ation, 16.5% of pat ients achi eved clinical remissio n at Week 8 (Sandborn et al. 2012a ).  
Similarly, in the pivotal GEMINI 1 study  of vedolizumab in pat ients with moderately to severely  
active disease, 47% achie ved a clinical response at Week 6,and up to 45% of these pat ients were 
in clinical remission at Week 52 (Feagan et al. 2013).  These data illustrate the unmet need for 
new med ications in UC.   
3.2.3. Interleukin -23 as a Therapeutic Target in Ulcerative Colitis
Interl eukin ( IL)
-23 is a m ember of the IL -12 family o f cytokines.  It i s a heterodimeric protein 
composed of 2 subunit s: the IL-12p40 subunit, which is shared by IL -12, and the IL-23p19 
subunit, which is specific to IL -23.
IL-23is a pro -inflammatory cytokine.  It is expressed by  activated innate immune cells, 
including dendrit ic cells and tissue -resident macrophages.  IL-23stabilizes the different iation 
and maturation of pro -inflammatory IL -23 receptor -expressing (IL -23R+) IL-17+CD4+T cells 
(Th17 cells) through mult iple mechanisms, including the maintenance of Rorc and Il17 gene 
expressio n, the induct ion of pro -inflammatory cytokine expressio n (Il22, Csf2 and Ifng),and 
positive feedback by  inducing expression of its own receptor, IL -23R.  IL-23also activates other 
IL-23R+immune cells, including γδ T cells, natural killer cells ,and group 3 innate lympho id 
cells (Gaffen et al. 2014; Teng et al. 2015).
Genet ic delet ion or pharmaco logic inhibit ion of IL -23p19 in mice ,ameliorates or prevents 
inflammat ion in mouse m odels of rheumatoi d arthri tis (collagen -induced arthrit is), mult iple 
sclerosi s (experimental autoimmune encephalo myelit is),and intest inal inflammat ion (Kikly et al.
2006).  
Interl eukin-23 expressio n is enriched in the intestine of pat ients with active UC and act ive 
Crohn’s disease.  In addition, recent genome -wide associ ation scans ident ified co mmo n variants 
(single nucleotid e polymorphisms) in mo lecules in the IL- 23 si gnaling pathway  that m odify  the 
risk of UC and/or Crohn’s disease in humans, including IL -23R, STAT3, and Janus kinase 2 
(Jostins et al. 
2012).  Taken together, these data provide evidence for IL -23 as a therape utic 
target in UC. 
I6T-MC-AMBG(a) Clinical Protocol Page 32
LY30748283.2.4. Preclinical and Clinical Studies of Mirikizumab
Mirikizumab binds to the IL-23p19 subunit of human IL -23 and prevents binding of IL -23 to the 
IL-23R, neutralizing the activit y of human IL -23 in vitro.  Mirikizumab also neutralizes human 
IL-23 in vivo, ameliorating the development of psoriasis -like skin inflammat ion in mice 
following subcutaneous (SC) inject ion of human IL -23.  Mirikizumab does not prevent IL -12 
signaling in vitro .
LSN2479016 is the mouse anti -mouse surrogate ant ibody  for mirikizumab .  This was developed 
to enable preclinical testing in mice, as mirikizumab does not cross -react with mouse IL -23.  
LSN247 9016 inhibits the development of skin inflammat ion in the imiquimod -induced 
psori asis-like mouse model, inhibits the development of colonic inflammat ion in the CD45RBhi
adoptive transfer mouse model of colit is, and reduces the development of curdlan -induced 
spondylo arthri tis and Crohn’s disease -like intestinal inflammat ion in SKG mice .  
Addit ional 
preclinical data are summarized in the Invest igator’s Brochure (IB).
A number of clinical studi esof mirikizumab have been co mpleted or are currently  ongoing in 
patients wi th psoriasis, UC, and Crohn’s disease .
Study I6T-MC-AMAA (AMAA) is a Phase 1, single -dose administration (up to 600 mg), 
dose-escalat ion study  that included 40 subjects wi th psoriasis and 5 healthy controls.  Efficacy
data from  this study  show improvement of psoriasis at Week 12,asassessed by the Psoriasis 
Area and Severit y Index(PASI), after a single dose of mirikizumab in the higher -dose cohorts .
Study  16T -MC-AMAF (AMAF) is a Phase 2, placebo -controlled, double -blind clinical tri al of 
mirikizumab in patients with psoriasis, for which preliminary primary analysis result s are 
available.  In Study  AMAF, pati ents wi th moderate -to-severe plaque psoriasis received placebo 
(n=52) or mirikizumab 30 mg (n =51), 100 mg (n =51) or 300 mg (n =51) SCat Weeks 0 
and8.  The primary  object ive was to evaluate the superiorit y of mirikizumab over pl acebo in 
achieving ≥90% improvement in Psoriasis Area and Severit y Index (PASI 90) response at 
Week 16.  The primary efficacy end po intat Week 16 was met for each dose group with PASI 90 
responses o f 0%, 29.4% (p<.01), 58.8% (p<.001) and 66.7% (p<.001), respectively , for patients 
treated with placebo and mirikizumab 30 mg, 100 mg and 300 mg(Reich et al. 2017a ). 
Study 16T
-MC-AMAC (AMAC) is a Phase 2, placebo -controlled, double -blind clinical trial o f 
mirikizumab in patients with moderate -to-severe UC, for which preliminary primary analysis 
resul ts are available.  Patients with moderately to severely act ive UC received placebo (n=63) or 
mirikizumab 50 mg (n =63), 200 m g (n=62) or 600 m g (n=61) intravenous ( IV)at Weeks 0, 4 
and 8.  Exposure -based dose adjustment swere applied in 2treatm ent groups.  Based on plasma 
concentrations of miriki zumab, dose l evels in subjects in the 50 mg and 200 mg groups could be 
increased at the Week 4 and Week 8 visit s if the projected trough concentrations for those visits 
fell below prespecified thresho lds: 73% of patients in the 50 mg mirikizumab group and 44% of 
patients in 200 m g mirikizumab group experienced exposure -based dose adj ustments before 
Week 12, resul ting in group mean doses of 100 mg and 250 mg, respectively in these groups.  
The 600
-mg dose group remained on a fixed dose throughout the induction period. The primary 
efficacy  endpoint was clinical remissio n at Week 12.  Clinical remissio n rates at Week 12 were 
I6T-MC-AMBG(a) Clinical Protocol Page 33
LY30748284.8%, 1 5.9% (p=.07), 22.6% (p<.01) ,and 11.5% (p=.14) for pati ents treated with placebo and 
mirikizumab 50 mg, 200 mg ,and 600 mg, respectively .  Clinical response rates at Week 12 were 
20.6%, 41.3%, 59.7% ,and 49.2% for pati ents treated with placebo and mirikizumab 50 mg, 200 
mg,and 600 mg, respectively .  Endoscopic healing rates ( ES=0 or1, excluding friabilit y;termed
“endoscopic remissio n” in this protocol ) were numeri cally  higher in the 50-mg mirikizumab 
group (23.8%) and 200-mg mirikizumab group (30.6%) compared to placebo (6.3%) .  
Symptom atic remissio n rates were numerically hig her in the 200-mg mirikizumab group 
(58.1%,) and 600-mg mirikizumab group (45.9%) compared to placebo (20.6%) .
Study  16T -MC-AMAG (AMAG) is a Phase 2, placebo -controlled, double -blind clinical trial o f 
mirikizumab in patients with act ive Crohn’s disease.  At the time of writ ing, this study is
ongoing.
Addit ional clinical trial data are summarized in t he IB.
3.2.5. Other IL -23 Targeted Therapies in Humans
IL-23-targeted therapy  is the m echanism o f action for several  com pounds under development for 
the treatment of inflammatory  diseases, including the human IL -12 and IL -23 antagoni st,
ustekinumab, which is a mo nocl
onal antibody  against IL -12p40, and the human IL -23 
antagonists ,guselkumab, risankizumab, tildrakizumab, and brazikumab, which are monoclonal 
antibodies against IL -23p19.
Ustekinumab binds IL -12p40, the subunit commo n to both IL -12 and IL -23, targeting both 
cytokines, rather than IL -23 specifically .  
Ustekinumab was the first bio logic therapy  with an 
anti-IL-23 acti on to show clinical benefit in psoriasis ( Leonardi et al. 2008; Papp et al . 2008), 
psori atic arthrit is (Gottlieb et al .
2009), and Crohn’s disease ( Sandborn et al . 2012b; Fea gan et al .
2016).  Blockade of the IL -12 pathway  may prevent ty pe 1 T helper cell (Th1) -induced inhibit ion 
of Th17 cell development, thus potentially  limiting the clinical act ivityof IL-
12p40- targeting 
antibodies.  Experimental studies suggest that blocking the IL -
23/Th17/IL- 17 immune axis, 
without bl ocking the IL -12/Th1/IFN -γ axis, is sufficient to treat autoimmune inflamma tion 
(Montel eone et al . 2009).
To date, guselkumab, an IL -23p19 ant ibody , has been approved for the treatment of psoriasis,
and other agents specifically targeting the IL- 23p19 subunit, including mirikizumab, have 
demonstrated clinical act ivity in psoriasis (Sofen et al. 2014; Kopp et al. 2015; Krueger et al. 
2015; Papp et al. 2015; Blauvelt et al .2017; Papp et al. 2017; Reich et al.2017b).  IL-23p19 
inhibit ion is also under investigation for the treatment of inflammatory  bowel  disease and several 
anti
-IL-23p19 ant ibodies have shown efficacy in the treatment of Crohn’s disease (Deepak and 
Sandborn 2017; Feagan et al . 201 7; Sands e t al. 2017 ).
3.3. Benefit/Risk Assessment
Ulcerat ive co litis remains an important public health challenge.  The data for currently available 
treatm ents demonstrate the unmet need for new medicat ions for UC (Section 3.2.2 ),and 
published literature supports the concept of IL- 23 as a therapeutic target for UC therapies 
(Secti on 3.2.3 ).  Based on data from the Phase 2 study of mirikizumab in pat ients with UC 
I6T-MC-AMBG(a) Clinical Protocol Page 34
LY3074828(Study  AMAC, Secti on 3.2.4 ), potential benefit s to pati ents who m ay receive mirikizumab while 
participat ing in Study AM BGmay be reasonably ant icipated.
At the time of this benefit/risk assessment, evaluat ion of unblin ded safety  data from  the 
completed or ongoing clinical studies, including the unblinded period of the Study  AMAC, 
which tests mirikizumab doses up to 600 mg IV Q4W, have not revealed any dose -related safet y 
or tol erabili ty concerns . In addit ion, evaluation of blinded safet y data in ongoing studies in 
psori asis,UC, and Crohn’s disease with doses up to 200/300 m g SC Q4W administered up to 92 
weeks ,and upto 1000 m g IV Q4W for up to 52 weeks have not revealed safet y or tol erabili ty 
concerns . Across ongoing studies, immediate hypersensit ivity react ions, including serious 
nonfatal  anaphylaxis, have been reported at the onset orduring IV infusio n of mirikizumab . As 
noted i n the IB, such react ions are considered by the sponsor to be related to mirikizumab and 
hence have been identified as adverse drug reactions (ADRs ).  Consult the most current IB for 
inform ation regarding ADRs and potential risks with mirikizumab.  
Adverse events of special interest (AESIs) —which are not necessarily ADRs but are of special 
interest based on standard drug registration to pics, safet y findings from previous studies in 
development program, potential risks associated wit h bio logic immuno modulators as noted in 
product labels and published literature, and comorbidit ies and risk factors prevalent in the 
studi ed popul ations—are n oted in Sect ion 9.2.2 of this protocol .  For all  AESIs, including 
hypersensit ivity events, the protocol and IB provide monitoring or management guidance to the 
investigator.  In addit ion, an independent, external data m onitoring committee (DMC )will 
review clinical tri al data at prespecified, regular intervals during the study  (Secti on 10.3.8 ).  Th is 
indepen dent assessment of clinical trial data will contribute to the overall ongoing evaluat ion and 
management of potential risks associated with mirikizumab administration.
The dose levels and regimens to be used in Study  AM BGwere chosen based on nonclinical 
safet y data and on analyses of safet y, efficacy, and pharmacokinetic ( PK)data from  the primary 
analysis of Study  AMAC (Secti on 5.5).
In summary, the efficacy  and safet y data fro m the Phase 2 UC study  support the conti nued 
clinical development of mirikizumab as a treatment for patients with UC.
More informat ion about the known and expected benefits, risks, serious ad
verse events (SAEs), 
and reasonably ant icipated adverse events (AEs) of mirikizumab are to be found in the IB.
I6T-MC-AMBG(a) Clinical Protocol Page 35
LY30748284.Objectives and Endpoints
Table AMBG .4.1shows the object ives and endpo ints of the study .
Table AMBG .
4.1. Objectives and Endpoints
Objective(s)/Endpoints:
Objectives Endpoints
Primarya
 To test the hypothesis that mirikizumab is superior 
to placebo in achieving clinical remission at 
Week 40 (Week 52 of continuous therapy) among 
patients induced into clinical response with 
mirikizumab in Study AMAN  The proportion of patients in clinical r emission at 
Week 40, defined as:
oStool frequency (SF) subscore = 0, or SF = 1 
with a ≥1-point decrease from induction 
baseline, and
oRectal bleeding (RB) subscore = 0, and
oEndoscopic subscore (ES) = 0 or 1 (excluding 
friability ).
Major Secondarya,b
 To evaluate the efficacy of mirikizumab compared 
to placebo in maintaining clinical remission at Week 
40 (Week 52 of continuous therapy) among patients 
induced into clinical remission with mirikizumab  The proportion of patients who were in clinical 
remiss ion at Week 40 among patients in clinical 
remission at Week 12 in Study AMAN (i.e. 
durable clinical remission). Clinical remission is 
defined as:
oSF subscore = 0 or SF = 1 with a ≥1-point 
decrease from induction baseline, and
oRB subscore = 0, and
oES subscore = 0 or 1 (excluding friability)
 To evaluate the efficacy of mirikizumab compared 
to placebo on endoscopic remission at Week 40
among patients induced into clinical response with 
mirikizumab The proportion of patients in endoscopic 
remission at We ek 40, defined as:
oES = 0 or 1 (excluding friability)
 To evaluate the efficacy of mirikizumab compared 
to placebo in achieving corticosteroid-free remission 
without surgery among patients i nduced into 
clinical response with mirikizumab and receiving 
corticosteroids at induc tion baseline Corticosteroid-free remission without surgery at 
Week 40, defined as:
oClinical remission at Week 40, and 
oSymptomatic remission at Week 28, and 
oNo corticosteroid use for ≥12 weeks prior to 
Week 40 
 To evaluate the efficacy of mirikizumab compared 
to placebo on histologic remission at Week 40
among patients induced into clinical response with 
mirikizumab Proportio n of patients in histologic remission at 
Week 40, as defined in the SAP 
I6T-MC-AMBG(a) Clinical Protocol Page 36
LY3074828 To evaluate the efficacy of mirikizumab compared 
to placebo on stable maintenance of symptomatic 
remission among patients who were induced into 
clinical response and symptomatic remission with 
mirikizumab  The proportion of patients in symptomatic 
remissio n defined as being in symptomatic 
remission for at least 7 out of 9 visits from 
Week 4 to Week 36 and being in symptomatic 
remission at Week 40 among patients in 
symptomatic remission at Week 12 of Study 
AMAN.
 Symptomatic remission is defined as:
oSF = 0, o r SF = 1 with a ≥1-point decrease 
from induction baseline and
oRB = 0
 To evaluate the efficacy of mirikizumab compared 
to placebo on bowel movement urgency 
improvement at Week 40, among patients who: (1) 
had bowel urgency symptoms at induction baseline 
and(2) were induced into clinical response with  
mirikizumab  The proportion of patients with bowel movement 
urgency improvement at Week 40 as defined in 
the study  SAP.
Other Secondary
 To evaluate the efficacy of mirikizumab compared 
to placebo in achieving clinical remission at Week 
40 among patients induced into clinical response 
with mirikizumab, in the subgroup of patients in 
whom biologic agents have failed or caused 
intolerance. Clinical remission at Week 40 in the subgroup of 
patients in whom biologic agents have failed or 
caused intolerance.  Clinical remission is defined 
as:
oSF subscore = 0 or SF = 1 with a ≥1-point 
decrease from induction baseline, and
oRB subscore = 0, and
oES = 0 or 1 (excluding friability)
 To evaluate the efficacy of mirikizumab compared 
to placebo in achieving endoscopic remission at 
Week 40 among patients induced into clinical 
response with mirikizumab, in the subgroup of 
patients in whom biologic agents ha ve failed or 
caused intolerance. Endoscopic remission at Week 40 in the subgroup 
of patients in whom biologic agents have failed or 
caused intolerance.  Endoscopic remission is 
defined as: ES = 0 or 1 (excluding friability)
 To evaluate the efficacy of mirikizumab as 
compared to placebo in maintaining clinical 
remission at Week 40 (Week 52 of continuous 
therapy ) among patients induced into clinical 
remission with mirikizumab, in the subgroup of 
patients in whom biologic agents have failed or 
caused intol erance The proportion of patients who were in clinical 
remission at Week 40 among patients in clinical 
remission at Week 12 in Study AMAN (i.e. 
durable clinical remission) in whom biologic 
agents have failed or caused intolerance.  Clinical 
remission is de fined as:
oSF subscore = 0 or SF = 1 with a ≥1-point 
decrease from induction baseline, and
oRB subscore = 0, and
oES = 0 or 1 (excluding friability)
 To evaluate the efficacy of mirikizumab compared 
to placebo in achieving corticosteroid-free remission 
withou t surgery among patients induced into 
clinical remission with mirikizumab and receiving 
corticosteroids at induction baseline Corticosteroid-free remission without surgery at 
Week 40 among induction clinical remitters, 
defined as:
oClinical remission at Week 40, and
oNo corticosteroid use for ≥12 weeks prior to 
Week 40 
I6T-MC-AMBG(a) Clinical Protocol Page 37
LY3074828 To evaluate the efficacy of mirikizumab compared 
to placebo in achieving clinical remission (using a 
more stringent ES) at Week 40  among patients 
induced into clinical response with  miri kizumab  The proportion of patients with clinical remission 
(using a more stringent ES) at Week 40, with 
clinical remission defined as:
oSF subscore = 0, or SF = 1 with a ≥1-point 
decrease from induction baseline, and
oRB subscore = 0; and
oES = 0
 To evaluate the efficacy of mirikizumab compared 
to placebo on achieving ES of 0 at Week 40among 
patients induced into clinical response with 
mirikizumab The proportion of patients achieving ES = 0
 To evaluate the efficacy of mirikizumab compared 
to pla cebo in achieving an endoscopic response at 
Week 40 among patients induced into clinical 
response with mirikizumab The proportion of patients in endoscopic 
response at Week 40 defined as:
oA decrease in ES of ≥1 point from induction 
baseline.
 To evaluate the treatment of mirikizumab compared 
with placebo on achieving the symptomatic 
components of clinical remission as defined by the 
modified Mayo score (MMS) at Week 40 The proportion of patients at Week 40 with SF 
subscore = 0, or SF = 1 with a ≥1-point de crease 
from induction baseline
 The proportion of patients at Week 40 with RB 
subscore =0 
 To evaluate the numerical value and change from 
baseline of the individual MMS subscores and the 
composite symptom subscore over time during 
maintenance between mirikizumab and placebo  The numerical value and change from induction 
baseline in each of the following items:
oSF at each post baseline visit
oRB at each post baseline visit
oES (Week 40 only)
oThe sum of the SF and RB subscores at each 
post baseline visit
 To evaluate the efficacy of mirikizumab compared 
to placebo in maintaining clinical response at
Week 40 amo ng patients induced into clinical 
response with mirikizumab Clinical response at Week 40.  Clinical response 
is defined as:
oA decrease in the MMS of ≥2 points and 
≥30% decrease from induction baseline, and
oA decrease of ≥1 point in the RB subscore or 
an RB subscore = 0 or 1
 To evaluate the efficacy of mirikizumab compared 
to placebo in reducing corticosteroid use over the 
course of maintenance treatment among patients 
induced into clinical response with mirikizumab 
and w ho entered the maintenance study on 
corticosteroids The change and percent change in daily 
(average) corticosteroid dose (prednisone 
equivalent) from maintenance baseline to end of 
maintenance study (Week 40), among clinical 
responders to mirikizumab induction who 
entered th e maintenance study on corticosteroids
I6T-MC-AMBG(a) Clinical Protocol Page 38
LY3074828 To evaluate the effect of mirikizumab compared to 
placebo in health outcome endpoints at Week 40  Change f rom inductio n baseline in:  
oIBDQ score at Week 40
oEQ-5D 5L index at Week 40
oWPAI:UC score at Week 40
oSF-36, V2 physical and mental component and 
domain scores at Week 40
 To evaluate the efficacy of mirikizumab compared 
to placebo in inducing combined clinical remission, 
with normalization of fecal calprotectin, and 
histologic remission The proportion of patient s with all of the 
following at Week 40:
oIn clinical remission, defined as:
oSF subscore = 0 or SF = 1 with a ≥1-point 
decrease from induction baseline, and
oRB subscore = 0, and
oES = 0 or 1 (excluding friability)
oIn histologic remission, as defined in the SAP
oFecal calprotectin within limits of normal 
 To evaluate the effect of mirikizumab compared to 
placebo on changes in inflammatory biomarkers  Change f rom baseline at various time points in 
the following biomarkers:
oC-reactive protein 
oFecal calprotectin
 To evaluate the efficacy of mirikizumab compared 
to placebo in achieving 24 -week corticosteroid -free 
remission without surgery among patients induced 
into clinical response with mirikizumab and 
receiving corticosteroids at induction baseline Corticosteroid-free remission without surgery at 
Week 40, defined as:
oClinical remission at Week 40, and 
oSymptomatic remission at Week 28, and 
oNo corticosteroid use for ≥24 weeks prior to 
Week 40 
 To evaluate the effect of mirikizumab compared to 
placebo on changes in Abdominal pain at Week 40 Change f rom inductio n baseline at Week 40 in the 
Abdominal pain NRS score
 To evaluate the efficacy of mirikizumab in reducing 
the proportion of patients un dergoing surgery for 
UC, colectomy, and hospitalization for UC The proportion of patients undergoing:
oSurgery  for UC (including colectomy)
oHospitalization for UC
 To evaluate the treatment of mirikizumab compared 
with placebo on achieving symptomatic remission  The proportion of patients with symptomatic 
remission at various time points, defined as:
oSF = 0, or SF = 1 with a ≥1-point decrease 
from induction baseline, and
oRB = 0
To evaluate key efficacy endpoints in biologic -failed 
and conventional -failed subgroups of patients 
(except those major secondary objectives noted 
above) Key efficacy  endpoints in the subgroup of 
patients in whom biologic agents have failed or
caused intolerance, and in whom conventional 
therapies have failed or caused intolerance
I6T-MC-AMBG(a) Clinical Protocol Page 39
LY3074828To evaluate key efficacy endpoints in the subgroups 
of patients on concomitant treatment for UC Key efficacy  endpoints in the subgroups of 
patients on concomitant medication for UC 
(corticosteroids and immunomodulators)
 To evaluate clinical remission, clinical response and 
endoscopic remission rates with extended induction 
in patients who did not respond to mirikizumab with 
initial induction  At Week 12 (Week 24 o f continuous therapy), 
oClinical remission, defined as:
oSF subscore = 0, or SF = 1 with a ≥1-
point decrease from induction baseline, 
and
oRB subscore = 0; and
oES = 0 or 1 (excluding friability)
oClinical response, defined as:
oA decrease in MMS of ≥2 points and 
≥30% decrease from induction baseline, 
and 
oA decrease of ≥1 point in the RB subscore 
from induction baseline or a RB score of 0 
or 1
oEndoscopic remission, defined as:
oES = 0 or 1 (excluding friability)
 To evaluate the e fficacy of mirikizumab compared 
to placebo on maintaining endoscopic remission at 
Week 40 among patients induced into endoscopic 
remission with mirikizumab The proportion of patients in durable endoscopic 
remission at Week 40, defined asES = 0 or 1 
(excluding friability)
 Evaluate the pharmacokinetics and 
pharmacokinetic/pharmacodynamic relationship of 
mirikizumab  Clearance and volume of distribution of 
mirikizumab
 Relationship between mirikizumab exposure and 
efficacy 
 To evaluate the potential de velopment of 
anti-mirikizumab antibodies and their potential 
relatio nship with efficacy, safety, and mirikizumab 
exposure Relationship between TE -ADA and efficacy 
 Relationship between TE -ADA and safety
 Relationship between TE -ADA and mirikizumab 
pharmacokinetics
 To evaluate the efficacy of mirikizumab compared 
to placebo in UCEIS endoscopic remission at Week 
40 among patients induced into clinical response
with  mirikizumab  The proportion of patients with a UCEIS score of 
≤1 at Week 40
 To evalu ate the efficacy of mirikizumab compared
to placebo in mucosal healing at Week 40 among 
patients induced into clinical response with 
mirikizumab  The proportion of patients with mucosal healing 
at Week 40, defined as achieveing both:  
oHistologic remission, as described in the 
SAP, and
oEndoscopic remission,  defined as ES = 0 or 
1 (excluding friability)
I6T-MC-AMBG(a) Clinical Protocol Page 40
LY3074828 To evaluate the effect of mirikizumab compared to 
placebo on change in fatigue at Week 40 Change f rom inductio n baseline at Week 40 in the 
Fatigue NRS score
Abbreviations:  EQ -5D 5L = European Quality of Life 5-Dimensions 5 Level; ES = endoscopic subscore; 
IBDQ =Inflammatory Bowel Disease Questionnaire; MMS =modified Mayo Score; NRS = numeric rating 
scale; RB = rectal bleeding; SAP = statistical analy sis plan; SF = stool frequency; SF -36 = Medical Outcomes 
Study 36 -Item Short Form Health Survey; UC = ulcerative colitis; WPAI:UC = Work Productivity and Activity 
Impairment Questionnaire Ulcerative Colitis; TE -ADA =treatment -emergent anti -drug antib ody; 
UCEIS =Ulcerative Colitis Endoscopic Index of Severity.
aAll primary and major secondary endpoints will be evaluated for mirikizumab versus placebo.   All primary and 
major secondary endpoint analyses will utilize the multiplicity control approach based on ‘graphical multiple 
testing procedure’ to control the overall family -wise type I error rate at a 2 -sided alpha level of 0.05.  The 
graphical multiple testing procedure described in Bretz et al. (2009) will be used.
bThe order of testing of the major secondary endpoints will be determined from the results of the statistical 
simulations. Therefore ,the o rder of the secondary endpoints does not reflect the order of the statistical testing.
I6T-MC-AMBG(a) Clinical Protocol Page 41
LY30748285.Study  Design
5.1. Overall Design
Study AMBG is a Phase 3, mult icenter, randomized, double -blind, placebo -controlled, 
parallel- arm study  evaluat ing the safet y and efficacy  of 200 m g mirikizumab Q4W SC in 
maintaining treatment response at Week 40 ( that is,52 weeks of continuous therapy ).  Th e study  
also willevaluate the safet y and efficacy o f:(a) extended induct ion with 300 mgmirikizumab 
IV for patients who did not have a clinical response at Week 12 ofStudy  AMAN, and (b) rescue 
induct ion for patients who achieve dclinical response in Study  AMAN and subsequent ly lose 
clinical response during Study  AMBG.   
Patient Population
Patients wi th moderately to severely act ive UC who completed Study  AMAN and who m eet 
eligibilit y requi rements will enroll in this study .  The s tudy will enroll  patients who achieve 
clinical response or clinical remissio n with blinded mirikizumab or placebo dosing in Study  
AMAN, as well as pat ients who do not achieve clinical response with blinded mi rikizumab or 
placebo during Study  AMAN.
Treatmen t Assignments
Maintenance study  treatm ent assignment will be dependent on whether patients responded to 
study  drug dosing in AMAN and whether they experi ence a lossof response (LOR) during thi s 
study  as fo llows:
Mirikizumab Responders from Study AMAN
Patients who achieve clinical response with blinded mirikizumab in induct ion Study  
AMAN will be rando mized to receive blinded 200 mg mirikizumab Q4W SC or blinded 
placebo SCQ4W (rando mized withdrawal) in a 2:1 rati o.  Randomizat ion will be 
stratified to achieve between -group com parabili ty, based on biologic-failed status ( yes or 
no), 
induction remissio n status (yes or no), baseline corticosteroi d use (y es or no), and 
region (North Am erica/Europe/Other) .
Patients will  cont inue on the randomized treatment a ssignment for the remainder of Study  
AMBG unless they develop secondary  LOR .  
Loss of Response (LOR) is defined as:
≥2-point increase fro m Study  AMBG baseline in the combined SF + RB scores 
AND co mbined SF + RB score of ≥4, on 2 consecutive visits ( ≥7days apart ), and 
with confirmat ion of negative C. difficile testing (first assessment can start as 
early  as Week 8 /Visi t 3), 
AND
Confirmed by centrally read endoscopic subscore (ES) of 2 or 3 not sooner than 
Week 12/Visit 4. 
I6T-MC-AMBG(a) Clinical Protocol Page 42
LY3074828SC dosing should be cont inued according to dosing schedule unt il endoscopy determines 
whether LOR is confirmed.  If LOR is confirmed based on endoscopy  at or after Week 12
(and C. difficile stool toxin testing is negat ive), patients will be rescued with open -label 
300 m g mirikizumab Q4W IV for 3 doses .The first IV rescue dose may be administered
as soon as LOR is confirmed by centrally  read endoscopy , if ≥7days fro m the most 
recent SC dose .  Subsequent doses will be given every 4 weeks for total of 3 doses .
If endoscopy  does not confirm secondary LOR, patients are encouraged to continue SC
study  drug dosing, m aintaining the scheduled dosing interval .  If study  drug dosing is 
continued, an addit ional endoscopy  woul d be perform ed at Week 40, early terminat ion 
visit ( ETV )or unsched uled visit ( UV
).
Patients who ,in the opinio n of the invest igator ,receive clinical benefit after com pletion 
of the LOR rescue therapy (12 weeks after first IV rescue dose) may be considered for 
enrollment into the long term  extensio n study  I6T-MC-AMAP (AMAP )to receive further 
SC dosing .Once the LOR IV rescue therapy  is initi ated, no further SC dosing will be 
available in AMBG. 
If study  drug i s discont inued, procedure sfor early termination fro m study  drug will be 
perform edand the pati ent shoul d unde rgo post-treatment follow-up as described in the 
schedule of act ivities (Section 2).
Placebo R esponders from Study AMAN
Patients who achieve clinical response with blinded placebo in the induct ion study will 
continue to receive blinded placebo for the remainder of the maintenance study .  Placebo 
SC inject ions will be administered Q4W to maintain study  blind. If LOR is confirmed 
based on endoscopy  at or after Week 12 (and C. difficile stool  toxin testing is negat ive), 
patients will  be rescued wi th open -label mirikizumab 300 m g Q4W IV for 3 doses. The 
same LOR assessments and procedures shoul d be perform ed as described for the 
mirikizumab responders from Study AMAN. 
Mirikizumab and Placebo Nonresponders from Study AMAN
Patients who do not achieve clinical response to blinded mirikizumab or blinded placebo 
inStudy  AMAN will receive open -label extended induct iontherapy  with300mg
mirikizumab IVat Weeks 0, 4, and 8
, and undergo endoscopy  at Week 12 .
Patients who achieve delayed clinical response (compared toinduct ion study baseline)
withextended mirikizumab induct iontherapy at Week 12 may subsequent ly receive 
open -label 200 mg mirikizumab Q4W SC starting at Week 12 .  Patients will cont inue on 
this dose regimen and undergo endoscopy  at Week 40.  Pati ents who, in the opinio n of 
the invest igator, receive clinical benefit may be considered for enrollment into the long 
term extensio n study  AMAP to receive further SC dosing.  Patients who discont inue 
study  drug before Wee k 40 will undergo endoscopy and procedures for early  terminat ion 
of the study  drug, including post-treatm ent follow-up as described in the schedule o f 
activit ies(Sect ion 2).
I6T-MC-AMBG(a) Clinical Protocol Page 43
LY3074828Patients who do not achieve clinical response to mirikizumab IV extended induct ion
therapy  at Week 12 , com pared to induct ion baseline, will discont inue study  drug and 
undergo procedure sfor early terminat ion of the study  drug ,including post-treatm ent 
follow-up as describe din the schedule of activit ies(Section 2).
Post-Treatment Follow -up Period
Patients will  undergo a maximum 16-week post -treatment fo llow -up period:
 Patients who discont inue study  drug wi th last dose administered IV will return for post -
treatm ent follow-up visits (Visi t 801 and 802) at 4 and 16 weeks after the 
end-of-treatm ent visi t. 
 Patients who discont inue study  drug with last dose administered SC will return for post -
treatm ent follow-up visit s(Visi t 801 and 802) at 4 and 12 weeks after the 
end-of-treatm ent visi t.
 Patients who subsequently enter the l ong term  extensio n study  AMAP do not need to 
complete the post- treatm ent follow-up peri od. 
Figure AMBG. 5.1illustrates the study  design.   Study  governance considerat ions are described in 
detail in Appendix 3 .
I6T-MC-AMBG(a) Clinical Protocol Page 44
LY3074828Figure AMBG. 5.1. Illustration of study design for Clinical Protocol I6T -MC-AMBG.Miri 200 mg Q4W SC
Placebo Q4W  SC
Placebo Q4W SC
PlaceboIV
Weeks          W0 W12                                                      W40                 
W12 of
Induc tion StudiesW52 continuous treatment 
End of Treatment VisitRBlinde d Ra ndomized Withdra wal Maintenance Period Blinde d Induction 
Study
For eligible  pati ents 
who complete W eek 
40 or LOR IV Re scue:  
Long Term  
Extension Study  
(AMAP ) 
For patients who 
discontinue study 
drug (SC or IV):
Post -Treatm ent 
Follow-Up Period2:1 Mi ri: PBO
Placebo IV 
D/C MiriOL Miri 200 mg Q4W SC
Responders Responders
Miri IV 300 mg NonrespondersLORa AMAP
D/C Miri  
LORa
LORa OL Miri 300 mg 
Q4W IV (x 3 doses)
Nonres pond ersBlinded Induction 
StudyOL               
Extended InductionStudy AMAN Study AMBG
OL Maintenance PeriodClin. 
Bene fit
Clin. 
Benef it
Clin. 
Benef itYes
YesYesNo
No
YesYes AMAP
AMAPNo
No D/C Miri D/C Miri 
(x3 dos es)OL Miri 300 mg Q4W IV OL Miri 300 mg 
Q4W IV (x 3 doses)OL Miri 300 mg 
Q4W IV (x 3 doses)Miri IV 300 mg 
I6T-MC-AMBG(a) Clinical Protocol Page 45
LY3074828Footnotes for Figure AMBG. 5.1
Abbreviations: D/C = discontinue; IV = intravenous; LOR = lossof response ; 
Miri = mirikizumab; OL = open -label; PBO = placebo; Q4W =every 4weeks; 
R = randomization; RB = rectal bleeding; SC = subcutaneous ; SF = stool frequency ; 
W = week.
Note:  LOR is defined as ≥2-point increase from maintenance baseline in the combined 
SF + RB scores, AND combined SF + RB score of ≥4 on 2 consecutive visits, AND 
confirmed by an endoscopic subscore of 2 o r 3.
a = Loss of response at or after Week 12 and up to and including Week 28 .
5.2. Number of Participants
The number of participants in Study  AMBG will depend on the number of patients complet ing 
the induction study and who fulfill the enrollment criteria. It is estimated that approximately 
1044 patients will enter Study AMBG fro m the inducti on study AMAN as eit her induct ion 
responders or nonresponders .
5.3. End of Study Definition
End of study is the date of the last visit or la st schedul ed procedure shown in the Schedule of 
Activities(Secti on 2)for the last patient .
5.4. Scientific Rationale for Study Design
The Phase 3 clinical trial program of mirikizumab in patients with moderate -to-severe UC 
consists of the fo llowing studi es:
StudyAMAN:  Aninduct ion study with a 12 -week treatm ent durati on.
Study  AMBG:  A maintenance study  with a 40
-week treatment duration.
Study  AMAP:  An open -label long -term extensio n study .
Study  AMBG is designed to evaluate the maintenance o f efficacy with blinded 200mg 
mirikizumab Q4W in pat ients induced into clinical response with mirikizumab during the 
12-week induction study , Study  AMAN.  Study  AMAN includes patients with moderate to 
severely  active UC.  
Randomized withdrawal of mirikizumab clinical respo nders from Study  AMAN to either 
placebo or continuat ion of mirikizumab administered SC ,will enable evaluat ion of the benefit s 
of maintenance dosing of mirikizumab following induct ion dosing.  
Because rando mized withdrawal of mirikizumab clinical responders to placebo may precipitate 
secondary  LOR ,300 m g mirikizumab IV rescue will be provided to LOR patients who l ose 
response after pati ents have completed at least 12 weeks of the maintenance study .  
Loss of 
response will be defined based on symptomat iccriteria (that is, SF and RB ) confirmed by 
endoscopi c criteria(see Secti on 5.1). 
The 40-week durati on of  this study  provi des a total of 52 weeks of cont inuous therapy (induction 
and maintenance) for mirikizumab patients who complete the 12-week induct ion study .  The 
40-week duration of rando mized wi thdrawal in the maintenance study  is expecte d to provide 
I6T-MC-AMBG(a) Clinical Protocol Page 46
LY3074828adequate time for separation of efficacy effects between mirikizumab and placebo a rms based on 
the approximate 10 -day half-life of mirikizumab . 
The primary  endpoint tests whether mirikizumab maintains clinical remissio n among pat ients 
who achieved clinical remissio n to induction treatment with mirikizumab . Clinical remissio n is a 
clinically relevant composite endpo int, as it com bines symptomat ic improvement as well as 
endoscopi c remissio n (anti
-inflammatory  effect) in the indiv idual patient.
Patients are allowed to remain on a stable background dose regimen o f convent ional UC 
therapi es during the study , except for oralcorticosteroi ds.  Corti costeroi d tapering using a 
standardized algorithm will be mandated per protocol for patients who achie ve clinical response 
to study  drug in Study  AMAN, or wi th extended induction for nonresponders from Study  
AMAN (see Secti on7.7).
Patients randomized to placebo in Study  AMAN and who achieved clinical response will be 
assigned to blinded placebo maintenance dosing in Study AMBG. These patients provide “true” 
placebo data for evaluat ion of safet y and efficacy  outcomes. Patients will continue on blinded 
placebo unless they  meet the criteria for LOR, at which point they will receive rescue treatment 
with mirikizumab 300 m g Q4W IV for 3 doses . 
An extended induction is available to pati ents who do not achieve clinical response at the end of 
the induction study .The extended induct ion dosing will only include IV mi rikizumab and is 
intended to increase the likelihood of the patient achieving clinical response. Patients who di d 
not respond to blinded placebo therapy  in the previous induct ion study will receive IV 
mirikizumab for the first time in Study  AMBG .
A daily  diary  will be used to record PROs, including SFand RB.  Use of a daily diary to collect 
data over a short recall period offers potential advantages over collect ing data intermittent ly at 
clinic visits .  
Daily diary entries will be used to assess the effect of mirikizumab onachieving the 
primary  and secondary endpoints .  
5.5. Justification for Dose
The maintenance dose regimen selected for this study  wasbased primarily on analyses o f interim 
PK, safet y, and efficacy  data f rom the Phase 2 Study  AMAC, safet y data from  other clinical 
studi es evaluat ing mirikizumab, and nonclinical safet y data.
Safety Consi derations
The safet y data collected in completed and ongoing clinical studies and in nonclinical toxico logy 
studi es support the proposed dose regimen .  In particular, there were no dose -related safety  or 
tolerabilit y issues observed in Study AMAC in patien tswith UC, for a peri od of  up to 92 week s
with doses up to 200 mg SC Q4W .
Single IV doses of up to 600 mg were evaluated in Study  AMAA (healt hy subjects and psoriasis 
patients) and up to 1200 mg in Study  I6T-JE-AMAD (AMAD) (healt hy subjects); no dose -
related safet y or tol erabili ty issues were observed in either study .  Study  AMAG i s evaluat ing 
dose regimens o f up to 1000 mg IV Q4W for up to 52 weeks in pat ients with Crohn’s disease , 
I6T-MC-AMBG(a) Clinical Protocol Page 47
LY3074828and up to 92 weeks with 300 mg SC Q4W .  Eval uation of  the unblinded safet y data available to 
date in the ongoing Phase 2 study  in pat ients with psori asis (Study AMAF ) and of the blinded 
safet y data available to date in the ongoing Phase 2 study  in pat ients with Crohn’s disease (Study  
AMAG) has not revealed a safet y concern that differs fro m the safety  findings noted for Study  
AMAC.
The nonclinical safet y profile of mirikizumab supports the proposed clinical study  on the basis of 
the no-observed- adverse -effect l evels (NOAELs) established in studies in monkeys.  The m argin 
of safet y (MOS) for the 300 mg Q4W (IV) LOR dose regimen proposed relat ive to the NOAEL 
level in the 6 -month nonclinical toxico logy study  in cyno molgus monkeys is 6.5, base d on area 
under the plasma concentration versus t ime curve. The MOS for the maintenance dose of 200 
mg Q4W (SC) is 23.
Considerations of Efficacy and Exposure -Response Relationship
200 mg SC Q4W Maintenance Dose Regimen
The available data from the maintenance period of Study AMAC indicate that the rates for 
efficacy  endpoints at Week 52 were similar between the 200 m g SC Q4W and 200 mg SC Q12W 
mirikizumab maintenance groups, although there was a trend for higher rates across clinical and 
symptom atic remissio n and response endpo ints in the Q4W group.  E xaminat ion of the rectal 
bleeding timecourse shows a pattern of loss of response before each dose administration in the 
200 m g SC Q12W arm .  Thi s suggest ion of increased bleeding between doses accompanies a 
finding that Q12W dosing results in mirikizumab trough concentrations below quant ifiable 
detection limit s at time periods between dos ing.  External experts have interpreted these patterns 
to suggest that Q12W dosing is inadequate on the basis of inadequately -treated underlying 
inflammat ion,as well as on the basis of bleeding symptoms between doses.  The Q12W regimen 
produced a more int ermittent mirikizumab concentration profile, while the Q4W concentration 
profile was more consistent, which may correl ate wi th more consistent m aintenance of lower 
(better) rectal  bleeding subscores.  The Q4W regimen also produced trough concentrations tha t 
were similar to the Week -12 trough concentration produced in the 200 mg induct ion cohort that 
achieved the best efficacy .  Subjects that achi eved clinical response or clinical remissio n at 
Week 52 al so tended to have higher maintenance exposures.  
There fore,a maintenance dose regimen of 200 mg SC Q4W was selected for Study  AMBG.
300 mg IV Q4W Loss of Response Dose Regimen
The dose regimen selected for patients that lose response du ring m aintenance isthe same dose 
and regimen as used during the 12-week induction study ,AMAN. The induct ion dose and 
regimen was based on the observed data in the Phase 2 study ,AMAC ,that showed s ignificant 
efficacy  relative to pl acebo at Week 12 in the 50-mg and 200-mg IV Q4W cohorts .  Due to the 
applicat ion of exposure- based dose adjust ments in Study  AMAC, the overall average induct ion 
dose received by subjects in the 50- and 200 -mg cohorts were 100 and 250 mg, respectively.   
Although exposure increased in proportion to dose, p atients in the 600- mg mirikizumab cohort 
did not respond bett er to treatment at Week 12 than patients in the 200 -mg mirikizumab cohort.  
I6T-MC-AMBG(a) Clinical Protocol Page 48
LY3074828Examinat ion of the relationship between observed individual subject mirikizumab exposures and 
Week 12 clinical response and remissio n,and model based analyses of these relat ionships,
suggests that the probabilit y of a subject achieving these clinical endpoints was not strongly  
dependent on exposure within the range of exposures that were evaluated in Study AMAC.  
However, model based analyses of the relat ionship between mirikizuma b exposure and reduction 
in the modified May o Score (MMS) at Week 12 indicated that doses below 300 mg may lead to 
decreased efficacy , while doses above 300mg are not likely to provide meaningful improvements 
in efficacy .  Furtherm ore, a dose of 300 mg is expected to produce a median average 
concentration that covers approximately  90% of individual subject exposures observed in the 
200-mg cohort in Study AMAC.  
Therefore, the observed results in Study  AMAC and the analyses o f exposure -response 
relationship s support the select ion of 300 mg IV Q4W for subjects that lose response during 
maintenance in Study  AMBG.
I6T-MC-AMBG(a) Clinical Protocol Page 49
LY30748286.Study  Population
Study  AMBG is a continuat ionof the induct ion StudyAMAN. The AMBG patient populat ion 
will consist of patients who complete Study AMAN through Week 12 and who meet all Study  
AMBG enrollment criteria ,irrespect ive of their treatm ent assignment in Study AMAN and their 
clinical response to the investigat ional product in that study .
Patients will  enter Study  AMBG direct ly from Study AMAN once they  sign a study -specific 
Institutional Review Board/Ethi cs Co mmittee -approved informed consent .A patient is 
considered enro lled into the study  once the pati ent is rando mized and assigned to treatment.  
Besides a m aximum  14-day window between the start of the Visit 5 (Week 12 ) visit of the 
induct ion study AMAN and the start of Visit 1 (Week 0) of Study  AMBG, n o screening period i s 
allowed for Study  AMBG. Data collected during the last visit of the induct ion study AMAN, 
including laboratory  evaluat ions, endoscopy , and PRO data, will be used to review enrollment
criteria for Study  AMBG. A visit window (14 days) is provi dedto allow laboratory resul ts and 
central  reading of the endoscopy  to be available for the invest igator to appropriately evaluate a 
patient and to ensure compliance with enrollment criteria. Patients who do not meet one or m ore 
hepat ic or hematologic laboratory  enrollment criteria may have these blood measures repeated 
one time at the investigator’s discret ionprior to study  entry ,as long as all  testing i s completed 
within 14calendar days fro m the start of theVisit 5 (Week 12 )visit ofStudy  AMAN .Patients 
who terminate from the induct ion study early for any  reason or permanently discont inue study  
drug during the induct ion study are not eligible to enter Study AMBG.
Prospective approval o f protocol  deviati ons to recrui tment and enro llment criteria, also known as 
protocol  waivers or exempt ions, are not permitted.
6.1. Inclusion Criteria
Patients are eligible to be included in the study  only  if they  meet all  of the f ollowing criteria at 
maintenance study  baseline, unless specifically  defined :
Informed Consent
[1.] Have given written informed consent approved by the ethical revie w board 
(ERB) governing the site prior to any  study -specific procedures being 
completed.
Patient Characteristics
[2.] Havecompleted Study  AMAN through the Week 12 visit (Visit 5) and have a 
Visit 5 MMS and have received at l east 1 study drug administration without 
early  terminat ion of study  drug .
[3.] Are willing and able to complete the scheduled study  assessments, including 
endoscopy  and daily  diary entry . 
I6T-MC-AMBG(a) Clinical Protocol Page 50
LY3074828[4.] Contraception 
[4a.] M ale pati ents:
No m ale contraception required except in compliance wit h specific 
local government study  requi rements
[
4b.] F emale pat ients:
Women of childbearing potential:
A.Must test negative for pregnancy prior to init iation of treatment as 
indicated by  a negat ive urine pregnancy test at V isit 1/Week 0 of this 
study .
AND
B.Must agree to either remain abstinent ,if complete abstinence is their 
preferred and usual lifest yle, or remain in same -sex rel ationships, if part 
of their pref erred and usual lifest yle, without sexual relat ionships wi th 
males.   
Periodic abst inence (for example, calenda r, ovulati on, 
symptothermal, or post -ovulation methods), decl aration of  abst inence 
just for the duration of a trial, and withdrawal are not acceptable 
methods of contraception.
OR
Must use 2 effect ive methods of contraception for the ent irety of the 
study .  Abst inence or con tracepti on m ust continue fo llowing co mpletion 
of study  drug administrati on for 20 weeks
i.2 effect ive methods of contraception (such as male or female 
condoms with spermicide, diaphragms with spermicide or cervical 
sponges) will be used .  The pati ent m ay choose to use a double 
barrier m ethod of contraception.  Barrier protection methods without 
concomitant use of a spermicide are not a reliable or acceptable 
method.  Thus, each barrier method must include use of a 
spermicide.  It should be noted that the use of male and female 
condoms as a double barrier method is not considered acceptable due 
to the high failure rate when these methods are combined.
ii.Of note, 1 of the 2 methods of contraception may  be a hi ghly 
effect ive (less than 1% failure rate) method of contraception (such as 
combinat ion oral  contraceptives, implanted contraceptives or 
intrauterine devices).
I6T-MC-AMBG(a) Clinical Protocol Page 51
LY3074828Women not of childbearing potential may participate and include those who are :
A.Infert ile due to surgical sterilization (hy sterectomy, bilateral  
oophorectomy , or tubal  ligation), congenital ano maly ,such as mullerian 
agenesis; or
B.Postmenopausal  
–defined as either 
i. Awoman at l east 50 years of age with an intact uterus, not on 
horm one therapy , who has had either 
 Cessati on of  menses for at l east 1 y ear or 
 At least 6 m onths of spontaneous amenorrhea with a 
follicle -stimulat ing horm one (FSH) >40mIU/mL; or
ii. Awoman 55 y ears or ol der not on hormone therapy , who has had at 
least 6 m onths of spontaneous amenorrhea; or
iii. Awoman at l east 55 years of age with a diagnosis of menopause prior 
to starti ng horm one repl acement therapy .
[5.] Have docum entati on of the following:
[
5a.] Asurveillance co lonoscopy  (perf ormed according to local standard) 
within 12 m onths before baseline for:
Patients wi th pancolit is of >8 years’ durati on, or
Patients wi th left-sided co litis of >12 y ears’ duration, or
Patients wi th primary  sclerosing chol angitis.
OR
[5b.] In patients for whom Inclusion Criterion [ 5a] does not apply, 
up-to-date screening for colorectal  cancer (performed according to 
local standard) .  
A full colonoscopy  can be perform ed as part of the Week 12 procedures inStudy  
AMAN to satisfy this inclusio n criterion for Study  AMBG.  
I6T-MC-AMBG(a) Clinical Protocol Page 52
LY30748286.2. Exclusion Criteria
Patients will be excluded fro m study  enro llment if they meet any o f the following cri teria at
maintenance study  baseline, unless specifically  defined :
Gastrointe stinal Exclusion Criteria
[6.] Have been diagnosed during the previous induct ion study AMAN with 
Crohn’s disease orInflammatory  Bowel  Disease -Unclassified ( IBD- U, 
formerly known as indeterminate colit is).
[7.] Have had bowel resect ion or other surgery  for the treatm ent of UC during the 
previ ous induct ion study AMAN ,or are likely to require surgery  for the 
treatm ent of UC during Study  AMBG . 
[8.] Have evidence of colonic dysplasia (including dysplasia in flat mucosa or 
dysplasia -associ ated l esion or m ass[DALM ]) at maintenance baseline ( Study  
AMAN Visit 5 [Week 12]endoscopy ) or have been diagnosed with cancer of 
the gastrointestinal tract during Study  AMAN . 
[9.] Have current adenomatous polyps that have not been removed .  Once 
removed ,the patient m ay be eligible for study after confirming no dysplasia 
or malignancy on l ocal histol ogy report .  
Infectious Disease Exclusion
[10.] Have been diagnosed with clinically important infection including ,but not 
limited to, hepatit is B, hepatit is C, HIV/AIDS, and active tuberculosis (TB)
during the induction study AMAN.
[11.] Have detectable hepat itis B virus ( HBV )DNA detected at any  time in Study  
AMAN 
[12.] Have been diagnosed with latent TB during the induction study AMAN and 
arenot willing to comply wit h complet ing TB t reatment as appropriate .
[13.] Intend to receive a Bacillus Calmette -Guerin (BCG) vaccinat ion or live 
attenuated vaccine(s) during the study .
General Exclusion Criteria
[14.] Initiation of a new prohibited medication (see Appendix 8 )during the 
induct ion study AMAN .
[15.] Presence of a hepat ic or hematologic laboratory  abnorm alityprior to 
Visit1/Week 0that woul d requi re perm anent di scontinuat ion from study 
drug ( seeSectio n 8.1.1 ).
I6T-MC-AMBG(a) Clinical Protocol Page 53
LY3074828[16.] Presence of significant uncontrolled neuropsy chiatri c disorder or j udged at 
risk of suicide in the opinion o f the invest igator; 
OR
Marked “yes”to Col umbia -Suici deSeverit y Rating Scale (C -SSRS) question 
4 or 5 on i deation prior to dosing;
OR
Marked “yes” to C -SSRS suicide behaviors questions prior to dosing at 
Week 0; 
AND
The ideat ion or behavior occurred within the past mo nth. 
[17.] Have an unstable or uncontrolled illness, including ,but not limited to ,
cerebro -cardiovascular, respiratory , gastrointestinal (excluding UC), hepat ic, 
renal, endocrine, hematologic or neurological disorders or malignancy that 
woul d potentially affect patient safet y within the study  or confound efficacy  
assessment.
[18.] Have a known systemic hypersensit ivity to any  component of this 
investigat ional product, or has experienced an acute systemic hypersensit ivity 
event wi th previ ous study  drug administration, that precludes mirikizumab 
therapy .
[19.] Are pregnant, l actati ng, or pl anning pregnancy (women only) while enrolled 
in the study , or wi thin 12 w eeks after receiving the last dose of study  drug (or 
within 20 weeks if pat ient received less than 2 SC doses and decide sto 
terminate study  parti cipat ion early for any  reaso n during Study AMBG) .
[20.] Became aLilly emplo yee, employeeof thirdparty  organi zations involved 
with the study , or invest igator site personnel directly affiliated with this study  
and/or their immediate families, during theprevious induct ion study AMAN .  
[21.] Have enro lled in another clinical trial invo lving an invest igational product or 
nonapproved use of a drug or device during Study  AMAN , OR are currently 
enrolled in any other clinical study  involving an investigational product or 
any other ty pe of medical re search j udged not to be sci entifically or 
medically co mpat ible with this study.
[22.] Have previously co mpleted or withdrawn fro m Study  AMBG or any  other 
study  invest igating mirikizumab ,except for completion of 12 weeks of 
induct ion study AMAN . 
[23.] Are unwilling or unable to comply  with the use of a data collect ion device to 
directly record data from the patient daily for the durati on of  Study  AMBG ,
or are unable to complete other study procedures. 
I6T-MC-AMBG(a) Clinical Protocol Page 54
LY30748286.3. Lifestyle Restrictions
Study  parti cipants shoul d be instructed not to donate blood or blood products during the study  
andfor 20weeks fo llowing their last dose (if last dose is given IV) or for 16 w eeks following 
their last dose (if last dose is given SC).  In order to particip ate in the study , pati ents m ust agree 
to the contraception, reproduction and breast feeding criteria detailed in inclusio n criterion [4] 
and exclusio n criterion [19].
6.4. Screen Failures
As described in Section 6, patients will  be entered into Study  AMBG direct ly from 
Study AMAN , with amaximum 14-day window between start of the Visit 5 ( Week 12)visit of 
the induction study AMAN and start of Visit 1 (Week 0) of Study AMBG . 
Data collected during the last visit of the induction trial will be used to review enrollment criteria 
and the suitabili ty of an inducti on pat ient proceeding to Study  AMBG .Patients who do not meet 
enrollment criteria m ay have one or more bl ood measures repeated on e time ,at the investigator’s 
discreti on,prior to study  entry  as long as all  testing is com pleted wi thin 14 calendar days fro m 
the start of the last induct ion visit .
I6T-MC-AMBG(a) Clinical Protocol Page 55
LY30748287.Treatment s
7.1. Treatments Administer ed
The treatments to which pat ients will be rando mized or assigned to will depend upon their 
clinical response at Visit 5 ( Week 12 )of induct ion study AMAN (Figure AMBG. 5.1).  Patients 
who achieved clinical response during the induct ion study  (defined in Table AMBG. 9.1) will 
follow the treatment regimens described in Table AMBG. 7.1.  Patients who did no tachieve 
clinical response during the induction study will follow the treatm ent regimens described in 
Table AMBG .7.2. Importantly , to preserve thestudy  blind:
All Study  AMAN responders, regardless of Study  AMBG treatm ent assignment, will be 
administered study  drug in Study AMBG in the same manner:
oBlinded SC study  drug for maintenance dosing , and open -label 300 mg
mirikizumab IV rescue dosing if they develop secondary LOR.
All Study  AMAN nonresponders will be administered study  drug in Study AMBG in the 
same m anner :
oOpen-label 300 m gmirikizumab IV, followed by open -label 200mg 
mirikizumab SC dosing if they  dem onstrate delayed clinical response with 
extended induct ion. 
Patients who m eet all criteria for enrollment and who have achieved clinical response to 
mirikizumab at the end of induct ion study AMAN will be rando mized 2:1 to double -blind 
treatm ent wi th either 200 m g mirikizumab Q4W SC or pl acebo Q4W SC at Visit 1.  Pati ents who 
achieved clinical response to placebo at the end of the induct ion study AMAN will continue to 
receive blinded placebo Q4W SC during the maint enance study  starting at Visit 1.
If the patient experiences LOR to either 200mg mirikizumab Q4W SC or to placebo Q4W SC at 
or after Week 12 of Study  AMBG, they  will receive rescue with open -label300 m g mirikizumab
IV Q4W for 3 doses.  Induction -study placebo responders who experience LOR on SC placebo 
will also receive open -label mirikizumab IV 300 mg Q4W for 3 dose s. No further treatment 
adjustm ents are permi tted. Once IV LOR dosing is co mplete, patients who, in the opinio n of the 
investigator, are receiving clinical benefit from mirikizumab therapy  may be considered for 
enrollment into the long term extensio n study  AMAP to receive further SC dosing. 
Patients who 
are not considered by the investigator to be receiving clinical benefit fro m mirikizumab IV 
rescue therapy ,will be di scontinued and procee d to post-treatm ent follow-up. 
Patients who m eet all enrollment criteria and who did not respond to study drug (either 
mirikizumab or placebo) in induct ion study AMAN will enter Study  AMBG as nonresponders. 
All induct ion nonresponders will receive open -label extended induction dosing wit h 300 m g 
mirikizumab IV Q4W for 3 doses . Patients who achieve delayed clinical response to
mirikizumab IV extended induct ion therapy  at Week 12, com pared to induction baseline, will 
subsequent ly receive open -label 200mg mirikizumab Q4W SC inject ions for the rem ainder of 
the 40-week treatment period. Patients who do not achieve clinical response to mirikizumab IV 
extended induct ion therapy  at Week 12 will discontinue study  drug and undergo early 
termination procedures andproceed to post-treatment fo llow-up.  
I6T-MC-AMBG(a) Clinical Protocol Page 56
LY3074828Table AMBG. 7.1. Treatment Regimens: Induction Clinical Responders
RegimenDose
Weeks 0 -8Dose
Weeks 12-40
Responders to blinded mirikizumab in induction study
Randomized
2:1Blinded 200 mg 
mirikizumab
Q4W SCWeeks 0, 4, 8 Continue blinded 200 mg mirikizumab SC at 
Weeks 12, 16, 20, 24, 28, 32, 36
Or, if LOR anytime between Week s12and 28 (inclusive) :
Change to open-label 300 mg mirikizumab IV 
Q4W for 3 doses
If no clinical benefit after 3 doses of rescue IV 
induction with mirikizumab , then discontinue 
mirikizumab
If clinical benefit ,may proceed to Study AMAP
Blinded Placebo
Q4W SCWeeks 0, 4, 8 Continue blinded placebo at Weeks 12, 16, 20, 24, 
28, 32, 36
Or, if LOR anytime between Weeks 12 and 28 (inclusive):
Change to open-label 300 mg mirikizumab IV 
Q4W for 3 doses
If no clinical benefit after 3 doses of rescue IV 
induction with mirikizumab , then discontinue 
mirikizumab
If clinical benefit ,may proceed to Study AMAP
Responders to blinded placebo in induction study
Blinded Placebo
Q4W SCWeeks 0, 4, 8 Continue blinded placebo at Weeks 12, 16, 20, 24, 
28, 32, 36
Or, if LOR anytime between Weeks 12 and 28 (inclusive):
Change to open-label 300 mg mirikizumab IV 
Q4W for 3 doses
If no clinical benefit after 3 doses of rescue IV 
induction with mirikizumab, then discontinue 
mirikizumab
If clinical benefit ,may proceed to Study AMAP
Abbreviations:  IV = intravenous; LOR = loss of response (defined as ≥2-point increase from maintenance baseline 
in the combined SF + RB scores, AND combined SF + RB score of ≥4 on 2 consecutive visits, AND confirmed by 
endoscopic subscore of 2 or 3); OL= open-label; Q4W =every 4 weeks; RB = rectal bleeding; SC =subcutaneous; 
SF=stool frequency .
I6T-MC-AMBG(a) Clinical Protocol Page 57
LY3074828Table AMBG .7.2. Treatment Regimens: Induction Clinical Nonresponders 
RegimenDose
Weeks 0 -8Dose
Weeks 12 -40
Nonresponders to blinded mirikizumab IV in induction study
Open -label 300 mg mirikizumab IV Weeks 0, 4, 8 Wee k 12 Extended Induction Responders
Open -
label 200 mg mirikizumab SC at Weeks 12, 
16, 20, 24, 28, 32, 36; t hen may  proceed to Study 
AMAP
If clinical benefit is lost, discontinue mirikizumab 
and enter post -treatment follow -up period
Week 12 Extended Induction Nonresponders:
Discontinue mirikizumab
Nonresponders to blinded placebo in induction study
Open -label 300mg mirikizumab IV Weeks 0, 4, 8 Wee k 12 Extended Induction Responders
Open -
label 200 mg mirikizumab SC at Weeks 12, 
16, 20, 24, 28, 32, 36; t hen may  proceed to Study 
AMAP
If clinical benefit is lost, discontinue mirikizumab 
and enter post -treatment follow -up period
Wee k 12 Extended Induction Nonresponders:
Discontinue mirikizumab
Abbreviations:  IV = intravenous; SC = subcutaneous .
Study Drug Administration
Subcutaneous administration of mirikizumab or placebo will be given in 2 injections (maximum 
volume is 1mL per inject ion).  
Intravenous infusio n of mirikizumab will occur over at l east 30 minutes.  All pat ients should be 
monitored for 1 hour or longer after dosing, or longer accordi ng to invest igator practice or local 
standard of care.  Sites m ust have resuscitat ion equipment, emergency medicat ions, and 
appropriately  trained staff available during the infusion and monitoring period.   Detailed 
instructi ons for invest igational product administratio n will be provided separately by  the sponsor.  
Invest igational product will be prep ared at the si te by  blinded pharmacists or other trained and 
qualified personnel as designated by  the invest igator. Invest igational product will be 
administered at the site by  a blinded nurse, pharmacist ,or other trained and qualified personnel 
as design ated by  the invest igator.
The invest igator or his/her designee is responsible for the fo llowing:
Explaining the correct use of the invest igational agent(s) to the si te personnel 
Verifying that instructions are fo llowed properly
Maintaining accurate record s of invest igational product dispensing and co llection
I6T-MC-AMBG(a) Clinical Protocol Page 58
LY3074828At the end of the study  returning all unused medication to Lilly, or its designee, 
unless the sponsor and sites have agreed all unused medicat ion is to be destroyed 
by the site, as allowed by local law .
7.1.1. Packaging and Label ing
Mirikizumab and pl acebo will  be supplied to the investigator by  Lilly or i ts desi gnee.  Clinical 
trial materials will be labeled according to the country ’s regul atory  requi rements.  All 
investigat ional products will be stored, inventoried, reconciled, and destroy ed according to 
applicable regulat ions.  Clinical trial materials are manufactured in accordance wit h current 
Good Manufacturing Practic es(GMP) .
Study  drug will be supplied as: 
Single -use so lution pre -filled syringe containing mirikizumab or placebo.  The 1-mL 
syringe of mirikizumab is manufactured to deliver 100mg.  
Single -use so lution vial containing mirikizumab .  The 15
-mL vial o f mirikizumab is 
manufactured to deliver 300mg (20 mg/ml).  
Mirikizumab cannot be di stinguished visually from placebo.
Study  drug will be provided with study -specific labels.  Sy ringes and vials will be supplied in 
cartons, with the appropriate quantit y specific to the pl anned dispensing schedule of the 
investigat ional product. No concomitant UC therapies will be provided by Lilly  or its designee.
7.2. Method of Treatment Assignment
Assignment to treatment groups for patients entering Study AMBG as clinical responders will be 
determined by a co mputer -generated random sequence using an interactive web -response system 
(IWRS) in adoubl e-blind manner .  To achieve between -group com parabili ty, pati ents will  be 
stratified to these arms based upon biologic-failed status (yes or no), baseline corticosteroi d use 
(yes or no), region (North America/Europe/Other) ,andinduct ion remissio n status (yes or no).  
This stratificat ion will be controlled by  IWRS.  
7.2.1. Selection and Timing of Doses
The doses will be administered at each scheduled visit as described in the Schedule of Act ivities
(Secti on 2).  The actual time of all dose administrations will be recorded in the patient’s 
electroni c case report form (eCRF ). Doses, other than rescue mirikizumab IV doses, should n ot 
be administered during unscheduled visits ,unless the unscheduled visit occurs during the next 
scheduled dosing window. Rescue mirikizumab IV doses may be administered during 
unscheduled visits if LOR has been confirmed and if it is ≥
7days fro m the most recent SC dose.  
Subsequent rescue mirikizumab IV doses will be given every  4 weeks (+/-3 day s)for total  of 
3doses.
7.3. Blinding
This is a double -blind study .  To preserve the blinding of the study , a minimum  number of Lilly  
personnel wi ll have access to the randomizat ion table and treatment assignments before the study 
I6T-MC-AMBG(a) Clinical Protocol Page 59
LY3074828is co mplete. These personnel will not have co mmunicat ion with site personnel. No unblinding 
at the investigational site for invest igational product preparation will be r equired.  A blinded 
study  site pharmacist or other trained and qualified person will prepare the invest igational 
product .
Emergency  unblinding for AEs m ay be perform ed through the IWRS , which m ay supplement or 
take the place of emergency  codes generated by a com puter drug -labeling system.  This option 
may be used ONLY if the patient’s well -being requires knowledge of the pati ent’s treatm ent 
assignment.  All notifications result ing in an unblinding event are recorded and reported by  
theIWRS .
In case of an e mergency, the invest igator has the sole responsibilit y for determining if unblinding 
of a pati ent’s treatm ent assignment is warranted for medical management of the event.  The 
patient’s safet y must always be the first consideration in making such a determi nation.  If a 
patient’s treatment assignment is unblinded, Lilly must be notified immediately.  If the 
investigator decides that unblinding is warranted, it is the responsibilit y of the investi gator to 
prom ptly docum ent the decisio n and rationale and notif y Lilly as soon as possible.
If an invest igator, site personnel performing assessments, or patient is unblinded, the patient 
must be discont inued fro m the study drug and must com plete the ETV and post-treatm ent 
follow-up as per protocol .  In cases where there are ethical reasons to have the patient remain on 
study  drug , the investigator must obtain specific approval from the sponsor or designee for the 
patient to continue in the study .
7.4. Dosage Modification
Dose adjust ments,other than the dose regimen change provided to patients who demonstrate a 
LOR ,described in Secti on 7.1, are not permitted in this study .
7.5. Preparation/Handling/St orage/Accountability
The invest igator or his/her designee is responsible for the fo llowing:
Confirming appropriate temperature condit ions have been maintained during 
transi t for all study  treatm ent received and any discrepancies are reported and 
resolved b efore use of the study  treatm ent.
Ensuring that only participants enrolled in the study may receive study treatment 
and only  authori zed si te staff may  supply  or administer study  treatm ent. All study 
treatm ents m ust be stored in a secure, environmentally  controlled, and mo nitored 
(manual  or autom ated) area i n accordance with the labeled storage condit ions 
with access limited to the invest igator and authorized site staff .
The invest igator, institution, or the head of the medical inst itution (where 
applicabl e) is responsible for study  treatm ent accountabilit y, reconciliat ion, and 
record m aintenance (such as ,recei pt, reconciliat ion,and final disposit ion 
records).
I6T-MC-AMBG(a) Clinical Protocol Page 60
LY3074828Detailed instructions regarding supplies and preparation and handling of mirikizumab will be 
provi ded by the sponsor.
Invest igational products will be supplied by Lilly or its designee , in accordance with current 
GMP and will be supplied with lot numbers, expiry dates, and certificates of analysis, as 
applicable.
Mirikizumab and pl acebo should be stored in refrigerated conditions 2̊C to 8̊ C (36̊F to 46̊ F).
7.6. Treatment Compliance
All doses o f study  medicat ion will be administered at the study  site by si te personnel.  Deviat ions 
from the prescribed dosage regimen should be recorded in the eCRF.
Every  attem pt will be m ade to sel ect pati ents who have the abilit y to understand and co mply with 
study  instructi ons.  The invest igator is responsible for discussing methods to ensure high 
treatm ent com pliance wi th the pati ent before randomizat ion.  
If a patient i s nonco mpliant with study  procedures and/or invest igational product administration, 
the invest igator should assess the patient to determine the reason for noncompliance and educate 
and/or manage the patient as appropriate to improve compliance. If, in consultat ion with Lilly  or 
its designee, the noncompliance is deemed to be significant such that it affects the safet y of the 
patient or the evaluation of the efficacy and safet y data in this study , the pati ent m ay be 
discontinued fro m the study .
7.7. Concomitant Therapy
All conco mitant m edicat ions taken during the study  must be recorded in the Conco mitant 
Medicat ion eCRF.  All patients are encouraged to maintain their usual medicat ion regimens for 
concomitant conditions or diseases throughout the study, unless those medicat ions are 
specifically excluded (Appendix 8 ).  
Patients taking permitted UC concomitant medicatio ns, other than oral corticosteroids, are to 
keep doses stable unless modificat ions are needed due to AEs,and follow the instructi ons 
regarding dose stabilizat ion as detailed in Appendix 9 .  Pati ents taking oral corticosteroi ds are to 
follow the corticosteroid taper instructions described below .  Ad ministration of prohibited UC
medicat ions, approved or invest igational, const itutes tre atment failure.  Use of such medicat ions 
shoul d not be wi thheld if, in the opinio n of the investigator, failure to prescribe them would 
compromise pat ient safet y.  Patients who require a prohibited medicat ion to treat their UC (see 
Appendix 8 ) need to be di scont inued fro m study  drug and com plete an ETV and post -treatm ent 
follow-up visits.
If a conco mitant m edicat ion is needed to treat an AE or for appropriate medical management ,the 
investigator should base decisio ns on the patient and clinical factors , considering prohibited 
medicat ions.  Local administration of corticosteroids ( for example, intranasal, inhaled, 
intraarti cular) are allowed as required for the management of pre -existing condit ions and AEs.   A 
patient who init iates a prohibited medicat ion for a non -UC indicat ion may either di scont inue the 
study  drug, or di scont inue the prohibited medicat ion.
I6T-MC-AMBG(a) Clinical Protocol Page 61
LY3074828Use of BCG vaccinat ion is prohibited throughout the duration of the study  and for 12 months 
after di scontinuati on of  study  drug.  Use of nonlive (killed, inact ivated or subunit) vaccinat ions 
are allowed for all patients; however ,their efficacy wi th concomi tant mirikizumab is unknown.  
Use of live, attenuated vaccines are prohib ited during the study and for 3 m onths after 
discontinuat ion of study  drug .  
The list of prohibited medicat ions and the list of permitted medicat ions wit h dose stabilizat ion 
guidance are provi ded in Appendix 8 and Appendix 9 , respectively .
Corticosteroid Taper
Patients who enter Study AMBG on corti costeroi d therapy  for treatm ent of thei r UC and who
achieved clinical response in the induct ion study AMAN will initiatecorticosteroi d tapering, as 
described below, at Week 0 of Study  AMBG .  Clinical nonresponders who undergo extended IV 
induct ion with mirikizumab willbegin corticosteroid tapering if clinical respo nse is achieved at 
Week 12 of the extended induct ion dosing, or earlier ifsymptom aticimprovement ,based on 
investigator discret ion,is evident at any time after starting extended IV induction dosing. 
For pati ents who cannot tolerate the corticosteroid taper without recurrence of clinical 
symptoms, corticosteroid taper may be paused and/or corticosteroid dose may be increased up to 
the original dose at induct ion baseline (should not exceed induct ion baseline dose). In such 
cases, attem pts to reinit iate corti costeroi dtapering shoul dbe made within 2 weeks of interruption 
of taper , with a goal to complete tapering no later than Week 12 of Study AMBG .
The recommended tapering schedule for oral corticosteroids (other than budesonide extended 
release tablets[budesonide MMX] or beclo methasone dipropionate [gastro -resistant prolonged-
release tabl et]) is asfollows:
Dose > 10 mg/day predniso ne or equivalent: taper daily  dose by  5 mg/week unt il 
receiving 10 mg/day, and then continue tapering at 2.5 mg/week unt il 0 mg/day .
Dose ≤10 mg/day predniso ne or equivalent: taper daily dose by 2.5 mg/week unt il 
0mg/day.
The recommended tapering schedule for patients receiving oral budesonide MMX 9mg/day is to 
reduce tabl ets to 9 mg every other day for 2 weeks, fo llowed by  9mg every third day for 
2weeks , and then discont inue.
The recommended tapering schedule for patien ts receiving oral beclo methasone dipropionate 
(gastro -resistant prol onged -release tabl et) 5 m g/day  is to reduce tablets to 5 mg every  other day  
for 4 weeks, and then discont inue.
7.8. Treatment after the End of the Study
7.8.1. Study Extensions 
Patients who com plete Week 40 in Study  AMBG will be assessed for eligibilit y to enter the 
open -label extensio n study  (Study  AMAP).  There is no extensio n peri od wi thin Study  AMBG.
If pat ients do not m eet enrollment criteria for Study AMAP or opt not to continue into Study 
I6T-MC-AMBG(a) Clinical Protocol Page 62
LY3074828AMAP, they  will be asked to com plete the post -treatm ent follow-up peri od,as described in the 
Schedule of Act ivities(Secti on 2),which will co mplete their study participat ion. 
7.8.2. Treatment after Study Completion
Mirikizumab will not be m ade available to patients after conclusio n of the study .
7.8.3. Special Treatment Considerations 
7.8.3.1. Premedication for Infusions
Prem edicat ion for the study  drug infusions or injecti onsis not pl anned. Any premedicat ion for 
infusio nsor inject ionsshoul d be discussed with the medical mo nitor.  Any premedicat ion given 
will be documented as a concomitant therapy .
7.8.3.2. Management of Hypersensitivity, Infusion -Related Events, Infusion Site 
Reactions and Injection Site Reactions
During and after study  drug administrati on, pati ents shoul d be cl osely m onitored f or signs or 
symptoms of AEs, including hypersensit ivityevents , 
other infusion -related events, and infusi on 
or inject ion site reacti ons.
Hypersensitivity Events
If a patient experiences a systemic hypersensit ivityreacti on invo lving the skin or mucous 
membranes, respiratory , cardi ovascular, gastroi ntestinal ,or urinary  systems, during or up to 
6hours after an infusio n of study  drug, the fo llowing gui dance shoul d be fo llowed (see 
Appendix 10 for addi tional information): 
Study drug infusio nshoul d be stopped immediately and appropri ate supportive care 
provi ded according to local standard practice (for example, administration of epinephrine, 
anti-histamine, systemic steroids ,and/or bronchodilators).
After patient’s stabilizat ion, an anti-drug antibody (ADA )and PK sample shoul d be 
collected; addit ional samples should be obtained 4 and 12 -16 weeks after the event.  
These samples will also be used for try ptase, com plement (C3/C4), and cy tokine panel 
assays.
The patient should be monitored until resol ution or stabilizat ion of the symptoms ,as 
clinically appropriate. 
Study  drug shoul d be permanent ly discontinued after a systemic drug administration 
reacti on.  The pati ent shoul d undergo post -treatm ent follow-up procedures after study  
drug di sconti nuati on.
The m edical  monitor shoul d be notified as soon as feasible .
Other Infusion -Related Events and Infusion Site Reactions
If a patient experiences areaction consist ing o f headache, rigors and/or temperature >38 °C (in 
the absence of signs or symptoms of a systemic hypersensit ivity react ion), or an infusio n site
reacti on,including urticaria, pruri tus,or angioedema localized to the IVinfusio nsite(inthe 
absence of other systemic hypersensit ivitysigns or symptoms ), during or up to 6 hours after an 
infusio n of study  drug, the fo llowing gui dance shoul d be f ollowed:
I6T-MC-AMBG(a) Clinical Protocol Page 63
LY3074828Study drug infusio n shoul d be interrupted and appropri ate medical  care shoul d be 
administered (for example, NSAIDS ,anti-pyreticsor antihistamines ). 
An ADA and PK sample should be collec ted at the time of the event (or as soon as 
possible after the event occurs) ,and 4 and 12 -16weeks after the event. These samples 
will also be used for try ptase, com plement (C3/C4), and cy tokine panel assays.
Resumpt ion of study  drug infusio n after interruption, possibly at a slower rate of 
administration, can be considered if symptoms resolve and i t is deemed to be m edically
appropriate based on the invest igator ’sdiscretion, and considering the risk/benefit of 
readminstration.
If the patient develo ps systemic hypersensit ivity symptom sor signs, they shoul d be 
managed as described above for a systemic hypersensit ivityreact ion.  Patient should 
remain in observat ion,as is clin ically appropriate for the patie nt’s symptom s.  
Prem edicat ion prior to sub sequent study  drug administrati on m ay be considered, if 
judged by  the invest igator to be appropriate for the individual pat ient.  
Injection Site Reactions
If a patient experiences a n inject ion site reacti on, including pain, ery thema, urticaria , pruri tus,or 
angioedema localized to the SC injection site (in the absence of systemic hypersensit ivity signs 
or symptoms), the following guidance should be followed:
Patient shoul d be instructed to contact the study  site 
to report any  symptom sexperienced 
following a SC inject ion. 
If the patient develops systemic hypersensit ivity symptom s, they  shoul d be m anaged as 
described above for a systemic hypersensit ivityreacti on.  
Prem edicat ion prior to subsequent study  drug administrati on m ay be considered as 
appropriate for the individual pat ient.  
I6T-MC-AMBG(a) Clinical Protocol Page 64
LY30748288.Discontinuation Criteria
8.1. Discontinuation from Study Treatment
8.1.1. Permanent Discontinuation from Study Treatment
Study  treatm ent may  be permanent ly discontinued during the study.  Patients who discont inue 
study  treatm ent early w ill undergo early terminat ion procedures, which include an ETV and 
post-treatm ent follow-up visits.  The investigator will also complete any AEreporting and 
follow-up that m ay be requi red (if applicable, see Section 9.2).  
If a patient's study  treatm ent is discont inued before the end of the Maintenance Study Dosing 
Period, the pati ent shoul d com plete the ETV and post -treatm ent follow-up peri od as fo llows:
Patients who discont inue invest igational product during extended induction IV dosing
or before receiving any SC dosing will return for post -treatm ent follow-up visits
(Visit801 and 802) 4and 16 weeks after the end-of- treatm ent visi t.
Patients who discont inue study  drug after having received ≥1 SC dose will return for 
post-treatm ent follow-up visit s (Visi t 801 and 802) 4 and 12 weeks after the 
end-of-treatm ent visi t.
Possible reasons leading to permanent discontinuatio n of invest igational product include the 
following (list is not exhaust ive):
Patient Decision
The patient requests to discont inue invest igational product.
Discontinuation due to a hepatic event or liver test abnormality   
Patients who are di scont inued fro m invest igational product due to a hep atic event or liver 
test abnorm ality shoul d have addi tional hepatic safety  data coll ected vi a the hepat ic 
eCRF packet .
Discontinuati on of  the invest igational product for abnormal liver tests should be
considered by the investigator when a patient meets one of the fo llowing condi tions af ter 
consultation wit h the Lilly -designated m edical m onitor:
 Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) 
>8x upper limit of normal (ULN)
 ALT or AST >5 xULN for m ore than 2 weeks
 ALT or AST > 3xULN and total bilirubin level (TBL) > 2xULN or 
internat ional norm alized rati o>1.5
 ALT or AST > 3xULN wi th the appearance of fat igue, nausea, vo miting, 
right upper -quadrant pain or tenderness, fever, rash, and/or eosinophilia 
(>5%)
 Alkaline phosphatase (ALP) >3x ULN
I6T-MC-AMBG(a) Clinical Protocol Page 65
LY3074828 ALP >2.5xULN and TBL >2 xULN
 ALP >2.5xULN wi th the appearance of fat igue, nausea, vo miting, right 
quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%)
Discontinuation due to Lack of Clinical Benefit or Disease Worsening
Induct ion study  respo nders who experience LOR and do not receive clinical benefit from 
mirikizumab IV rescue induct ion
Induct ion study nonresponders who do not achieve clinical response with 3 doses of 
mirikizumab IV extended induct ion
Induct ion study nonresponders who achieve clinical response with mirikizumab extended 
IV induct ion,but subsequent ly lose clinical benefit with open -label mirikizumab SC 
dosing ,shoul dbe discont inued .Loss of clinical benefit may be based on demonstrating 
LOR criteria (see Section 5.1 ) or by  other cri teria according to invest igator discret ion
Patients who requi re treatm ent wi th a prohibited UC medicat ion (Appendix 8 ), an 
increase in immuno modulatory  medication, or a course of corticosteroids that exceeds the 
baseline dose 
Patients who undergo surgery  for UC
Safety Criteria for Study Drug Discontinuation
The patient requires a prohibited medicat ionto treat thei r UC ( Appendix 8 ). A patient 
who init iates a prohibited medicat ion for a non -UC indication may either discont inue the 
study  drug, or discont inue the prohibited medicat ion.
The patient requires a colectomy , proctocol ectomy, or parti al colectomy during the study .
A diagnosis o f cancer , other than squamous cell or basal cell carcino maof the skin ,
during the study .
Dysplasia occurring in flat m ucosa or DALM.
A diagnosis o f active TB durin g the study .
A diagnosis o f HIV/AIDS during the study .
A diagnosis o f hepatitis B during the study or development of detectable HBV DNA 
during the study (see Section 9.4.5.2 ).
A diagnosis o f hepatitis C during the study  or development of detectabl e hepat itis C virus 
(HCV )RNA during the study (see Sect ion 9.4.5.4 ).
The patient beco mes pregnant.  Pregnant patients will not undergo a n endoscopy at 
theETV . 
The parti cipant has an AE or SAE which, in the opinio n of the investigator or sponsor, 
woul d precl ude the parti cipant from  cont inuing to receive study drug.
I6T-MC-AMBG(a) Clinical Protocol Page 66
LY3074828Systemic hypersen sitivity event or anaphylaxis to study  drug.
It is recommended that the patient be assessed by  an appropri ately trained professio nal to assist 
in deciding whether the pa tient is to be discont inued fro m the study  if:
The patient scores a 3 for Item 12 (Thoughts of Death or Suicide) on the Quick Inventory  
of Depressive Symptom atology—Self -Report (16 Items ) (QIDS -SR16 )at any time in the 
study , or
The patient reports suicidal ideat ion or suicide -related behaviors during the study
Other Reasons for Study Drug Discontinuation
If an invest igator, site personnel performing assessments, or patient is unblinded, the 
patient m ust be di scont inued fro m the study  drug an d continue to post -treatm ent 
follow
-up.  In cases where there are ethical reasons to have the patient continue on study 
drug, the investigator must obtain specific approval fro m the sponsor or designee for the 
patient to continue in the study .
Inadvertent enrollment (see Section 8.1.3 )
Patients di scont inuing fro m the invest igational product prematurely for any  reason shoul d 
complete AEand other fo llow-up procedures per Section 2(Schedule of Act ivities), Section 9.2
(Adverse Events), and Section 9.4(Safet y) of this protocol .
8.1.2. Temporary Interruption (Withholding) of Study Treatment
Some possible reasons for temporarily wit hholding the investigational produc t include (but are 
not limited to):
Patient devel ops a clinically important intestinal or extraintest inal infect ion during the 
study , including latent tuberculosis infect ion (LTBI) .
Patient requi res maj or surgery  (resum e administratio n of the investigational product only 
after adequate wound healing) .
Patient devel ops a confirmed absolute neutrophil count <1x109/L (<1x103/µL or <1 GI/L)
(2assessments below this thresho ld).
Patient devel ops absolute lymphocyte count <500 cells/µL (<0.5x103/µL or <0.50 GI/L) .  
Azathioprine , 6-MPor methotrexate must be discont inued, if applicable, for a confirmed 
absolute lymphocy te count <0.5 x103/µL (2 assessments below this thresho ld). The 
hematol ogy must be repeated in 2 weeks. If the absolute lymphocy te count remains 
<0.5x103/µL, the hematology  will be repeated again in 2 weeks ( that is, prior to the next 
dose of study  drug).  If the abso lute lymphocy te count rem ains <0.5 x103/µL, the next 
dose of study  drug will not be administered. The hematology will b e repeated again in 2 
weeks. If the abso lute lymphocy te coun tremains <0.5x103/µL, study  drug will be 
perm anent ly discont inued. White blood cell and lymphocy te counts will be fo llowed for 
these patients unt il they return to an acceptable level.
I6T-MC-AMBG(a) Clinical Protocol Page 67
LY3074828Cases that may merit tem porary  withhol ding of the study  treatm ent will be discussed wit h the 
medical mo nitor.  The m edical mo nitor, in consult ation wi th the invest igator, will determine 
when it i s appropri ate to recommence study  treatment.
8.1.3. Discontinuation of Ina dvertently Enrolled Patients
If the sponsor or invest igator ident ify a pat ientwho did not meet enrollment criteria and was 
inadvertent ly enro lled, then the patient should be discontinued fro m study  treatm ent unless there 
are extenuat ing circumstances that make it medically  necessary  for the pati ent to conti nue on 
study  treatm ent.  If the invest igator and the sponsor agree it is medically appropriate to continue
on study  treatm ent, the invest igator must obtain documented approval from the sponsor to allow 
the inadvertently enro lled patientto continue in the study . Patients who are discont inued from 
study  treatm ent shoul d have safet y follow-up is as outlined in Sect ion2(Schedule of Act ivities), 
Secti on9.2(Adverse Events), and Section 9.4(Safety) of the protocol.
8.2. Discontinuation from the Study
Patients will be discont inued in the fo llowing ci rcumstances:
Enrollment in any other clinical study  involving an invest igational product or 
enrollment in any other type o f medical research judged not to be 
scientifically or medically co mpatible wit h this study
Participation in the study  needs to be stopped for medical, safet y, regul atory , 
or other reasons consistent with applicable laws, regulat ions, and good clinical 
practi ce 
Invest igator decision
oThe invest igator decides that the patient shoul d be discontinued from the 
study
oIf the patient
, for any reason, requires treatment with another therapeutic 
agent that has been demonstrated to be effect ive for treatm ent of the study  
indicat ion, discont inuat ion from the study  occurs pri or to introducti on of  
the new agent
Patientdecision
oThe pati
ent requests to be discontinued from the study
Patients discont inuing fro m the study  prem aturely for any  reason shoul d com plete AEand other 
safet y follow-up per Secti on2(Schedule of Activit ies), Section 9.2(Adverse Events) ,and 
Secti on 9.4(Safet y) of this protocol .
8.3. Lost to Follow -Up
A patientwill be considered lost to fo llow-up if he or she repeatedly  fails to return for scheduled 
visits and is unable to be con tacted by  the study  site.  Site personnel are expected to make 
diligent attempts to contact patients who fail to return for a sch eduled visit or were otherwise 
unable to be fo llowed up by  the si te.
I6T-MC-AMBG(a) Clinical Protocol Page 68
LY30748289.Study  Assessments and Procedures
Secti on 2lists the Schedule of Act ivities, wi th the study  procedures and their timing (including 
tolerance limit s for timing).
Appendix 2 lists the laboratory tests that will be performed for this study.
Unless otherwise stated in the subsect ions below, all samples collected for specified laboratory 
tests will be destroy ed wi thin 60 days of rece ipt of confi rmed test resul ts.  Certain samples may 
be retained for a longer period, if necessary, to comply wit h applicable laws, regulat ions, or 
laboratory  certificati on standards.
I6T-MC-AMBG(a) Clinical Protocol Page 69
LY30748289.1. Efficacy Assessments
Table AMBG. 9.1. Endpoint Definitions in Study AMBG
Endpoint Definition
Clinical remissionStool frequency (SF) subscore = 0, or SF = 1 with a ≥1-point decrease from 
inductio n baseline, and
Rectal bleeding (RB) subscore = 0; and
Endoscopic subscore (ES) = 0 or 1 (excluding friability)
Clinical remission (using 
a more stringent ES) SF subscore = 0, or SF = 1 with a ≥1-point decrease from induction baseline, and
RB subscore = 0; and
ES = 0 
Clinical responseA decrease in the modified Mayo score (MMS) of ≥2 points and ≥30% decrease 
from baseline, and 
A decrease of ≥1 point in the RB subscore from baseline or a RB score of 0 or 1
Corticosteroid -free 
remission without 
surgery at Week 40aClinical remission at Week 40, and
Symptomatic remission at Week 28, and 
No corticosteroid use for ≥12 weeks prior to Week 40
Endoscopic remission ES = 0 or 1 (excluding friability)
Endoscopic response A decrease in the ES of ≥1 point compared to baseline
Histologic remission This definition will be specified in the SAP
Mucosal healingHistologic remission as described in the SAP and
endoscopic remission defined as ES = 0 or 1 (excluding friability)
Symptomatic remissionSF = 0, or SF = 1 with a ≥1-point decrease from induction baseline , and
RB = 0
Stable maintenance of 
symptomatic remissionbSymptomatic remission for at least 7 out of 9 visits from Week 4 to Week 36 
Symptomatic inremissio n at Week 40
Bowel movement urgency 
improvement The definition will be specified in the study SAP
Abbreviations: ES = endoscopic subscore; MMS = modified Mayo score; RB = rectal bleeding; SAP = statistical 
analy sis plan; SF = stool frequency.
aAmong patients induced into clinical response with mirikizumab during the induction study and who were 
receiving corticosteroids at induction baseline.
bAmong patients in symptomatic remission at Week 12 of Study  AMAN .
9.1.1. Primary Efficacy Assessments
9.1.1.1. Primary Endpoint
The primary  endpoint is clinical remission at Week 40 , among pati ents induced into clinical 
response with mirikizumab induct ion treatment (StudyAMAN ). Clinical remissio n is based on 
the MMS and is defined inTable AMBG. 9.1.
9.1.1.2. Mayo Score
This study  utilizes components of the May o Score (Schroeder et al. 1987) to assess UC disease 
activit y for the primary and major secondary  endpoints (see Appendix 6 ).  Complete and 
accurate recording of the Mayo SF and RB subscores by patients in their daily electronic 
diary is necessary for the success of the study .Adequate bowel preparation and an endoscopy  
with adequate visualizat ion of the mucosa will enable calculat ion of the May oES.  
I6T-MC-AMBG(a) Clinical Protocol Page 70
LY3074828The May o score is a com posite instrum ent com prised of the fo llowing 4 subscores:
SF Subscore :  The SF subscore i s a patient -reported m easure.  This item reports the 
number of stools in a 24 -hour peri od, rel ative to the normal number of stools for that 
patient in the same period, on a 4-point scale (see Appendix 6 ). A stool is defined as a 
trip to the toilet when the patient has either a bowel movement, or passes blood 
alone, blood and mucus, or mucus only .  The absol
ute number of stool s passed in a 
24-hour peri od will be recorded by  the patient in a daily  electronic di ary.  The reference 
“norm al” SF for that patient will be recorded electronically at the induct ion study  
screening visit.  Study  software will use the patient -reported daily SF and the refe rence 
norm al SF to autom atically calculate the Mayo SF subscore.  The patient will record this 
in an el ectroni c diary  (Appendix 7 ).  Further detail s on the analysis of diary  items are 
contained in the statistical analysis plan ( SAP). 
Normal SF: The Normal SF is a patient -reported measure. This item reports the number 
of stools in a 24
-hour peri od when the pati ent was in remissio n or, if the patien t has never 
achieved remissio n, the reported SF before init ial onset of signs and symptoms of UC.  
Remissio n refers to a period of time since being diagnosed with UC when the patient is 
not experiencing any signs or symptoms relat ing to UC. This peri od of time may  last a 
few weeks or a few months or may even last several years. The patient will  record thi s 
electroni cally as source data in the tablet device at the screening study  visitof Study  
AMAN .
Rectal Bleeding (RB) : The RB subscore is a patient -reported measure.  This item 
reports the most severe amount of blood passed with stool for a given day , on a 4-point 
scale (see Appendix 6 ).  The patient will record this in a daily  electronic di ary(Appendix 
7).  Further details on the analysis o f diary  items are contained in the SAP.
Endoscopic Subscore (ES) : The ESis a physician -reported m easure that reports the 
worst appearance of the mucosa on flexible sigmo idoscopy or col onoscopy ,on a 4-point 
scale (see Appendix 6 ).  Determinat ion of the ES is further detailed in Sect ion 9.1.1.3 .  
Consistent with current clinical practice and regulatory  advice, this study  excludes 
friabilit y from the definit ion of an ES of 1.
Physician’s Global Assessment (PGA) : The Physician’s Glob al Assessment ( PGA )is a 
physician -reported m easure that summarizes the investigator’s assessment of the patient’s 
UC di sease act ivity on a 4-point scale (see Appendix 6 ) .  The invest igator will record the 
PGA electronically  as source data in the tablet device at appropriate study  visits.  
Consistent wi th regul atory guidance , the PGA will not be used for efficacy assessment in 
this study .
Each subscore is scored on a 4-point scale, ranging fro m 0 to 3 .  The MMS is a 9 -point score, 
calculated by combining the SF, RB , and ES sub- scores.  The PGA is co llected in this study to 
facilitate historical co mpar isons of study  data. 
I6T-MC-AMBG(a) Clinical Protocol Page 71
LY30748289.1.1.3. Endoscopy
Endosco py will be used to determine the Mayo ES at the time points described in the Schedule 
of Activities (Secti on 2). 
Flexible sigmo idoscopy  is the standard endoscopic procedure for assessment of endoscopic 
disease act ivity in this study .  However, col onoscopy  can be perform ed instead of flexible 
sigmoidoscopy  within this study  in order to surveille for dysplasia, screen for colorectal  cancer
(see Inclusio n Criterion [5]), or for other clinically indicated reasons, in the judgement of the 
investigator and after discussio n with the m edical m onitor as appropri ate.   
Endoscopic disease act ivity assessed atWeek 12 of Stud yAMAN will serve as the baseline 
assessment of endoscopi c disea se activit y in Study AMBG. 
In pati ents who enter Study  AMBG in clinical response or clinical remissio n, endoscopy  will be 
perform ed at Week 40 , 
ETV, UV , or if LOR is suspected in these patients based on SF/RB 
scores, endoscopy  can be perform edat or after Week 12 to confirm secondary  LOR .Secondary  
LOR m ust be confi rmed endoscopi cally  before rescue mirikizumab IV induct ion dosing is 
initiated.  If endoscopy  does not confirm secondary  LOR, patients are encouraged to continue 
study  drug dosing.  If  study  drug dosing is continued, an addit ional endoscopy  woul d be 
perform ed at Week 40, ETV ,or UV.
In patients who enter Study  AMBG as i nduct ion study  nonresponders , 
endoscopy  will be 
perform ed at Week 12 ,following extended mirikizumabIV induct ion.An addit ional endoscopy  
will be performed at Week 40, ETV ,orUV.Patients who plan to con tinue in the long term 
extensio n study  AMAP and who requi reanannual surveillance co lonoscopy  to rem ain 
up-to-date in screening for colorectal cancer (see Inclusion Criterion [ 5]),will undergo
colonoscopy  as the endoscopy  method at Week 40.
If a patient becomes pregnant during the study , no addi tional endoscopi es will be performed. 
If a patient undergoes ear ly terminat ion soon after baseline, loss of response, or at the end of 
extended induct ion endoscopy , the need for ETV endoscopy  shoul d be discussed wit h the 
medical mo nitor.
The endoscopy  report and histopathology  report (if bi opsies are sent to alocal histopathol ogy 
laboratory ) must be available in the source documents.
The endoscopist will be a licensed physician, who is qualified by educat ion, training ,and 
experience to perform colonoscopies .  Invest igators may delegate endoscopy to other members 
of the study  team .  However, all study  staff performing endoscopy  must receive training from the 
sponsor or designee in the determinat ion and calculat ion of the May o ES.  The si te endoscopi st 
will determine the May o ES at each endoscopy  and it will be record edin the eCRF.  
All endoscopi c procedures will be video recorded using a storage medium provided by  the 
sponsor or designee.  The video images will be sent for independent central reading.  A detailed 
image review charter fro m the central  reading laboratory  will outline t he standard study  
procedures used to capture and transmit video recordings of endoscopic procedures throughout 
the study , and the qualificat ions requi red of the central  reader.
I6T-MC-AMBG(a) Clinical Protocol Page 72
LY3074828The central reader will determine centrally -read Mayo ES at each col onoscopy  ina blinded 
manner, as detailed in the image review charter.
Disagreement between the site and the central  read will be adjudicated by  an addi tional blinded 
central  reader, as detailed in the image review charter. The adjudicated May o ES will be 
provi ded to the si tes fro m the central  reader vendor. 
9.1.1.4. Endoscopic Biopsies
Biopsies will be obtained at each endoscopy  to support assessment of the histopathology  
endpo ints in this study ,and where permitted, for the assessment of exploratory  biomarkers.  
These will be sent to the central study  laboratory  for processing.  Histopathologic scoring o f 
these biopsies will be performed by a blinded central reader.  A detailed histopathol ogycharter 
will outline the procedures to be used for specimen transfer, processing, slide preparat ion,and 
digitization of slides for histopathologic scoring.  Centrally read histopathology  resul ts will  not 
be made available to study  sites. 
9.1.2. Secondary Efficacy Assessments
9.1.2.1. Major Secondary E ndpoint s
The m ajor se condary endpo ints are as fo llows(see Table AMBG. 9.1for definit ions):
Clinical remission at Week 40, among pat ients induced into clinical remission with 
mirikizumab at Week 12 of induct ion study (StudyAMAN)
Endoscopic remissio n at Week 40 , among pat ients induced into clinical response with 
mirikizumab at Week 12 of the induct ion study
Corti costeroi d-free remissio n without surgery  at Week 40, among p atients induced into 
clinical response with mirikizumab at Week 12 of the induction study  and were receiving 
corticosteroi ds at induct ion baseline
  
Histologic remissio n at Week 40 , among pat ients induced into clinical response with 
mirikizumab at Week 12 of induct ion study
Stabl e maintenance of symptomat ic remissio n, among patients induced into clinical 
response with mirikizumab and were in symptomatic remissio n at Week 12 of induction 
study
Bowel  movement urgency  improvement am ong pati ents induced into clinical response
with mirikizumab at Week 12 of induction study
9.1.2.1.1. Histopathology Scoring Instruments 
The histopathology  instrum ents that will be used for the evaluat ion of microscopic inflammat ion 
and histopathologic disease activit y will be spec ified in the histopathology  charter.
9.1.2.1.2. Patient Reported Outcome Instruments
The Urgency NRS (see Appendix 7 for descri ption) is a PRO instrum entused to collect bowel 
movement urgency  data in the patient eDiary . The Urgency  NRS will  be used to determine the 
secondary  endpoint for bowel  movement urgency  improvement (see Table AMBG .4.1for 
definit ion).
I6T-MC-AMBG(a) Clinical Protocol Page 73
LY30748289.1.2.2. Other Secondary Endpoints
Other secondary  endpoints are found in Table AMBG .4.1.
9.1.2.2.1. Physician Reported Instrument
The Ul cerative Co litis Endoscopic Index of Severity  (UCEIS) i s a physician reported instrument 
for measuring the endoscopic disease act ivity of UC on flexible sigmo idoscopy  or col onoscopy , 
that includes 3 descriptors of vascular pattern, bleeding ,and eros ions/ulcerat ions(Arai et al . 
2016; Ikey a et al . 2016; Tontini et al. 2014) .  Only blinded central reading of endoscopies will be 
used to determine the UCEIS score for each endoscopy .
9.1.2.2.2. PRO Instruments Used to Assess Secondary Endpoints
The fo llowing are a ddit
ional PRO instrum ents collected using a patient e lectronic diary (eDiary ).  
Please see Appendix 7 for addi tional descri ption
s.
Abdo minal Pain Numeric Rat ing Scale (NRS )
Fatigue NRS (collected at site visits unt il Visit 10 when collected via electronic diary ) 
The fo llowing are addi tional PRO instrum ents collected using a tablet device. Please see 
Appendix 7 for addi tional descripti ons.
Inflammatory  Bowel  Disease Quest ionnaire ( IBDQ )
European Qualit y of Life 5 -Dimension 5 Level ( EQ-5D 5L )
Medical Outcomes Study  36-Item Short Form  Health Survey (SF -36) Versi on 2
Work Productivit y and Act ivity Impairment Questionnaire : Ulcerat ive Co litis
(WPAI:UC)
9.1.3. Exploratory Endpoints
Exploratory  endpo ints are defined in the SAP.
9.1.3.1. Inflammatory Biomarkers
C-reactive protein (CRP): CRP is an acute phase protein expressed by hepatocytes in response 
to inflammatory  cytokines, parti cularly  IL-6, tumor necrosi s factor ,and IL -1β (Sands 2015).  C-
reactive protein will be obtained at the time po intsdescribed in the Schedule of Act ivities
(Section 2).  Investigators will be blinded to CRP results. 
Fecal calprotectin: Fecal calprotectin is a complex consist ing of the calcium -binding proteins 
S100A8 and S100A9 (Sands 2015) .  It is expressed by act ivated neutrophils (and to a lesser 
extent by  macrophages and m onocy tes) and fecal levels correlate with the number of neutro phils 
in the gut.  It is used as a bio marker of intestinal inflammat ion in clinical pract ice.  Fecal 
calprotectin will be obtained at time po intsdescribed in the Schedule of Act ivities (Section2).  
Invest igators will be blinded to fecal calprotectin results. 
9.1.3.2. Extraintestinal Manifestations
Review of extraintestinal manifestations (EIMs) will be performed at the time points described in 
the Schedule of Activities (Secti on2).  If new events are reported or ongoing events change in 
severit y, they  are to be reported as AEs.  
Extraintestinal manifestations include, but are not 
limited to:  uveit is, episclerit is, peripheral arthrit is, dactylit is, enthesit is, sacro ileitis, ankylo sing 
I6T-MC-AMBG(a) Clinical Protocol Page 74
LY3074828spondylit is, ery thema nodosum , pyoderm a gangrenosum , primary  sclerosing cholangit is, and 
oral aphthous ul cers.
9.1.3.3. PRO Instruments Used to Assess Exploratory Endpoints
The Pati ent UC Symptom  Diary  is a set of 8 i tems that assess UC -related symptom s in the past 
24 hours (Appendix 7 ).  In addit ion to the SF, RB, abdo minal pain ,and urgency items mentioned 
above, t he diary also includes items that asks the patient to report stool consistency, the 
frequency  of night -time stool s, and overall disease severit y.
The following exploratory  endpo intswill be assessed via the electronic diary tool and/or at 
applicable study  visits using the tabl et device :
Nocturnal  Stool (collected at site visits until Visit 10 when collected via electronic diary)
Patient’s Global Rating of Severit y (PGRS) (collected via electronic diary )
Bristol Stool  Scale (collected at site visits until Visit 10 when co llected via electronic 
diary)
In addit ion to those exploratory  endpoints assessed by  the Symptom  Diary , the PGRC will be 
administered at applicable study  visit s using the tablet device. Addit ional descript ions of these 
PRO instrum ents can be found in Appendix 7 .
9.1.4. Appr opriateness of Assessments
The clinical safet y parameters in this study  are routine elements of clinical healt h assessment and 
Phase 3 drug development.  The disease act ivity measurements are used in clinical pract ice and 
UC clinical trials.
9.2. Adverse Events
Invest igators are responsible for monitoring the safety of patientswho have entered this study  
and for al erting Lilly  or its designee to any  event that seems unusual, even if this event may be 
considered an unant icipated benefit to the patient.
The inves tigator i s responsible for the appropriate medical care of patientsduring the study.
Invest igators must document their review of each laboratory  safety  report.
The invest igator remains responsible for fo llowing, through an appropriate health care option, 
AEs that are serious or otherwise medically important, considered related to the invest igational 
product or the study , or that caused the patient to discontinue the invest igational product before 
completing the study.  The patientshoul d be f ollowed unt il the event resol ves, stabilizes with 
appropriate diagnostic evaluation, or is reasonably explained.  The frequency o f follow-up 
evaluat ions of the AE is left to the discret ion of the invest igator.
Lack of drug effect is not an AE in clinical studies, becaus e the purpose of the clinical study  is to 
establish treatment effect.
I6T-MC-AMBG(a) Clinical Protocol Page 75
LY3074828After the informed consent form (ICF) is signed, study  site personnel  will record vi a eCRF the 
occurrence and nature of each patient ’s preexist ing conditions, including clinically signif icant 
signs and symptoms of the disease under treatment in the study .  
In addit ion, site personnel will record any  change in the condi tion(s) , including exacerbation of 
UC, and any new condit ions as AEs.
Invest igators should record their assessment of th e potenti al relatedness of each AE to protocol 
procedure or invest igational product via eCRF.
The invest igator will interpret and document whether or not an AE has a reasonable possibilit y 
of being related to study  treatm ent, study  device, or a study  proce dure, taki ng into account the 
disease, concomitant treatment, or pathologies.
A “reasonable possibilit y” means that there is a cause and effect relat ionship between the 
investigat ional product, study  device ,and/or study  procedure and the AE.   The invest igator 
answers yes/no when making this assessment.
Planned surgeries and nonsurgical intervent ions should not be reported as AEs unless the 
underlying medical condit ion has worsened during the course of the study .
If a patient ’s investigational produ ct is discontinued as a result of an AE, study  site personnel  
must report this to Lilly or its designee via eCRF ,clarifying if possible, the circumstances 
leading to any  dosagemodifications, or discontinuations o f treatm ent.
9.2.1. Serious Adverse Events
An SA E is any  AE from this study  that resul ts in any of the f ollowing outcom es:
Death
Initial or prolonged inpat ient hospi talizat ion
Alife-threatening experience (that is, immediate risk of dying)
Persistent or si gnificant disabilit y/incapacit y
Congeni tal anom aly/bi rth defect
Important medical events that may not be immediately life -threatening or result in 
death or hospitali zation,but may  jeopardi ze the pati ent or may  requi re 
intervent ion to prevent one of the other outcomes listed in the definit ion above.   
Examples of such medical events include allergic bronchospasm requiring 
intensive treatm ent in an emergency  room  or at home, blood dyscrasias or 
convulsio ns that do not result in inpatient hospitalization, or the development of 
drug dependency  or drug abuse.
All AEs occurring after signing the ICF are recorded in the e CRF and assessed for serious 
criteria.  The SAE reporting to the sponsor begins after the patient has signed the ICF and has 
received invest igational product.  However, if an SAE occurs after signing the ICF, but prior to 
receiving invest igational product, the SAE should be reported to the sponsor as per SAE 
I6T-MC-AMBG(a) Clinical Protocol Page 76
LY3074828reporting requirements and t imelines (see Sect ion9.2) if it is considered reasonably possibl y 
related to study  procedure.
Study  site personnel  must al ert Lilly or i ts desi gnee of  any SAE within 24 hours of invest igator 
awareness o f the event via a sponsor -approved method.  If alerts are issued via telephone, they 
are to be immediately fo llowed wi th official  notificati on on study -specific SAE forms.  This 
24-hour notificat ion requirement refers to the init ial SAE information and all fo llow -up SAE 
inform ation.Patients with a seri ous hepat ic AEshoul d have addi tional data collected using the 
hepat ic eCRF packet .
Pregnancy ( during maternal or paternal exposure to invest igational product) does not meet the 
definit ion of an AE.  However, to fulfill regulatory requirements any pregnancy should be 
reported fo llowing the SAE process to collect data on the outcom e for both m other and fetus.
Invest igators are not obligated to actively seek AEs or SAEs in patients once they  have 
discontinued and/or completed the study  (the patientdisposit ion eCRF has been co mpleted).  
However, if the invest igator learns of any SAE, including a death, at any time after a patienthas 
been discharged from the study , and he/she considers the event reasonably  possibly  related to the 
study  treatm ent or study  parti cipat ion, the invest igator m ust prom ptly notify Lilly .
9.2.1.1. Suspected Unexpected Serious Adverse Reactions
Suspected unexpected serious adverse react ions (SUSARs) are serious events that are not listed 
in the IB and that the investigator ident ifies as related to i nvestigational product or procedure.  
United States 21 CFR 312.32 and European Unio n Clinical Trial Direct ive 2001/20/EC and the 
associ ated detailed guidances or nati onal regulatory  requirements in parti cipat ing countries 
requi re the reporting of SUSARs.  Lilly has procedures that will be fo llowed for the 
ident ificat ion, recording ,and expedited reporting of SUSARs that are consistent with global 
regul ations and the associated detailed guidances.
9.2.2. Adverse Event sof Special Interest
Adverse events of special interest are AEs which the sponsor specifies as being of special 
interest based on standard drug registration topics, safet y findings from previous studies in 
development program, potential risks associated wit h bio logic immuno modulators as noted in 
produc t labels and published literature, and comorbidit ies and risk factors prevalent in the 
studi ed popul ations.  The AESIs for this study  are defined in the SAP, and may  include but not 
be limited to:
Opportuni stic infect ions
Hypersensit ivity events, including anaphylaxis 
Inject ion site events
Cerebro -cardi ovascular events
Malignancies
Depressio n, or suicidal ideat ion and behavior
Hepati c AEs.
I6T-MC-AMBG(a) Clinical Protocol Page 77
LY3074828For some AESIs, sites should provide addit ional inform ation regarding the event, as instructed 
on the eCRF.
Opportunistic Infections
Infections will be categorized by Lilly as opportunist ic according to Opportunistic Infections and 
Biologic Therapies in Immune -Mediated Inflammatory Diseases: Consensus Recommendations 
for Infection Reporting during Clinical Trials and Postmarketing Surveillance by Wint hrop et al . 
(2015).
Hypersensitivity Events 
Site personnel should educate patients and/or caregivers about the symptoms and signs of 
hypersensit ivity events and provide instructions on dealing with these events. For 
recommendat ions on the management and fo llow-up of hypersensit ivity events, see 
Secti on7.8.3.2 .
Cerebro -Cardiovascular Event Adjudication
Data collected regarding a potential or actual cerebro -cardiovascular AE will be provided to, and 
adjudicated by, an independent, external  adjudication committee.  The role of the committee is to 
adjudicate the reported cardiovascular AEs in a blinded, consiste nt, and unbiased manner 
throughout the course of the study , thereby ensuring that all such reported events are evaluated 
uniformly.
9.2.3. Complaint Handling
Lilly co llects product complaints on invest igational products and drug delivery systems used in 
clinical studi es in order to ensure the safet y of study  parti cipants, m onitor quali ty, and to 
facilitate process and product improvements.
Patients will be instructed to contact the investigator as soon as possible if he or she has a 
complaint or probl em wi th the invest igational product so that the situation can be assessed.
9.3. Treatment of Overdose
In case of suspected overdose, hematology , chemistry , vital signs, and oxy gen saturati on shoul d 
be monitored and supportive care provided as necessary .  There is no known ant idote for 
mirikizumab .
9.4. Safety
When mult iple safet y assessments are scheduled for the same t ime point, the preferred order of 
completion isas fo llows:  vital signs, electrocardiogram (ECG ), and then blood sampling. 
9.4.1. Vital Signs
For each patient, vi tal signs measurements should be conducted according to the Schedule of 
Activities (Section 2).  
I6T-MC-AMBG(a) Clinical Protocol Page 78
LY3074828Sitting bl ood pressure and pul se rate shoul d be measured after the patient has been sitting for at 
least 5 minutes.  Any clinically significant findings fro m vital signs measurement that result in a 
diagnosis and that occur after the patient receives the first dose of study  treatm ent shoul d be 
reported to Lilly  or its designee as an AE via eCRF. 
9.4.2. Electrocardiograms
For e ach patient, ECGs should be co llected according to the Schedule of Activit ies (Secti on 2).  
Electrocardiograms shoul d be com pleted pri or to any  blood draw.  Pati ents shoul d be supine for 
approximately  5to 10 minutes before ECG collect ion and remain supine but awake during ECG 
collect ion.  Electrocardi ogram swill be read l ocally. Any clinically significant findings from 
ECGs that result in a diagnos is and that occur after the patientreceives the first dose of the 
investigat ional treatm ent shoul d be reported to Lilly  or its designee as an AE via eCRF . 
9.4.3. Laboratory Tests
For each patient ,laboratory  tests detailed in Appendix 2 shoul d be conducted accordi ng to the 
Schedule of Act ivities (Secti on 2). Retesting is allowed 1time between the last induct ion visit 
and V isit 1 of Study  AMBG .
With the exception o f laboratory  test resul ts that may  unblind the study , Lilly or its desi gnee will 
provi de the invest igator with the results of laboratory  tests analyzed by  a central vendor, if a 
central vendor i s used for the clinical trial. The investigator or designee is expected to review 
laboratory  reports in a timely manner throughout the s tudy.
Any clinically  significant findings from laboratory tests that result in a diagnosis and require 
medical or surgical intervent ion or resul t in study  treatm ent discont inuat ion
,and that occur after 
the pati ent receives the first dose of invest igationa l product should be reported to Lilly  or its 
designee as an AE via eCRF.
9.4.3.1. Pregnancy Testing
Pregnancy testing is to be performed on all females ≤60 y ears ol d, unless they  meet the cri teria 
describing wo men not of childbearing potential, outlined in Inclusion Criterion[4b].
Urine pregnancy  testing will  be perform ed locally  during designated scheduled visits , as 
described in the Schedule of Act ivities (Section 2).  The urine pregnancy test must be “negat ive”
within 24 hours prior to administration of invest igational product.  
Urine pregnancy  testing may  be perf ormed at addi tional time po intsduring the treatm ent peri od 
and/or fo llow-up peri od, at the di scret ion of the investigator or if this is required by local 
regul ations.
If a urine pregnancy test is not available, a serum pregnancy test is an acceptable alternative.
Assessment of FSH l evels can a ssist in determining if a wom an meets the definit ion of 
“postmenopausal ,”as outlined in Inclusion Criterion [ 4b]. Follicle -stimulat ing hormone can also 
be opti onally obtained at any  visit during the study, as indicated in the Schedule of Activities
I6T-MC-AMBG(a) Clinical Protocol Page 79
LY3074828(Secti on 2), to determine if a wom an meets the definit ion of “post menopausal ,”as outlined in 
Inclusio n Criterion [4b].
9.4.4. Immunogenicity Assessments 
Venous blood samples will be collected to determine ant ibody  producti on against mirikizumab at 
the visits and times specified in the Schedule of Activit ies (Section 2).  To ai d interpretati on of  
theseresul ts, a blood sample for PK analysis will be collected at the same t ime points.  Samples 
for ADA and acco mpanying PK analysis shoul d be taken prior to dosing
.  
In the event of a drug hy persensi tivity event (immediate or nonimmediate), additional samples 
for ADA and PK will be co llected as close to the onset of the event as possible ,and at 4 and 
12-16 weeks after the event . These samples will also be used for try ptase, com plement (C3/C4), 
and cy tokine panel  assays. Instructi ons for the collection and handling of blood samples will be 
provi ded by the sponsor.  The actual date and time (24 -hour clock time) of each sampling will be 
recorded.  
Samples will  be retained for a m aximum  of 15 y ears after the last patient visit, or for a shorter 
period if local  regulat ions and E RBs allow, at a facilit y selected by  the sponsor.  The durati on 
allows the sponsor to respond to future regulatory  requests r elated to mirikizumab .  Any samples 
remaining after 15 y ears will be destroy ed.
9.4.5. Other Tests
9.4.5.1. Physical Examination
Physical examinat ion will be performed as specified in the Schedule of Activit ies (Secti on 2).  
Physical examinat ion shoul d include a symptom -directed evaluat ion as well as examinat ion of 
heart, l ungs, abdo men, and visual examinat ion of the skin, and exclude pelvic, rectal, and breast 
examinat ions.  Phy sical examinat ion is mandated at Week 40 (or ETV ), and must also be 
perform ed at Week 0 if not performed at Week 12 of induct ion study .  
Physical examinat ioncan 
also be performed at the discret ion of the invest igator at any  addi tional time points ,for example , 
to assist in the evaluation o f a new symptom during the study .Any clinically significant findings 
from physical examinat ion that result in a diagnosis, and that occur after the patient receives the 
first dose of invest igational product ,should be reported to Lilly or its designee as an AE via 
eCRF .
9.4.5.2. Tuberculosis
Diagnosis of LTBI during Study
Patients di agnosed wi th LTBI during the study  must have study  drug interrupted.  If treatment 
for LTBI is considered to be appropriate, the patient must complete at least 4 weeks of 
appropriate therapy  for LTBI, based on theUnited States Centers for Disease Control and 
Prevent ionguidance (CDC [WWW]) for the United S tatesor the Worl d Heal th Organizat ion 
guidance for the treatment of LTBI for all countries outside o f the United States (WHO a
[WWW] ), and have no evidence of hepatotoxicit y (ALT and AST levels must remain ≤2xULN) 
upon retesting of serum ALT and AST levels after at l east 4 weeks of LTBI treatment.  Such 
I6T-MC-AMBG(a) Clinical Protocol Page 80
LY3074828patients m ay then resum e study  drug treatm ent and must continue wit h and co mplete a full 
course of treatment for LTBI in order to continue on study  drug.  Noncom pliance wi th LTBI 
treatm ent during the study  is a reason for permanent discont inuat ion from study drug.  
Household Contact
Patients who have had household contact with a person with active TB must be evaluated for TB 
infect ion.
Active TB 
If a patient is diagnosed with act ive TB during the study, the study  drug will  be discont inued, the 
patient will undergo an ETV and then enter the post -treatment fo llow-up peri od.  The pati ent 
shoul d also be referred by the invest igator for appropriate TB treatment and fo llow-up.
9.4.5.3. Hepatitis B
Patients who are HBsAg - anti-HBc+ will be allowed to enter Study  AMBG if the fo llowing 
criteria are fulfilled:
HBV DNA is not detected at Visit 5(Week 12) of Study  AMAN and
If HBV DNA was tested at other times in Study  AMAN, HBV DNA was not detected
and
The other inclusio n/exclusio n criteria of Study  AMBG are m et.
Such patients will undergo HBV DNA testing at the following time points:
Weeks 12, 24, and 40 (or ETV) per the Schedule of Activities (Secti on 2)and
If an elevated ALT or AST level >3xULN is detected .  In this circumstance, if 
HBV DNA is not detected, the investigator should consult with the Lilly -designated 
medical mo nitor regarding further managem ent of the pati ent.  
If HBV DNA is detected during Study AMBG, the study  drug will be discont inued ,an early 
termination visit will take place and the patient will then enter the post -treatm ent follow-up 
period.  The sponsor recommends that a hepatologist (or a physician with a specialist interest in 
viral hepatology ) is consul ted and that i t is determi ned whether it is appropriate to start antiviral 
therapy  prior to discont inuat ion of any  immunosuppressant or immunomodulatory  therapy , or the 
study  drug.  Such pati ents shoul d also receive appropriate fo llow-up m edical care   
If HBV DNA is detected during the study , the investi gator shoul d consider using one of the 
following term s to report the AE:
“Detectable HBV DNA”, if HBV DNA is detected without an increase in 
aminotransferase levels.  
“React ivation of hepat itis B”, if HBV DNA is detected with an inc rease in 
aminotransferase levels.
Anyo ne wit h a new diagnosis of hepat itis B made during th isstudy  will be discont inued fro m 
study  treatm ent, undergo ETV and post -treatm ent foll ow-up, and receive appropriate fo llow-up 
medical care. 
I6T-MC-AMBG(a) Clinical Protocol Page 81
LY30748289.4.5.4. Hepatitis C 
Patients who test positive for HCV RNA during the induct ion study AMAN will be excluded.
Any pat ient with a history  of HCV infecti on who devel ops el evated ALT >3xULN will be tested 
for HCV RNA (see Sect ion 9.4.6.1 ).
Patients diagnosed wi th hepat itis C during the study  (test posi tive for HCV RNA) will be 
discontinued fro m study treatm ent, undergo ETV and post -treatm ent follow
-up, and receive 
appropriate fo llow-up m edical care. 
9.4.5.5. Depression and Suicidality
Suicide-related events (behavior and/or ideat ions) will be assessed and evaluated at Week 0 with 
the administration o f the C-SSRS, the Self -Harm  Suppl ement For m, and the Self-Harm  “Foll ow-
Up” Form (if applicable).  Depressive symptomology  will be assessed with the QIDS -SR16 at 
Week 0, Week 12, Week 24, and Week 40 or ETV .  These assessments are described below, and 
further informat ion is provided in Appendix 11 .
Columbia Suicide Severity Rating Scale:   The C -SSRS (Columbia Universit y Medical  
Center [WWW]) is a scale that captures the occurrence, severit y,and frequency of 
suicide-related i deations and behaviors during the assessment period.  The scale includes 
suggested questions to solicit the ty pe of information needed to determine if suicidal 
ideat ion and/or behavior occurred.  The C -SSRS i s administere d by an appropri ately  
trained health care professio nal with at least 1 year of pat ient care/clinical experience.  
Patient data for the C -SSRS will be recorded in the eCRF.
Self-Harm Supplement Form:  The Self -Harm  Suppl ement Form  is a single quest ion to 
enter the number of suicidal behavior events, possible suicide behaviors, or nonsuicidal 
self-injuri ous behaviors the patient has experienced since the last assessment. For each 
unique event ident ified, a questionnaire (Self -Harm  “Follow-Up”Form ) thatcollects 
supplemental  inform ation on the self -injuri ous behavi or is to be com pleted. This 
inform ation is then documented in the eCRF. 
Quick Inventory of Depressive Symptomatology—Self -Report (16 Items):   The 
QIDS -SR16 is a self-administered, 16-item instrum ent intended to assess the existence 
and severit y of symptom s of depressio n as listed in the American Psychiatric 
Associ ation’s Diagnostic and Statistical Manual o f Mental Disorders, 5th Edition 
(DSM -V) (APA 2013).  Patients will record their responses to the QIDS -SR16 
electroni cally as source data in the tablet device 
according to the Schedule o f Activities 
(Secti on 2).
Spontaneous AE collect ion shoul d occur pri or to the co llection of the C -SSRS or QIDS. If a 
suicide-related event is discovered during the C -
SSRS but was not captured during the 
spontaneous AE collect ionat Week 0 , sites shoul d not change the AE form.  If an event i s 
serious or l eads to di scont inuat ion, thi s is an excepti on where the SAE and/or AE leading to 
discontinuat ion shoul d be included on the AE form and the process for reporting SAEs should be 
followed.
I6T-MC-AMBG(a) Clinical Protocol Page 82
LY30748289.4.5.6. Stool Testing
In assessing secondary  LOR, a stool  sample for C. difficile toxin will be obtained at the first of 
the LOR assessments.  C. difficile testing will also be performed at UVs and ETV when UC
disease exacerbat ion is suspected . 
This assay  tests for the presence of C. difficile toxin protein, followed by a confirmatory  test f or 
C. difficile toxin gene expression in the stool sample.  C. difficile testing must be negative for 
patients to be eligib leto receive IV mirikizumab rescue dosing.  If the C. difficile test confirms 
active C. difficile infect ion, pati ents shoul d be treated as considered appropriate by  the 
investigator, and study  treatm ent dosing may  be withheld if infect ion is assessed to be clinically 
important ( Section 8.1.2 ).  An AEshoul d be reported if, in the judgement of the invest igator, the 
patient’s signs, symptom s,and posi tiveC. difficile test results are consistent with a C. difficile 
infect ion.
In the event of a positive test, re-testing is allowed if ,in the judgement of the invest igator, the 
patient’s symptom s or si gns are not consistent with C. difficile infect ion.
Addit ional local stool  culture/testing is allowed at the invest igator’s discretion at the time of
LOR evaluat ion or as deemed appropriate by the investigator.
9.4.6. Safety Monitoring 
Lilly will periodically  review evolving aggregate safet y data wi thin the study  by 
appropriate methods.
In the event that safet y monitoring uncovers an issue that needs to be addressed by unblinding at 
the group l evel, only  members of the data monitoring board (an advisory  group for thi s study  
formed to protect the integrity  of data; refer to Interim Analyses section [Secti on 10.3.8 ]) can 
conduct addit ional analyses of the safet y data.
9.4.6.1. Hepatic Safety Monitoring
If a study  patient experiences elevated ALT ≥3xULN, ALP ≥2xULN, or el evated TBL ≥2xULN, 
liver testing (Appendix 4 ) shoul d be repeated wi thin 3 to5 days ,including ALT, AST, ALP, 
TBL, direct bilirubin , 
gamma -glutamyl transferase, and creatine kinase ,to confirm the 
abnorm ality and to determine if it is increasing or decreasing.  If the abnormalit y persists or 
worsens, clinical and laboratory  monitoring shoul d be ini tiated by  the invest igator and in 
consultation wit h the study  medical m onitor. Monitoring of ALT, AST, TBL, and ALP should 
continue until levels normalize or return to approximate baseline levels. 
Hepatic Safety Data Collection
Addit ional safet y data should be co llected via the hepat ic eCRF packet if 1 or more of the 
following condit ions occur: 
Elevat ion of serum ALT to ≥5xULN on 2 or more consecut ive blood tests
Elevated serum TBL to ≥ 2xULN (except for cases of known Gilbert’s syndrome )
Elevat ion of serum ALP to ≥2xULN on 2 or more consecut ive blood tests
I 6 T -M C -A M B G( a) Cli ni c al Pr ot o c ol P a g e 8 3 
L Y 3 0 7 4 8 2 8 Pati e nt disc o nt i n ue d fr o m treat me nt d ue t o a he pati c e ve nt or a b n or malit y of 
li ver t ests 
He pati c e ve nt c o nsi dere d t o be a nS A E 
P ati e nt wi t h  a hist or y  of  H C V i nfect i o n de vel o ps ele vate d A L T > 3 x U L N.  Patie nt 
will be teste d f or H C V R N A 
P ati e nt e x peri e nces a n A L T or A S T > 3 x U L N a n d T B L > 2 x U L N or i nter nat i o nal 
n or m alize d rati o > 1. 5.  T he st u d y  m e dical m o nit or s h o ul d be c o ns ul te d as s o o n as 
p ossi ble f or f urt her g ui da nce 
9. 5. P h ar m a c o ki n eti c s 
At  t he visit s a n d t i mes s pecifie d i n t he Sc he d ule of Act i vit ie s ( S ecti o n 2), ve n o us bl o o d sa m ples 
of  a p pr o xi matel y  2m L eac h will  b e c ollecte d t o deter mi ne t he ser u m  c o nce ntrati o ns of 
mir i kiz u ma b .
S a m ples will  b e a nal yze d at a l a b orat or y  a p pr o ve d b y  t he s p o ns or a n d st ore d at a facilit y 
desi g nate d b y  t he s p o ns or.  Ser u m  c o nce ntrati o ns of mir i k iz u ma b will be deter mi ne d usi n g a 
vali date d e nz y me -li n ke d i m m u n os or be nt assa y. It is n ot i nte n de d t hat sa m ples c o llecte d fr o m 
pl ace b o -treate d pati e nts will be a nal yze d. A d dit i o nal sa m ples ma y be c ollecte d a n d use d f or 
e x pl orat or y  a nal yses s uc h as bi oa nal y ti cal met h o d de vel o p me nt or vali dat i o n e xercises. 
A ma xi m u m of 3 sa m ples m a y be c ollecte d at a d diti o nal t i me p o i nt s d uri n g t he st u d y  i f 
warra nte d a n d a gree d u p o n bet wee n b ot h t he i n vesti gat or a n d s p o ns or.  I nstr ucti o ns f or t he 
c ollect i o n a n d ha n dli n g of bl o o d sa m ples will be pr o vi de d b y t he s p o ns or .  T he act ual date a n d 
ti me ( 2 4- h o ur cl oc k ti me )of  eac h sa m pli n g will be rec or de d. 
Dr u g c o nce ntrati o n i nf or mat i o n t hat m a y  u n bli n d t he st u d y  will n ot be re p orte d t o i n vest i gat i ve 
si tes or bli n de d pers o n nel. 
Bi oa nal y ti c al  sa m ples c ollecte d t o m eas ure i n vest i gati o nal pr o d uct c o n ce ntrati o n will be retai ne d 
f o r a ma xi m u m of 1 year f oll o wi n g last patie nt visit f or t he st u d y .  
 
 
 
 
 
9. 6. P h ar m a c o d y n a mi c s 
See Secti o n 9. 8 .C CI 
I 6 T -M C -A M B G( a) Cli ni c al Pr ot o c ol P a g e 8 4 
L Y 3 0 7 4 8 2 8   
 
 
 
 
 
 
 
 
  
 
 
 
 
 
9. 9. M e di c al R e s o ur c e Utili z ati o n a n d H e alt h E c o n o mi c s 
Me dical Res o urce Utilizat i o n a n d Healt h Ec o n o mics para meters are n ot e val uate d i n t his st u d y .C CI 
I6T-MC-AMBG(a) Clinical Protocol Page 85 
LY3074828 10. Statistical Considerations 
10.1. Sample Size Determination 
Assuming that 90% of patients complete Study AMAN (which is expected to randomize 
approximately 1160 patients), Eli Lilly and Co mpany (Lilly) anticip ates approximately 
1044 patients will enroll in Study AMBG.  It is expected that approximately 470 of these patients 
will enter Study AMBG as clinical  responders to mirikizumab a nd then will be randomized 2:1 
to 200 mg mirikizumab SC (approximately  313 patients) and placebo (approximately 
157 patients).  Among the expected 470 mirikizumab clinical responders, approximately 180 mirikizumab clinical remitters will be randomized to 200 mg mirikizumab SC 
(approximately 120 patients) and placebo (appro ximately 60 patients).  This assumes that: 
 The induction study (AMAN, which has a mixed population with approximately 50% 
biologic-failed patients) is expected to have an overall clinical re mission rate of 23% and 
response rate of 60% with mirikizumab. 
 75% of induction patients receive treatm ent with mirikizumab, based on a 3:1 
randomization ratio for the induction study. 
 10% dropout rate from induction to maintenance. 
 
The primary endpoint, clinical remission at W eek 40, will be assessed on patients who achieved 
clinical response to mirikizumab induction tr eatment.  Assuming mirikizumab and placebo 
clinical remission rates of 47% and 27%, respec tively, this study based on the 470 mirikizumab 
induction responders is expected to have >95% power to dem onstrate that mirikizumab is 
superior to placebo by using a chi-square test with a 2-sided significance level of 0.05.  In 
addition, the sample size is expected to provi de adequate power (>80%) to demonstrate that 
mirikizumab is superior to placebo for e ndoscopic remission, histologic remission, and 
corticosteroid-free remission at Week 40, among responders to mirikizumab induction treatment 
by using a chi-square test with a 2-sided significance level of 0.05. 
10.2. Populations for Analyses 
For purposes of analysis, the populations described in Table AMBG.10.1  are defined. 
I6T-MC-AMBG(a) Clinical Protocol Page 86
LY3074828Table AMBG.10.1. Analysis Populations in Study AMBG
Population Description
Intent -to-treat (ITT) Population All randomized/assigned patients. Patients will be analyzed according to the 
treatment to which they were assigned
Modified Intent -to-treat (mITT) 
PopulationAll randomized/assigned patients who received at least 1 dose of study 
treatment in Study AMBG , regardless of whether correct treatment was 
administered or whether protocol was followe d, will be analyzed according to 
the treatment to which they were assigned .
Safety Population Same as mITT Population
Per-Protocol (PP) Population All mITT patients who are not deemed noncompliant with treatment, who do 
not have significant protocol deviations (defined in the SAP), and whose 
investigator site does not have significant GCP deviations that require a report to 
regulato ry agencies (regardless of study period).  Qualifications and 
identification of the specific significant protocol deviations that result in 
exclusion from the PP population will be determined while the study remains 
blinded, prior to the database lock
Pharmacokinetic Evaluable All patient s who received at least 1 dose of investigational product and have 
sufficient blood sampling to allow for pharmacokinetic evaluation
Abbreviations:  GCP = good clinical practice; SAP = statistical analysis plan.
Four analysis cohorts have been defined ( Table AMBG.10 .2).
Table AMBG.10.2. Analysis Cohorts in Study AMBG
Cohort ID Cohort Description
1 Main cohort 
(mirikizumab induction 
responders)Patients who are randomized and responded to mirikizumab
inductio n dosing andthenare rerandomized to 200 mg 
mirikizumab SC o r placebo
2 Mirikizumab induction 
nonrespondersPatients who are randomized and did not respond to 
mirikizumab induction dosing and then are e nrolled into 
Study AMBG
3 Placebo induction 
respondersPatients who are randomized and responded to placebo in 
inductio n study  and then enrolled into Study AMBG
4 Placebo induction 
nonrespondersPatients who are randomized and did not respond to placebo 
in inductio n study and then enrolled into Study AMBG
10.3. Statistical Analyses
10.3.1. General Statistical Considerations
Statistical analysis o f this study  will be the responsibilit y of Lilly o r its desi gnee.   
Both efficacy and safet y analysis will be conducted on the modified intent -to-treat (mITT) 
popul ation.  The efficacy analysis of the primary  endpoint and m ajor secondary  endpoints will  be 
repeated for intent-totreat popul ation and the per -protocol  popul ationin the main cohort 
(mirikizumab induction responders) .Additional analyses may be performed as deemed 
appropriate.
I6T-MC-AMBG(a) Clinical Protocol Page 87
LY3074828For efficacy  analysis, the baseline will be defined as the init ial baseline value before the patient 
is rando mized into the induct ion study  (Study  AMAN), unless otherwise specified. For safety 
analysis, the baseline will be defined as the visit atWeek 12 value in the induct ion study  and 
prior to enroll ment in Study  AMBG, unless otherwise specified.
Unless otherwise specified, t he main efficacy and safet y analyses will be conducted on the main 
cohort for patients who respond to mirikizumab inducti on dosing and then are rerandomized to 
200 m g mirikizumab SC dosing or placebo. For other cohorts of patients, efficacy and safet y 
will be descript ive wit hout statistical test ing.
Summary  statistics for con tinuous variables may include mean, standard deviat ion, median, and 
minimum and maximum values.  Categorical variables will be presented as counts and 
percentages.  Unless otherwise specified, variables will be analyzed in the original scale on 
which they  are measured.  The parametric approach will be emplo yed by default for statist ical 
analysis ,except when nonparametric analysis, such as by  a rank -based method, i s assessed to be 
more fitting.  Addi tional expl oratory  analyses o f the data may be conducted as deemed 
appropriate.  All hypothesis tests of treatm ent effects will be 2-sided , unless otherwise stated.
For assessments of the primary endpo int and other categorical efficacy endpo intsamong induced 
responders , the CMH chi -square test will be used to compare mirikizumab and placebo wi th 
stratificat ion factors:  (a) previou s bio logic therapy failure (y es or no),(b) baseline corticosteroi d 
use (yes or no), ( c) region (North America/Europe/Other) ,and (d) induct ion remissio n status 
(yes/no).   The CMH chi -square p- value and the relative risk along wit h its 95% 2 -sided 
confidence interval (CI) will be provided.  In additio n, the abso lute treatment difference in 
proporti ons will  be provi ded al ong wi th the 95% 2 -sided CIestimate. The differences between 
mirikizumab and placebo will also be tested separately  using a l ogistic regres sion model that 
control s for the stratificat ion factors .  If deemed necessary, addit ional analyses of categorical 
efficacy  variables m ay be conducted to address sparse data and/or small sample sizes.  
Treatment comparisons of continuous efficacy and healt
h outcome variables will be made using 
mixed -effects model ofrepeated m easures (MMRM) analysis.  When the MMRM model is used, 
the model includes:  (a) t reatment group, (b) previous bio logic therapy  failure (y es or no), (c) 
corticosteroi d use (y es or no), ( d) regi on (North America/Europe/Other), ( e) baseline value in the 
model, (f) visi t, (g) induct ion remissio n status (if analysis is amo ng induced responders), and ( h) 
the interactions of treatment -by-visit and baseline -by-visit as fixed factors.  The covariance 
structure to model the within -patient errors will be unstructured.  If the unstructured covariance 
matri x result s in a l ack of convergence, the heterogeneous Toeplitz covariance structure, 
followed by the heterogeneous autoregressive covariance structure will be used.  The 
Kenward -Roger m ethod will be used to estimate the deno minator degrees of freedo m.  Type III 
sums of squares for the least squares (LS) m eans will be used for the statist ical co mpar ison; the 
95% CI will also be reported.
Treatment comparisons of continuous efficacy and healt h outcome variables wit h a single 
post-baseline time po intwill be made using analysis of covariance wit h:  (a) treatm ent group, 
(b)previou s bio logic therapy  failure (y es or no),(c) corti costeroi d use (y es or no), ( d) regi on 
I6T-MC-AMBG(a) Clinical Protocol Page 88
LY3074828(North America/Europe/Other), (e) baseline value in the model , and (f ) induct ion remissio n 
status .  Type III sums of squares for LS means will be used for statist ical comparison between
treatm ent groups.  The LS mean difference, standard error, p -value, and 95% CI, unless 
otherwi se specified, will also be reported.  
Any change to the data analysis methods described in the protocol will req uire an amendment 
ONLY if it changes a principal feature of the protocol.  Any other change to the data analysis 
methods described in the protocol, and the just ification for making the change, will be described 
in the clinical study  report (CSR) .  Addition al exploratory  analyses of the data will be conducted 
as deemed appropriate.
10.3.1.1. Missing Data Imputation: 
While every  effort will be made to reduce missing data, the missing data imputation methods 
described below will be used to provide a conservative approach for assessing efficacy endpo ints 
when pat ients are permanent ly discont inued fro m study  drug or otherwise have missing data.
Nonresponder imputation (NRI) : For analysis of categorical efficacy and healt h 
outcom es variables, missing data will be im puted using an NRI m ethod.  Patients will be 
considered a nonresponder for the NRI analysis if they do not meet the categorical 
response criteria, have missing clinical response data at a time point of interest , or take 
rescue dosi ng wit h mirikizumab prior to the time point of interest . 
Mixed -effects model ofrepeated m easures: For cont inuous variables, the primary 
analysis will be MMRM wit h the missing at random assumpt ion for handling missing 
data.  This analysis takes into account both missingness of data and the correlat ion of the 
repeated m easurem ents.  The data collected after rescue medicat ion will be censored in 
the primary  analysis. No addi tional imputati on m ethods will be applied to the MMRM 
analysis.
Sensit ivity analyses, including addit ional methods of handling missing data or analyzing the data 
that may  be requi red to sati sfy regulatory  needs will be specified in the SAP.
10.3.1.2. Multiplicity Control
A prespecified mult iple testing scheme based on graphical approach (Bretz et al. 2009, 2011) 
will beused to test theprimary and major secondary hypotheses at overall family wise ty pe 1 
error rate (FWER) of 0.05 .  The graphical approach is a closed testing procedure; hence, it 
strongly  control s the FWER across all endpo ints (Alosh et al. 2014).  Details of the specific 
graphical test ing scheme (including testing order, interrelationships, type I error allocat ion for 
the major secondary  endpoints, and the associated propagation) will be prespecified in the SAPs 
prior to fi rst unblinding of efficacy .
10.3.2. Treat ment Group Comparability
10.3.2.1. Patient Disposition
The number of enrolled pat ients will be summarized by  cohort and by treatment. Frequency 
counts and percentages of all pat ients who are enroll ed and complete the study  or discont inue the 
I6T-MC-AMBG(a) Clinical Protocol Page 89
LY3074828study  drug/study  early will be presented.  Reasons for discont inuing the study drug/study  will be 
summarized.
10.3.2.2. Patient Characteristics
Year of birth, sex, weight, smoking habits, prior biologic therapy , and other dem ographic and 
disease characteri stics will be summarized for all enrolled patients.  Age and body  mass index 
will be calculated.  Demographic and baseline disease characteristics will be summarized for 
each treatment group and by cohort . Certain characterist ics, such as weight, that are collected 
after baseline, will b e reported as a list ing.
10.3.2.3. Concomitant Therapy 
Concomitant therapy  will be collected at each visit , and the reported term will be classified by  
the World Healt h Organizat ion drug dict ionary.  Medi cations started pri or to randomizat ion and 
medicat ions starte d on study  after randomizat ion will be presented separately  in frequency tables 
by drug name and by cohort for all enrolled patients.  
Patients who are noncompliant will be listed by treatment and by cohort . The details o f 
nonco mpliance will be defined i n SAP. A contingency table of numbers of nonco mpliant 
patients by  treatm ent and by cohort will be provi ded.
10.3.3. Efficacy Analyses
10.3.3.1. Primary Analyses
The primary  endpoint is the proporti on of  patients wi th clinical remission at Week 40 (Week 52 
of continuous the rapy) among the pati ents who are responders to 300 mg mirikizumab IV at 
12weeks of induct ion dosing.
For study  visits that include endoscopy
 as a study  procedure ( for example , Visit 11 [Week 40]), 
the SF and RB subscores of the May o score will becalculated fro m daily electronic diary  data by  
averaging the most recent 3 valid days (possibly  noncon secutive) in the 7 day s prior to 
commencing bowel preparation for endoscopy . At other study  visits, where endoscopy  is not 
perform ed, SF and RB subscore s will be calculated fro m the daily  electroni c diary  data by  
averaging the most recent 3 valid days (possibly  nonconsecut ive) in the 7 day s prior to that study  
visit. If data for fewer th an3 valid days are available, the subscores will be considered missing.  
Patient di ary data obtained onthe following days will be excluded: (i)days when bowel 
preparati on was taken prior to endoscopy , (ii) the day  of the endoscopy , and (iii) the day  after the 
endoscop y.  
Rates of clinical remission at Week 40among inducti on responders will be analyzed.  Patients 
who do not achieve clinical remissio n or who do not reach the Week 40assessment will be 
considered to be nonremitters. In addit ion,patients who take rescue dosing with mirikizumab
will be considere d nonremitters.
The primary  endpoint analysis will ut ilize the CMH test as described in Sect ion 10.3.1 .
Addit ional analyses of the primary endpo int may be considered and will be fully  detailed in 
theSAP.
I6T-MC-AMBG(a) Clinical Protocol Page 90
LY307482810.3.3.2. Secondary Analyses
The secondary  efficacy and heal th outcom e endpoints of the trial are presented in 
Table AMBG .4.1and details of the analysis methods that will be utilized are provided in 
Secti on10.3.1 .
The endpo ints for the maj or secondary  object ives will be analyzed using the similar CMH test 
used for the primary endpo int. Mult iplicityadjustment for ty pe 1 error control  to the m ajor 
secondary  endpoints i s described in Section 10.3.1.2 .
Addit ional analyses of the secondary  efficacy  and healt h outcom e endpo ints may be considered 
and will be fully detailed in the SAP.
10.3.3.3. Exploratory Analyses
Details o f the analysis o f exploratory  endpoints will be fully detailed in the SAP. Addit ional 
analyses o f exploratory  health outcom e endpo ints may be considered and will be fully detailed in 
the SAP.
10.3.4. Safety Analyses
Safety will be assessed by evaluat ing exposure, AE(for example, treatm ent-emergent AE
[TEAE ], SAE, treatment related AE , discont inuat ion due to AE ), AESI (for example ,
infect ion, 
MACE, injection site event , hypersensi tivity event , etc.), laboratory  analytes, vi tal signs, ECGs, 
C-SSRS, etc.
Adverse events will be coded according to the Medical Dict ionary for Regul atory  Activit ies and 
summarized by  system  organ cl ass, preferred term , severit y, and rel ationship to invest igational 
product. A TEAE is defined as an event that first occurred or wors ened in severit y after 
baseline, which is the on -study  AE recorded at Week 12 in the induct ion study . For each event 
classificat ion term , the number of patients experiencing a TEAE with that classificat ion term  will 
be tabulated. 
The safet y analyses for the main cohort will co mpare mirikizumab to placebo during the 
maintenance treatment. For other cohorts, the safety  data will be summarized wit hout treatment 
comparison.
The Fisher exact test will be used to perform the between- treatm ent group com parisons for AEs, 
discontinuat ions, and other categorical safet y data.  The change from baseline in cont inuous vital 
signs, physical characterist ics, and other continuous safet y variables, including laboratory  
variables, will be summarized by visit and treatment. The change fro m baseline to last 
observat ion value will be analyzed with the ANOVA model wit h baseline as a covariate. The 
last non -missing observat ion in the treatment period will be used as the last observation.
Shift tables for categorical safet y analyses ( for example, “ high” or “low” laboratory  resul ts) will 
also be produced. 
10.3.5. Pharmacokinetic/Pharmacodynamic Analyses
The PK of mirikizumab will be characterized using graphical evaluat ions and mixed- effect 
(popul ation PK) m odeling approaches.  Various s tructural and error models will be evaluated 
I6T-MC-AMBG(a) Clinical Protocol Page 91
LY3074828during development of the mixed -effect m odel.  Intri nsic factors (such as ,age, body  weight, 
gender, ADAs , etc. ) and extrinsic factors (such as ,co-medications) will be invest igated to assess 
their influence on model parameters.  Model  evaluati on will include a visual predict ive check.  
Estimates of PK model parameters and covariate effects and the corresponding 90% CIs will be 
reported.
Analyses of exposure -response relat ionships will be conducted using both exp loratory  graphical  
approaches and model based approaches.  Exploratory  graphical analysis approaches may  consist 
of graphs showing the percentage of patients who achieve clinical response, clinical remissio n, 
and endoscopic remission at different percentil es (for example, quartiles) of exposure of 
mirikizumab at Week 40.  Measures of exposure may  include populat ion PK estimated average 
concentrations (C avg) between Week 0 and Week 40, or estimated or observed trough 
concentrations at Week 40.  Model based a nalyses will ut ilize populat ion exposure -response 
logistic regressio n models, where maximum effect (E max) or other m odel structures m ay be used 
to rel ate exposure to the probabilit y of achieving clinical response, clinical remission, and 
endoscopi c remissio n. These models may be used to evaluate patient factors that may impact the 
relationship between exposure and the probabilit y of achieving the endpo int. Longitudinal 
exposure -response models for SF and RB subscores may be developed, which relate the time 
course and m agnitude of  mirikizumab exposure to the time course of these subscores.
Addit ional analyses m ay be conducted if they are deemed appropriate.  Data from this study  may 
be co mbined with other study data, if appropriate.  Further details on PK and PK/PD analyses 
will be provided in the PK/PD analysis plan.
10.3.6. Evaluation of Immunogenicity
The frequency and percentage of patients with preexist ing(baseline) ADA , ADA at any  time 
post baseline, and wi th treatment -emergent (TE) -ADA to mirikizumab will be tabulated.  If no 
ADAs are detected at baseline, TE -ADA are defined as those with a titer 2-fold (1 dilut ion) 
greater than the minimum required dilut ion of the assay.  For samples with ADA detected at 
baseline ,TE
-ADA are defined as those with a 4 -fold (2 dilut ions) increase in t iter compared to 
baseline.   For patients who have TE-ADA ,the distribution of maximum t iters will be described.  
The frequency of neutralizing antibodies will also be tabulated.
The rel ationship between the presence of antibodies and the PK parameters and PD response ,
including safet y and efficacy  to mirikizumab ,may be assessed.
10.3.7. Other Analyses
10.3.7.1. Subgroup Analyses 
Subgroup analyses will be conducted for the primary  endpo int and select edmajo rsecondary  
endpo ints.  Subgroups to be evaluated willinclude sex, age category , body  weight, race, 
geographi c regi on, baseline disease severit y, duration of disease, previous biologic-failed status 
(yes or no), corticosteroid use (yes or no), UC concomitant therapy use(corticosteroi d, 
immuno modulators) , induct ion remissio n status (yes or no) for endpoints among induct ion 
responders. The treatment -
by-subgroup interaction will be tested at the significance level 
I6T-MC-AMBG(a) Clinical Protocol Page 92
LY3074828of0.10.  If any treatm ent group within the subgroup is less than 10% of t he total mITT
popul ationfor the m ain cohort, only  summaries of the efficacy  data will  be provi ded (that i s, no 
inferential testing will be done ). 
Detailed subgroup analysis will be defined in the SAP.
10.3.8. Interim Analyses
One DMC consist ing of members extern al to Lilly will  be established for peri odic monitoring of 
clinical trial data across all Phase 3 trials for the UC adul t program .  Thi s commit tee will  consist 
of a minimum of 3 members, including a physician with expert ise in gastroenterology  and a 
statis tician.  No m ember of the DMC may have contact with study  sites.  A statistical  analysis 
center (SAC) will prepare and provide unblinded data to the DMC. The SAC members may be 
Lilly emplo yees or from third- party organi zations designated by  Lilly . However, they  will be 
external to the study  team  and will have no contact with sites and no privileges to influence 
changes to the ongoing studies. The timing and frequency o f the periodic clinical trial data 
review by  the DMC will  bedetailed in the DMC charter for the UC adult program.
A primary  database l ock is planned after all patients com plete the Week 40 visit or the ETV . 
The analysis based on data fro m the primary  database l ock will  be conducted by  the sponsor or a 
designee and no further mult iplicit y adjust ment 
will be implemented . The final database lock 
willoccur after all pat ients complete the entire study ,including safet y follow-up. 
The DMC is authorized to evaluate unblinded interim efficacy and safet y analyses during the 
periodic safet y review .The DMC will make recommendat ion to the Lilly  Research Laboratori es 
Senior Management Designee, who may order the immediate implementation of the DMC 
recommendat ion, or m ay convene an internal review committee (IRC) , which is independent 
from the study  team , to review the recommendat ion according to standard Lilly  policy .  Study  
sites will receive information about interim results ONLY if they need to know for the safet y of 
their patients .
In addit ion to DMC, SAC, and po tential IRC, a limi ted number of pre -ident ified individuals may 
gain access to the limited unblinded data, as specified in the unblinding plan, prior to the interim 
or final database lock, in order to init iate the final populat ion PK/PD model development 
processes for interim or final analyses.  Informat ion that m ay unblind the study  during the 
analyses will not be shared to the study  sites or the blinded study  team  until the study has been 
unblinded.   
Unblinding details will be specified in the unblinding plan sect ion of the SAP or a 
separate unblinding plan document.
I6T-MC-AMBG(a) Clinical Protocol Page 93
LY307482811. References
Alosh M, Bretz F, Huque M. Advanced mult iplicit y adjust ment methods in clinical tri als. Stat 
Med. 2014;33(4) :693-713.
[APA] American Psychiatric Associat ion. Di agnosti c and stati stical manual  of mental  disorders 
(DSM -V). 5th ed. Washington DC: APA; 2013.
Arai M, Naganuma M, Sugimoto S, Kiyo hara H, Ono K, Mori K, Saigusa K, Nanki K, 
Mutaguchi M, Mizuno S, Bessho R, Nakazato Y, Hosoe N, Matsuoka K, Inoue N, Ogata H, 
Iwao Y, Kanai T. Th e Ulcerative Co litis Endoscopic Index o f Severit y is useful to predict 
medium -to long-term prognosi s in ulcerative co litis pat ients with clinical remissio n. J Crohns 
Colitis. 2016;10 (11):1303 -
1309.
Blauvel t A, Papp KA, Griffit hs CE, Randazzo B, Wasfi Y, Shen YK, Li S, Kimball AB. Efficacy 
and safet y ofguselkumab , an ant i-interleukin- 23 monocl onal ant ibody , com pared wi th 
adalimumab for the continuous treatment of patients with moderate to severe psori asis: Resul ts 
from the phase III, double -blinded, place bo-and active co mparator -controlled VOYAGE 1 
trial. J Am Acad Dermatol . 2017 ;76(3):405- 417.
Bretz F, Maurer W, Brannath W, Posch M. A graphical approach to sequentially reject ive 
multiple test procedures. Stat Med. 2009;28(4):586 -604.
Bretz F, Posch M, Gl imm E, Klinglmueller F, Maurer W, Rohmeyer K. Graphical approaches for 
multiple comparison procedures using weighted Bonferroni, Simes, or parametric tests. 
Biom J. 2011;53(6) :894-913.
[CDC] Centers for Disease Control and Prevent ion. Fact sheet: tuberculi n skin testing. CDC web 
site. Available at: https://www.cdc.gov/tb/topic/treatment/default.ht m. Accessed 
November 21,
2017.
[Columbia Universit y Medical  Center] Col umbia –Suicide Severi ty Rating Scale (C -SSRS). The 
Columbia Lighthouse Proj ect web site. Avai lable at: http://www.cssrs.columbia.edu. Accessed 
August 28,2017.
Deepak P, Sandborn WJ. Ustekinumab and anti -Interl eukin -23 agents in Crohn's disease.  
Gastroenterol Clin North Am . 2017;46(3):603 -626. 
Dignass A, Lindsay  JO, Sturm  A, Windsor A, Colombel JF, Allez M, D'Haens G, D'Hoore A, 
Mantzaris G, Novacek G, Oresland T, Reinisch W, Sans M, Stange E, Vermeire S, Travis S, 
Van Assche G. Second European evidence -based consensus on the diagnosis and management 
of ulcerat ive co litis part 2: current manageme nt. J Crohns Colitis . 2012;6(10):991 -1030.
EuroQol  Group. EQ -5D- 5L User Guide. Version 2.1. 2015. Available at:  https://euroqol.org/wp -
content/uploads/2016/09/EQ -
5D-5L_UserGuide_2015.pdf . Accessed May 1, 2017.
[EuroQol  Group] EQ -5D. Available at:  http://www. euroqol.org/eq-5d- instruments/eq-5d- 5l-
about/.  Acessed March 12, 2018.
Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colo mbel JF, Sandborn WJ, Van Assche G, 
Axler J, Kim HJ, Danese S, Fox I, Milch C, Sankoh S, Wyant T, Xu J, Parikh A; GEMINI 1 
Study  Group. Vedolizumab as induct ion and maint enance therapy  for ulcerative colit is. N Engl 
J Med . 2013;369(8):699 -710.
I6T-MC-AMBG(a) Clinical Protocol Page 94
LY3074828Feagan BG, Sandborn WJ, D'Haens G, Panés J, Kaser A, Ferrante M, Louis E, Franchimo nt D, 
Dewi t O, Sei dler U, Kim K -J, Neurath MF, Schre iber S, Scholl P, Pamulapat i C, Lal ovic B, 
Visvanathan S, Padula SJ, Herichova I, Soaita A, Hall DB , Böcher WO. Induction therapy  
with the select ive interleukin- 23 inhibitor risankizumab in pat ients with moderate -to-severe 
Crohn's disease: a rando mised, double- blind, pl acebo -controlled phase 2 study . Lancet . 
2017;389(10080):1699-1709.
Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, Blank MA, Johanns J, 
Gao L -L, Miao Y, Adedokun OJ, Sands BE, Hanauer SB, Vermeire S, Targan S, Ghosh S, d e 
Villiers WJ, Colo mbel J -F, Tul assay Z, Sei dler U, Sal zberg BA, Desreumaux P, Lee SD, 
Loftus EV Jr, Dieleman LA, Katz S , Rutgeerts P. Ustekinumab as Induct ion and Maintenance 
Therapy  for Crohn’s Disease. N Engl J Med . 2016;375(20):1946- 1960.
Gaffen SL, Jain R, Garg AV, Cua DJ. The IL -23-IL-17 immune axis: fro m mechanisms to 
therapeuti c testing. Nat Rev Immunol . 2014;14(9):585 -
600.
Gottlieb A, Menter A, Mendelso hn A, Shen YK, Li S, Guzzo C, Fretzin S, Kunynetz R, 
Kavanaugh A. Ustekinumab , a human interl eukin 12/23 monoclonal ant ibody , forpsori atic 
arthri tis: randomised, doubl e-blind, placebo -controlled, crossover trial. Lancet . 
2009;373(9664):633- 640. Erratum in: Lancet . 2010;376(9752):1542.
Guyatt G, Mi tchell A, Irvine EJ, Singer J, Williams N, Goodacre R , Tompkins C . A new 
measure of health status for clinical trials in inflammatory  bowel  disease. Gastroenterology.
1989;96(3):804 -810.
Herdm an M, Gudex C, Llo yd A, Janssen MF, Kind P, Parkin D, Bonsel G, Badia X. 
Development and preliminary  testing of the n ew five -level versio n of EQ -5D (EQ -
5D-5L). 
Qual Life Res . 2011;20(10):1727- 1736.
Horsburgh CR Jr, Rubin EJ. Latent Tuberculosis Infect ion in the United States. N Engl J Med.
2011;364 (15):1441 -1448.
Ikeya K, Hanai H, Sugimoto K, Osawa S, Kawasaki S, Iida T, Maruyama Y, Watanabe F. The 
ulcerat ive co litis endoscopic index of severit y more accurately re ﬂects clinical outcom es and 
long-term prognosi s than the May o endoscopi c score. J Crohns Colitis . 2016;10:286
-295.
Irvine EJ, Feagan B, Rochon J, Archambault A, Fedorak RN, Groll A, Kinnear D, Saibil F, 
McDonald JW . Quali ty of life: a valid and reliable measure of therapeutic efficacy  in the 
treatm ent of inflammatory  bowel  disease. Canadian Crohn’s Relapse Prevention Trial Study  
Group. Gastroenterology . 1994;106(2):287 -296.
Irvine EJ, Zhou Q, Thompson AK. The Short Inflammatory Bowel  
Disease Questi onnai re: a 
qualit y of life instrument for communit y physicians m anaging inflammatory  bowel  disease. 
CCRPT invest igators. Canadian Crohn’s Relapse Prevent ion Trial. Am J G astroenterol . 
1996;91(8):1571 -1578.
Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY, Lee JC, Schumm LP, 
Sharma Y, Anderson CA, Essers J, Mitrovic M, Ning K, Cleynen I, Theatre E, Spain SL, 
Raychaudhuri S, Goy ette P, Wei  Z, Abraham C, Achkar J P, Ahmad T, Amininejad L, 
Ananthakrishnan AN, Andersen V, Andrews JM, Baidoo L, Balschun T, Bampton PA, 
BittonA, Boucher G, Brand S, Büning C, Cohain A, Cichon S, D’Amato M, De Jong D, 
Devaney  KL, Dubinsky M, Edwards C, Ellinghaus D, Ferguson LR, Franchim ont D, 
I6T-MC-AMBG(a) Clinical Protocol Page 95
LY3074828Fransen K, Gearry  R, Georges M, Gieger C, Glas J, Haritunians T, Hart A, Hawkey  C, 
Hedl M, Hu X, Karl sen TH, Kupcinskas L, Kugathasan S, Latiano A, Laukens D, 
Lawrance IC, Lees CW, Louis E, Mahy  G, Mansfiel d J, Morgan AR, Mowat C, Newman W, 
Palmieri O, Ponsi oen CY, Potocni k U, Prescott NJ, Regueiro M, Rotter JI, Russell RK, 
Sanderson JD, Sans M, Satsangi J, Schreiber S, Simms LA, Sventorait yte J, Targan SR, 
Taylor KD, Tremelling M, Verspaget HW, De Vos M, Wijmenga C, Wilson DC, 
Winkelmann J, Xavier R J, Zeissig S, Zhang B, Zhang CK, Zhao H; International IBD 
Genet icsConsorti um (IIBDGC), Silverberg MS, Annese V, Hakonarson H, Brant SR, 
Radford -Smit hG, Mathew CG, Ri oux JD, Schadt EE, Daly MJ, Franke A, Parkes M, 
Verm eire S, Barrett JC, Cho JH. Host -microbe interacti ons have shaped the genet ic 
architecture of inflammatory  bowel  disease. Nature . 2012;491(7422):119- 124.
Kikly  K, Liu L, Na S, Sedgwick JD. The IL -23/Th(17) axis: therapeut ic targets for autoimmune 
inflammat ion. Curr Opin Immunol . 2006;18(6):6 70-675.
Kopp T, Riedl E, Bangert C, Bowman EP, Greisenegger E, Horowitz A, Kittler H, 
Blumenschein WM, McClanahan TK, Marbury T, Zachariae C, Xu D, Hou XS, Mehta A, 
Zandvliet AS, Montgomery D, van Aarle F, Khalilieh S. Clinical improvement in psoriasis 
with specific targeting of interleukin -23. Nature . 2015;521(7551):222-226.
Krueger JG, Ferris LK, Menter A, Wagner F, Whit e A, Vi svanathan S, Lal ovic B, Aslanyan S, 
Wang EE, Hall D, Solinger A, Padula S, Scholl P. Ant i–IL-23A mAb BI 655066 for treatment 
of moderate -to-severe psoriasis: safet y, efficacy, pharmacokinet ics, and bio marker results of a 
single
-rising-dose, randomized, double -blind, pl acebo -controlled trial. J Allergy Clin Immunol. 
2015;136(1):116 -124. e7. 
Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, Li S, Dooley LT, Gordon 
KB; PHOENIX 1 study  investigators. Efficacy and safet y ofustekinumab , a human 
interleukin -12/23 m onocl onal antibody , in patients with psori asis: 76-week results from a 
rando mised, double -blind, pl acebo -controlle d trial  (PHOENIX 1). Lancet . 
2008;371(9625):1665- 1674. Erratum in: Lancet . 2008;371(9627):1838.
Levesque BG, Sandborn WJ, Ruel J, Feagan BG, Sands BE, Colo mbel JF. Converging goals of 
treatm ent of inflammatory  bowel  disease from  clinical trials and pract ice. Gastroenterology . 
2015;148(1):37 -51.e1.
Lewinsohn DM, Leonard MK, LoBue PA, Cohn DL, Daley CL, Desmo nd E, Keane J, 
Lewinsohn DA, Loeffler AM, Mazurek GH, O'Brien RJ, Pai M, Richeldi L, Salfinger M, 
Shinnick TM, Sterling TR, Warshauer DM , Woods GL. Offi cial Ameri can Thoraci c 
Society/Infecti ous Diseases Soci ety of America/Centers for Disease Control and Prevent ion 
Clinical Practice Guidelines: diagnosis of tuberculosis in adults and children. Clin Infect Dis . 
2017;64(2):111 -115.
Maruish ME , ed.User’s man ual for the SF -36v2 Health Survey . 3rd ed. Linco ln, RI: 
Qualit yMetri c Incorporated ; 2011.
Monteleone I, Pallo ne F, Monteleone G. Interleukin -23 and Th17 cells in the control of gut 
inflammat ion. Mediators Inflamm .2009;2009:297645.
Papp KA, Blauvelt A, Bukhalo M, Gooderham M, Krueger JG, Lacour JP, Menter A, Philipp S, 
Sofen H, Ty ring S, Berner BR, Visvanathan S, Pamulapat i C, Bennett N, Fl ack M, Scho ll P, 
I6T-MC-AMBG(a) Clinical Protocol Page 96
LY3074828Padul a SJ. Risankizumab versus Ustekinumab for Moderate -to-Severe Plaque Psori asis. 
NEngl J Med . 2017;376(16):1551- 1560.
Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary  P, Yeilding N, Guzzo C, Hsu MC, 
Wang Y, Li S, Dooley  LT, Rei ch K; PHOENIX 2 study  invest igators. Efficacy and safet y 
ofustekinumab , a hum an interleukin -12/23 m onocl onal antibody , in pat ients withpsori asis: 
52-week results fro m a rando mised, double -blind, pl acebo - controlled trial (PHOENIX 2). 
Lancet . 2008;371(9625):1675 -1684.
Papp K, Thaçi D, Reich K, Riedl E, Langley RG, Krueger JG, Gottlieb AB, Nakagawa H, 
Bow man EP, Mehta A, Li Q, Zhou Y, Shames R. Tildrakizumab (MK -3222), an ant i-
interleukin -23p19 m onoclonal antibody , improves psori asisin a phase IIb rando mized 
placebo -controlled trial. Br J Dermatol . 2015;173(4):930-939.
Reich K, Armstrong AW, Foley P, Song M, Wasfi Y, Randazzo B, Li S, Shen YK, Gordon KB. 
Efficacy and safet y ofguselkumab , an ant i-interleukin -23 m onocl onal ant ibody, co mpared 
with adalimumab for the treatment of patients with moderate to severe psori asiswith 
rando mized withdrawal and retrea tment: Resul ts from the phase III, double -blind, pl acebo -
and act ive co mparator -controlled VOYAGE 2 trial. J Am Acad Dermatol . 
2017b;76(3):418 -431.
Reich K, Bissonnette R, Menter A, Klekotka P, Patel D, Li J, Tuttle J, Papp K. Efficacy and 
safet y of mirikizumab (LY3074828) in the treatment of moderate -to-severe plaque psoriasis: 
resul ts from a phase II study . Psori asis Gene to Clinic, 8th International Congress. The Queen 
Elizabeth II Conference Centre, London, U.K., 30th November –2nd December 2017. Br J 
Dermatol . 2017a;177:e249 . 
[Reilly  Associates] Reilly Associates WPAI Scoring. Available at:  
http://www.reillyassociates.net/WPAI_Scoring.html. Accessed March 12, 2018.
Reilly MC, Zbrozek AS, Dukes EM. The validit y and reproducibilit y of a work productivi ty and 
activit y impairment instrument. Pharmacoeconomics . 1993;4(5):353 -365.
Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, 
Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, 
Colombel JF. Infliximab for induct ion and m aintenance therapy  for ulcerative colit is. N Engl J 
Med. 2005;353(23):2462 -2476.
Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, Adedokun OJ, Guzzo C, 
Colombel JF, Reinisch W, Gibson PR, Collins J, Järnerot G, Hibi T, Rutgeerts P; 
PURSUIT -SC Study Group. Subcutaneous golimumab induces clinical response and remissio n 
in patients with moderate -to-severe ulcerat ive co litis. Gastroenterology . 2014a;146(1):85- 95; 
quiz e14 -15.
Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, Adedokun OJ, Guzzo C, 
Colombel JF, Reinisch W, Gibson PR, Collins J, Järnerot G, Rutgeerts P; 
PURSUIT -Maintenance Study Group. Subcutaneous golimumab maintains clinical response in 
patients wi th moderate -to-severe ulcerat ive colit is. Gastroenterology . 2014b;146(1):96-109. e1. 
Sandborn WJ, Gasink C, Gao L -L, Blank MA, Johanns J, Guzzo C, Sands BE, Hanauer SB, 
Targan S, Rutgeerts P, Ghosh S, de Villiers WJS, Panaccione R, Greenberg G, Schreiber S, 
I6T-MC-AMBG(a) Clinical Protocol Page 97
LY3074828Lichtiger S , Feagan BG ,CERTIFI Stud y Group . Ustekinumab induct ion and m aintenance 
therapy  in refractory Crohn's disease . N Engl J Med . 2012b;367(16):1519-1528.
Sandborn WJ, van Assche G, Reinisch W, Colo mbel JF, D’Haens G, Wolf DC, Kron M, Tighe 
MB, Lazar A, Thakkar RB. Adalimumab induces a nd maintains clinical remission in pat ients 
with moderate -to-severe ulcerat ive colit is. Gastroenterology. 2012a;142(2):257 -265.e1 - 3.
Sands BE. Bio markers of inflammat ion in inflammatory  bowel  disease. Gastroenterology.
2015;149(5):1275 -1285.e2.
Sands BE, Chen J, Feagan BG, Penney M, Rees WA, Danese S, Higgins PDR, Newbo ld P, 
Faggio ni R, Patra K, Li  J, Klekotka P, Morehouse C, Pul kstenis E, Drappa J, van der Merwe R, 
Gasser RA Jr. Efficacy  and Saf ety of MEDI2070, an Ant ibody  Against Interleukin 23, in 
Patients Wit h Moderate to Severe Crohn’s Disease: A Phase 2a Study. Gastroenterology . 
2017;153(1):77 -86.e6.
Scherl EJ, Pruitt R, Gordon GL, Lamet M, Shaw A, Huang S, Marey a S, Forbes WP.  Safet y and 
efficacy  of a new 3.3 g b.i .d. tablet form ulation in patients with mild-to-moderately- active 
ulcerat ive co litis: a mult icenter, randomized, double -blind, placebo -controlled study . Am J 
Gastroenterol . 2009;104(6) :1452 -1459.
Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5- aminosalicylic acid therapy  for mildly 
to moderately act ive ulcerative colit is. A rando mized study. N Engl J Med . 
1987;317(26):1625 -1629.
Sofen H, Smit h S, Matheson RT, Leonardi CL, Calderon C, Brodmerkel C, Li K, Campbell K, 
Marciniak SJ Jr, Wasfi Y, Wang Y, Szapary  P, Krueger JG. Guselkumab (an IL-23-specific 
mAb) demonstrates clinical and mo lecular response in patients with moderate -to-severe 
psori asis. J Allergy Clin Immunol . 2014;133(4):1032
-1040.
Teng MW, Bowman EP, McElwee JJ, Smyt h MJ, Casanova JL, Cooper AM, Cua DJ. IL -12 and 
IL-23 cy tokin es: from discovery  to targeted therapies for immune -mediated inflammatory  
diseases. Nat Med . 2015;21(7):719 -729.
Tontini GE, Bi sschops R, Neumann H. Endoscopic scoring systems for in ﬂammatory  bowel  
disease: Pros and cons. Expert Rev Gastroenterol Hepatol. 2014;8:543 -554. 
Ware JE Jr. SF -36 health survey update. Spine (Phila Pa 1976) .2000;25(24):3130 -3139. 
Ware JE Jr, Sherboune CD. The MOS 36- item short -form health survey  (SF-36). I. Conceptual 
framework and item select ion. Med Care . 1992;30(6) :473-483.
[WHOa] World Healt h Organization. WHO guidelines on tuberculosis. Available at: 
http://www.who.int/publications/guidelines/tuberculosis/en
.Accessed November 21, 2017.
[WHO b] Worl d Heal th Organizat ion. Use of high burden country  lists for TB by  WHO in the 
post -2015 era. Available at: 
http://www.who.int/tb/publicat ions/gl obal_report/high_tb_burdencountrylists2016 -2020.pdf. 
Accessed September 5, 2017.
Wint hrop KL, Novosad SA, Baddley JW, Calabrese L, Chiller T, Polgreen P, Bartalesi F, 
Lipman M, Mariette X, Lorth olary  O, Weinblatt ME, Saag M , Smolen J. Opportunist ic 
infect ions and bio logic therapies in immune -mediated i nflammatory  diseases: consensus 
I6T-MC-AMBG(a) Clinical Protocol Page 98
LY3074828recommendat ions for infecti on reporting during clinical trials and postmarket ing surveillance. 
Ann Rheum Dis . 2015;74(12) :2107 –2116.
I6T-MC-AMBG(a) Clinical Protocol Page 99
LY307482812. Appendices
I6T-MC-AMBG(a) Clinical Protocol Page 100
LY3074828Appendix 1. Abbreviations and Definitions
I6T-MC-AMBG(a) Clinical Protocol Page 101
LY3074828Term Definition
5-ASA 5-aminosalicylic acid
6-MP 6-mercaptopurine
ADA Anti-
drug antibody
ADR adverse drug reactions
AE adverse event:  Any untoward medical occurrence in a patient or clinical investigation 
patient administered a pharmaceutical product that does not necessarily have a causal 
relatio nship with this treatment.  An adverse event can therefore be any unfavorable and 
unintended sign (including an abnormal laboratory finding), symptom, or disease 
temporally  associated with the use of a medicinal (investigational) product, whether or not 
related to the medicinal (invest igational) product.
AESI adverse events of special interest
ALP alkaline phosphatase
ALT alanine aminotransferase
anti- HBc anti-hepatitis B core antibody
AST aspartate aminotransferase
AZA azathioprine
BCG Bacillus Calmette -Guerin
blinding A double -blind study is on e in which neither the patient nor the investigator or sponsor 
staff who are involved in the treatment or clinical evaluation of the patient s are aware of 
the treatment received.
CI confidence interval
clinical research 
physician Individual responsible for the medical conduct of the study.  Responsibilities of the 
clinical research physician may be performed by a physician, clinical research scientist, 
global safety physician, or other medical officer.
CMH Cochran -Mantel -Haenszel
complaint Any written, electronic, or oral communication that alleges deficiencies related to the 
identity, quality, purity, durability, reliability, safety or effectiveness, or performance of a 
drug o r drug delivery system.
compliance Adherence to all study -related, good clinical practice, and applicable regulatory 
requirements.
CRP C-reactive protein
CSR clinical study report
I6T-MC-AMBG(a) Clinical Protocol Page 102
LY3074828C-SSRS Columbia -Suicide Severity Rating Scale
DALM dysplasia -associated lesion or mass
DMC Data Monitoring Committee
ECG electrocardiogram
eCOA electronic clinical outcome assessment
eCRF electronic case report form
EIM extraintestinal manifestations
enroll The act of assigning a patient to a treatment.  Patients who are enrolled in the study are 
those who have been assigned to a treatment.
enter Patients entered into a study are those who sign the informed consent form directly or 
through their legally acceptable representatives.
EQ-5D 5L European Quality of Life 5-Dimension 5 Level
ERB ethical review board
ES endoscopic subscore(s)
ETV early  termination visit
EUDRA European Union Drug Regulatory Authorities
FSH follicle -stimulating hormone
FWER family -wise type I error rate
GEMINI 1 Phase 3, Randomized, Placebo -Controlled, Blinded, Multicenter Study of the Induction 
and Maintenance of Clinical Response and Remission by Vedolizumab (MLN0002) in 
Patients with Moderate to Severe Ulcerative Colitis (GEMINI 1)
GCP Good Clinical Practice
GMP Good Manufacturing Practices
HBsAg hepatitis B surface antigen
HBV hepatitis B virus
HCV hepatitis C virus
IB Investigator’s Brochure
IBDQ Inflammato ry Bowel Disease Questionnaire
ICF informed consent form
I6T-MC-AMBG(a) Clinical Protocol Page 103
LY3074828ICH International Council for Harmonisation
IgG4 immunoglobulin G4
IL interleukin
IRC internal review committee
IV intravenous
informed consent A process by which a patient voluntarily confirms his or her willingness to participate in a 
particular study after having been informed of all aspects of the study that are relevant to 
the patient decision to pa rticipate.  Informed consent is documented by means of a written, 
signed ,and dated informed consent form.
interim analysis An analy sis of clinical study data, separated into treatment groups, that is conducted 
before the final reporting database is creat ed/locked.
investigational product A pharmaceutical form of an active ingredient or placebo being tested or used as a 
reference in a clinical trial, including products already on the market when used or 
assembled (formulated or packaged) in a way differen t from the authorized form, or 
marketed products used for an unauthorized indication, or marketed products used to gain 
further information about the authorized form.
IWRS interactive web -response sy stem
LOR Loss of Response
LS least squares
LTBI latent tuberculosis infection 
mITT All randomized/enrolled patients who received at least 1 dose of study treatment, do not 
receive the correct treatment, or otherwise do not follow the protocol. Patients will be 
analy zed according to the treatment to w hich they were assigned
MMRM mixed-effects model ofrepeated measures
MMS modified Mayo Score
MOS margin of safety
NOAEL no-observed -adverse -effect level
NRI nonresponder imputation
NRS numeric rating scale
PASI Psoriasis Area and Severity Index
PD pharmacodynamic(s)
I6T-MC-AMBG(a) Clinical Protocol Page 104
LY3074828PGA Physician’s Global Assessment
PGRC Patient’s Global Rating of Change
PGRS Patient’s Global Rating of Severity
PK pharmacokinetic (s)
PRO patient -reported outcomes
Q4W every 4 weeks
QIDS -SR16 Quick Inventory of Depressive Symptomatology
—Self -Report (16 Items )
RB rectal bleeding
SAE serious adverse event
SAC statistical analysis center
SAP statistical analysis plan
SC subcutaneous
SF stool frequency
SF-36 Medical Outcomes Study 36 -Item Short Form Health Survey
screen The act of determining if an individual meets minimum requirements to become part of a 
pool of potential candidates for participation in a clinical study. 
SUSAR suspected unexpected serious adverse reaction
TB tuberculosis
TBL total bilirubin le vel
TE-ADA treatment -emergent antidrug antibody
TEAE treatment -emergent adverse event
UC ulcerative colitis
UCEIS Ulcerative Colitis Endoscopic Index of Severity
ULN upper limit of normal
UV unscheduled visit 
WPAI:UC Work Productivity and Activity Impairment Questionnaire Ulcerative Colitis
I6T-MC-AMBG(a) Clinical Protocol Page 105
LY3074828Appendix 2. Clinical Laboratory  Tests
I 6 T -M C -A M B G( a) Cli ni c al Pr ot o c ol P a g e 1 0 6 
L Y 3 0 7 4 8 2 8 He m at ol o g y a, b Cli nic al C he mistr y a, b 
He m o gl o bi n Ser u m C o nce ntr ati o ns of: 
He mat ocrit S o di u m 
Er y t hr oc y te c o u nt ( R B C) C hl ori de 
Mea n cell v ol u me Bicar b o nate 
Mea n cell he m o gl o bi n P otassi u m 
Mea n cell he m o gl o bi n c o nce ntrati o n T otal bilir u bi n 
Le u k oc ytes ( W B C) T otal pr otei n 
Cell m or p h ol o g y Direct bilir u bi n 
Ne utr o p hils, se g me nte d Al kali ne p h os p hatase ( A L P) 
L y m p h oc y t es Ala ni ne a mi n otra nsferase ( A L T) 
M o n oc ytes As partate a mi n otra nsferase ( A S T) 
E osi n o p hils Ga m ma -Gl uta m yl Tra nsferase ( G G T) 
Bas o p hils Bl o o d urea nitr o ge n ( B U N) 
Platelets Creati ni ne 
Ur ic aci d 
Calci u m 
Gl uc ose 
Al b u mi n 
C h olester ol (t otal) 
Tri gl yceri des 
Li pi d Pa nel (fasti n g) c
H D L ch olester ol 
L D L ch olester ol 
Creati ne ki nase ( C K) 
Ot her Tests a
He patitis B D N A P C R (if i n dicate d) b, d
Pre g na nc y test ( ur i ne e)
F S H b, e
 
A nti- miri kiz u ma b a nti b o dies (i m m u n o ge nicit y) 
Ser u m miri kiz u ma b c o nce ntrati o n ( P K) 
C- reacti ve pr otei n, hi g h -se nsiti vit y 
Cl ostri di u m difficile f,ga n d St o ol C ult ure g
Fecal cal pr otecti n 
E x pl o rat or y  c y t o ki nes 
Tr y ptase h
C o m ple me nt ( C 3/ C 4) h
C y t o ki ne pa nel h
F o ot n otes o n next p a ge. C CI 
I6T-MC-AMBG(a) Clinical Protocol Page 107
LY3074828Abbreviations:  ADA = anti -drug antibody; anti-HBc+  = positive anti -hepatitis B core antibody ; 
DNA =deoxyribonucleic acid; FSH =follicle -stimulating hormone; HBsAg - =negative hepatitis B surface 
antigen; HBV = hepatitis B virus; HDL = high density lipoprotein; LDL = low density lipoprotein 
PCR =polymerase chain reaction; PK = pharmacokinetic; RBC = red blood cell; RNA = ribonucleic acid; 
SC=subcutaneous; WBC =white blood cell.
aAssay ed by Lilly -designated laboratory.
bResult s will be confirmed by the Central Lab oratory/other at the time of initial testing.
cFor the fasting lipid profile ,patients should not eat or drink anything except water for 12 hours prior to test .
dHepatitis B PCR testing will be performed in patients known from induction study to be HBsAg -, anti -HBc+, 
and in whom HBV DNA wasnot detected .
eUrine pregnancy test will be evaluated locally.   FSH test can be performed to confirm that women ≥50 years of
age with spontaneous amenorrhea for at least 6 months lack childbearing potential, see Inclusion Criteria [ 4b].
fTo be performed only for patients with secondary loss of response after at least 3 maintenance SC doses to 
determine eligibility for rescue d osing.
gCan be done locally by investigator as needed
hPerformed only i n the event of systemic allergic/hypersensitivity events, along with ADA and PK .
I6T-MC-AMBG(a) Clinical Protocol Page 108
LY3074828Appendix 3. Study  Governance Considerations
I6T-MC-AMBG(a) Clinical Protocol Page 109
LY3074828Appendix 3.1.Regulatory and Ethical Considerations, Including the 
Informed Consent Process
Appendix 3.1.1 .Informed Consent
The invest igator is responsible for:
Ensuring that the patient /patient’s legal representative understands the nature 
of the study , the potenti al risks and benefi ts of participat ing in the study , and
that their participat ion isvoluntary .
Ensuring that informed consent is given by each patientor legal 
representative.  This includes obtaining the appropriate signatures and dates 
on the informed consent form ( ICF) prior to the performance o f any protoc ol 
procedures and prior to the administration of investigat ional product.
Answering any quest ions the patient /patient’s legal representative may have 
throughout the study  and sharing in a timely manner any  new informat ion 
that may  be relevant to the patien t’s/patient’s legal representative ’s
willingness to continue his or her participat ion in the study .
Ensuring that a copy  of the ICF is provi ded to the parti cipant or the 
participant’s l egal representative and is kept on file.
Ensuring that the medical reco rd includes a statement that written informed 
consent was obtained before the participant was enrolled in the study  and the 
date the written consent was obtained. The authorized person obtaining the 
inform ed consent m ust al so sign the ICF.
Appendix 3.1.2 .Recruitment
Eli Lilly and Com pany  (Lilly) is responsible for the central recruit ment strategy  for pati ents.  
Individual investigators may have addit ional local requirements or processes.
Appendix 3.1. 3. Ethical Review
The invest igator must give assurance that the ethical review board (ERB) was properly 
constituted and convened as required by Internat ional Council for Harm onisati on (ICH) 
guidelines and other applicable laws and regulations.
Docum entati on of  ERB approval  of the protocol and the ICF must be provided to Lilly  before the 
study  may begin at the investi gative si te(s).  Lilly  or its representatives must approve the ICF, 
including any  changes made by the ERB (s), before it i s used at the invest igative site(s).  Al l ICFs 
must be compliant with the ICH guideline on Good Clinical Pract ice (GCP ).
The study  site’s ERB(s) shoul d be provided wi th the f ollowing:
Theprotocol  and rel ated am endments and addenda ,current Invest igator 
Brochure ( IB),and updates during the cour se of the study
ICF
I6T-MC-AMBG(a) Clinical Protocol Page 110
LY3074828Other relevant docum ents ( for example , curri cula vi tae, adverti sements)
Appendix 3.1. 4. Regulatory Considerations
This study  will be conducted in accordance wit hthe protocol and with the:
Consensus ethics principles derived fro m internat ional ethics guidelines, 
including the Declarat ion of Helsinki and Council forInternational
Organizat ionsofMedical Sciences (CIOMS ) Internat ional Ethi cal Guidelines
Applicable ICH GCP Guidelines
Applicable laws and regulations
Some of the obligat ions of the sponsor will be assigned to a third party .
Appendix 3.1. 5. Investigator Information
Physicians with a specialt y in gastroenterol ogywill participate as investigators in this clinical 
trial.  Site-specifi c contact informat ion may be provided in a separate document.  
Appendix 3.1. 6. Protocol Signatures
The sponsor’s responsible medical o fficer will approve the protocol, confirming that, to the best 
of his or her knowledge, the protocol accurately  describes the planned design and conduct of 
thestudy .
After reading the protocol, each principal invest igator will sign the protocol signature page and 
send a copy  of the signed page to a Lilly representative.
Appendix 3.1. 7. Final Report Signature
The clinical study  report ( CSR )coordinating investigator will sign the final CSR for this study , 
indicat ing agreement that, to the best of his or her knowledge, the report accurately describes the 
conduct and results of the study .
TheCSR coordinat inginvest igator wil lbe selected by the study  team .  If this invest igator is 
unable to fulfill this funct ion, another invest igator will be chosen by Lilly to serve as the CSR 
coordinat ing investigator.
The sponsor’s responsible medical o fficer and statistician will approve t he final CSR for thi s 
study , confirming that, to the best of his or her knowledge, the report accurately describes the 
conduct and results of the study .
Appendi x 3.2. Data Quality Assurance
To ensure accurate, complete, and reliable data, Lilly or its repr esentatives will do the fo llowing:
Provide instructi onal material to the study  sites, as appropriate
Sponsor start -up training to instruct the investigators and study coordinators.  This 
training will give instruction on the protocol, the complet ion of the electroni c case 
report forms ( eCRFs ), and study  procedures.
I6T-MC-AMBG(a) Clinical Protocol Page 111
LY3074828Make peri odic visi ts to the study  site
Beavailable for consultation and stay  in contact wit h the study  site personnel  by 
mail, tel ephone, and/or fax
Review and evaluate eCRF data and use standard computer edits to detect errors 
in data collect ion
Conduct a qualit y review of the database
In addit ion, Lilly or its representatives will per iodically check a sample of the patient data 
recorded against source documents at the study  site.  The study  may be audi ted by  Lilly or i ts 
representatives, and/or regulatory  agencies at any  time.  Invest igators wi ll be given noti ce before 
an audit occurs.
The invest igator will keep records of all original source data.  This might include laboratory 
tests, m edical records, and clinical notes.  If requested, the invest igator will provide the sponsor, 
applicable regul atory  agencies, and applicable ERBs with direct access to original source 
docum ents.
Appendix 3.2.1. Data Capture System
An eCRF system  will be used in this study .The site maintains a separate source for the data 
entered by  the si te into the sponsor -provided eCRF system .  The eCRF data will be encoded and 
stored in a clinical trial database.
Electronic clinical outcome assessments (eCOA) measures (quest ionnaires, scales, self -reported 
diary data, etc .) will be collected by the patients and si te personnel at the time that the 
inform ation is obtained.  In these instances, where there is no prior written or electronic source 
data at the site, the eCOA data record will serve as the source.  The eCOA data will be stored at a 
third party  site.  Invest igator sites will have continuous access to the source documents during 
the study  and will  receive an archival copy  at the end of the study  for retenti on.  Any data for 
which the eCOA instrument record will serve to collect source data will be id entified and 
docum ented by  each si te in that si te’s study  file.  
Data m anaged by  a central  vendor, such as laboratory  test data or endoscopy  data, will be stored 
electroni cally in the central vendor’s database syst em.Data will subsequent ly be transferred 
from the central  vendor to the Lilly data warehouse. 
Data from co mplaint forms submitted to Lilly will be encoded and stored in the global product 
complaint management sy stem .
Appendix 3.3. Study and Site Closure
Appendix 3.3.1. Discontinuation of Study Sites
Study  site parti cipat ion may be discont inued if Lilly  or its desi gnee , the invest igator, or the ERB 
of the study  sitejudges it necessa ry for medical , safet y, regulatory , or other reasons consistent 
with applicable l aws, regul ations, and GCP.
I6T-MC-AMBG(a) Clinical Protocol Page 112
LY3074828Appendix 3.3.2. Discontinuation of the Study
The study  will be di scontinued if Lilly or its designee judges it necessary  for m edical, safet y, 
regul atory, or other reasons consistent with applicable laws, regulat ions, and GCP.
Appendix 3. 4. Publication Policy
The publicat ion policy for Study  I6T-MC-AMBG (AMBG) is described in the letters of 
agreem ent between the sponsor and the invest igators and institutions.
I6T-MC-AMBG(a) Clinical Protocol Page 113
LY3074828Appendix 4. Hepatic Monitoring Tests for 
Treatment -Emergent A bnormality
I6T-MC-AMBG(a) Clinical Protocol Page 114
LY3074828Selected tests m ay be obtained in the event of a treatment -emergent hepatic abnormalit y and may  
be required in fo llow-up wi th patients in consultat ion with the Lilly , or i ts desi gnee, clinical 
research physician.   These tests will be performed at a Lilly -designated l aboratory .
Hepatic Monitoring Tests
Hepatic Hematology Haptoglobin
Hemoglobin
Hematocrit Hepatic Coagulation
RBCs Prothrombin Time
WBCs Prothrombin Time, INR
Neutrophils, segmented
Lymphocy tes Hepatic Serologiesa
Monocytes Hepatitis A antibody, total
Eosinophils Hepatitis A antibody, IgM
Basophils Hepatitis B surface antigen
Platelets Hepatitis B surface antibody
Hepatitis B core antibody 
Hepatic Chemistry Hepatitis C antibody 
Total bilirubin Hepatitis E antibody, IgG
Direct bilirubin Hepatitis E antibody, IgM
Alkaline phosphatase
ALT Anti -nuclear antibody
AST
GGT Alkaline phosphatase isoenzymes
CPK
Anti -smooth muscle antibody (or anti-actin 
antibody)
Abbreviations:  ALT = alanine aminotransferase; AST = aspartate aminotransferase; CPK = creatinine 
phosphokinase; GGT = gamma -glutamyl transferase; Ig = immunoglobulin; INR = international normalized 
ratio; RBC = red blood cell; WBC = white blood cell.
aReflex/confirmation dependent on regulatory requirements and/or testing availability.
I6T-MC-AMBG(a) Clinical Protocol Page 115
LY3074828Appendix 5. Risk Factors for Latent Tuberculosis Infection 
I6T-MC-AMBG(a) Clinical Protocol Page 116
LY3074828Risk Factors for Latent Tuberculosis Infection
Household contact or recent exposure to an active case
Birth or residency in a high burden country (>20/100,000)
Residents and employees of high risk congregate settings, for example, prisons, homeless ness, intravenous drug use
Source:  Adapted from Horsburgh andRubin (2011) and Lewinsohn et al. (2017 ).
Risk Factors for Increased Likelihood of Progression from LTB I to Active TB
Household contact or close contact with an active case
HIV
Radiographic evidence of old, healed TB that was not treated
Silicosis
Treatment with ≥15 mg prednisone (or equivalent) per day
Children <5 years of age
Chro nic renal failure
Treatment with an anti -TNF antibody
Poorly controlled diabetes
Intravenous drug use
Weight ≥10% below normal
Smoking
Abbreviations:  HIV = human immunodeficiency virus; LTBI = latent tuberculosis infection; TB = tuberculosis ; 
TNF =tumor necrosis factor .
Source:  Adapted from Horsburgh andRubin (2011).
WHO List of High Burden Countries (as at 28Oct2015 , includes but may not be limited to)
Angola India Peru
Azerbaijan Indonesia Philippines
Bangladesh Keny a Russian Federation
Belarus Kazak hstan Sierra Leone
Botswana Democratic People’s Republic of Korea Somalia
Brazil Kyrgyzstan South Af rica
Cambodia Lesotho Swaziland
Cameroon Liberia Tajikistan
Central African Republic Malawi United Republic of Tanzania
Chad Republic of Moldova Thailand
China Mozambique Uganda
Congo Myanmar Ukraine
Democratic Republic of the Congo Namibia Uzbekistan
Ethiopia Nigeria Vietnam
Ghana Pakistan Zambia
Guinea -Bissau Papua New Guinea Zimbabwe
Source: WHO b[WWW]
I6T-MC-AMBG(a) Clinical Protocol Page 117
LY3074828Appendix 6. Mayo Scoring Sy stem for the A ssessment of 
Ulcerative Colitis A ctivity
I6T-MC-AMBG(a) Clinical Protocol Page 118
LY3074828Stool Frequency (SF) Subscore Score
Normal number of stools for subject 0
1 to 2 stools more than normal 1
3 to 4 stools more than normal 2
5 or mo restools than normal 3
Rectal Bleeding (RB) Subscore Score
No blood seen 0
Streaks of blood with stool less than half of the time 1
Obvious blood (more than just streaks) or streaks of blood with stool most of the 
time2
Blood alone passed 3
Endoscopic Subscore (ES) Score
Normal o r inactive disease 0
Mild disease (erythema, decreased vascular pattern) 1
Moderate disease (marked erythema, absent vascular pattern, friability, erosions) 2
Severe disease (spontaneous bleeding, ulceration) 3
Physician’s Global Assessment (PGA) Score
Normal 0
Mild disease 1
Moderate disease 2
Severe disease 3
Mayo Score = Stool Frequency (SF) + Rectal Bleeding (RB) + Endoscopic Subscore (ES) + Physician's Global 
Assessment (PGA)
Note:  The Mayo score ranges from 0 to 12, with higher scores indicating more severe disease.  Modified Mayo 
score excludes PGA and ranges from 0 to 9.  Composite SF and RB score ranges from 0 to 6.  The original 
description of the Mayo score included fria bility in the definition of an ESof 1.  Consistent with current clinical 
practice and regulatory guidance, this study excludes friability from the definition of an ESof 1.
Stool frequency reports the number of stools in a 24 -hour period, relative to the normal number of stools for that 
patient. The reference “normal” stool frequency for that patient will be recorded electronically at the screening visit
in Study AMAN .  The Normal SF refers to when the patient was in remission or, if the patient has never achieved 
remission, the reported SF before initial onset of signs and symptoms of ulcerative colitis .  Remission refers to a 
period of time since being diagnosed with ulcerative colitis when the patient is not experiencing any signs or 
symptoms relating to ulcerative colitis .This period of time may last a few weeks or a few months or may even last 
several years. The patient will record this electronically as source data in the tablet device at the screening study 
visit in Study AMAN .
Source:  Adapted from Schroeder et al. (1987) andScherl et al. (2009)
I6T-MC-AMBG(a) Clinical Protocol Page 119
LY3074828Appendix 7. Patient -Reported Outcome Instruments
I6T-MC-AMBG(a) Clinical Protocol Page 120
LY3074828Daily Diary Review
Rectal Bleedinga
Stool Frequencya
Urgency NRSa
Abdominal Pain NRSa
PGRSa
Nocturnal Stoolb
Fatigue NRSb
Bristol Stool Scaleb
Abbreviations: NRS = numeric rating scale; PGRS = Patient’s Global Rating of Severity
aQuestion will be administered daily through Week 40 or early termination visit.
bQuestion will be administered at Visits 2 through 10 (Weeks 4 through 36), and daily between Visit 10 and 
Visit
11.
The fo llowing are descript ions of additionalpatient-reported outcome instruments used in Study 
AMBG using Pati ent eDi aryor tablet device :
Urgency Numeric Rating Scale ( NRS )
:  Asingle item that measures the severit y ofthe 
urgency (sudden or immediate need) to have a bowel mo vement in the past 24 hours ,
using an 11- point NRS ranging fro m 0 (no urgency) to 10 (worst possible urgency ).  
Patients will be provided wit h an electronic diary  tool during screening to record 
inform ation daily pertaining to their severit y of urgency .
Abdominal Pain NRS: Asingle item that measures the “worst abdo minal pain in the 
past 24 hours” using an 11 -point NRS ranging from 0 (no pain) to 10 ( worstpossible 
pain).  Pati ents will  be provi ded wi th an el ectroni c diary tool during screening to record 
inform ation daily pertaining to their worst abdominal pain experience.
Patient’s Global Rating of Severity (PGRS): The PGRS is a 1- item patient-rated 
questionnaire designed to assess the patients’ rating of their disease symptom severit y 
over the past 24 hours. Responses are graded on a 6- point scale in which a score of 1 
indicates that the patient has no symptoms ( that is, “none”) and a score of 6 indicates that 
the pati ent’s symptom(s) are “very severe.” Patients will  be provi ded wi th an el ectroni c 
diary tool during screening to record informat ion daily  pertaining to thei r disease 
experience. 
Nocturnal Stool :The Nocturnal Stool instrument is a single item asking the patient to 
record the number of stools they  had during the night (or day , for shift workers) ,causing 
them to waken fro m sleep. Patients will be provided with an electronic diary tool during 
screeni ng to record i nformat ion daily pertaining to their nocturnal stool count during 
appropriate time periods. Patients will also record their response to the nocturnal stool 
count el ectronically  as source data in the tablet device at appropriate visits .
Fatigue NRS :  The Fatigue NRS is a single item that measures the “worst fat igue 
(weariness, tiredness) in the past 24 hours” using an 11 -point NRS ranging fro m 0 (no 
fatigue) to 10 (fat igue as bad as you can imagine). Patients will be provided with an 
electron ic diary tool during screening to record information daily pertaining to their worst 
fatigue experience during appropriate time periods .  Patients will also record their 
I6T-MC-AMBG(a) Clinical Protocol Page 121
LY3074828response to the Fatigue NRS electronically  as source data in the tablet device at 
appropriate visit s.
Bristol Stool Scale: The Bri stol Stool  Scale i s a single i tem that provi des a pi ctorial and 
verbal descript ion of stool consistency and form ,ranging fro m Type 1 ( hard lumps) to 
Type 7 ( watery /liquid).  Pati ents will  be provi ded wi th an el ectroni c diary  tool during 
screening to record informat ion daily pertaining to their stool during appropriate time 
periods.Patients will also record their response to the Bristol Stool Scale electronically 
as source data in the tablet device at appropria te visi ts.
Patient’s Global Rating of Change (PGRC): The PGRC scale is a patient -rated 
instrum ent desi gned to assess the patients’ rating of change in their symptom(s).   
Responses are graded on a 7 -point Likert scale ,in which a score of 1 indicates that the 
subject’s symptom(s) is “very  much better,” a score of 4 indicates that the subject’s 
symptom (s)has experienced “no change,” and a score of 7 indicates that the subject’s 
symptom (s) is “very  much worse.” Patients will record their response to the PGR C 
electroni cally as source data in the tablet device at appropriate visit s.
Inflammatory Bowel Disease Questionnaire (IBDQ) :  A 32- item patient-completed 
questionnaire that measures 4 aspects of patients’ lives:  symptoms direct ly related to the 
primary  bowel disturbance, systemic symptoms, emot ional funct ion, and social funct ion 
(Guy att et al.
1989; Irvine et al. 1994, 1996).  Responses are graded on a 7- point Likert 
scale ,in which 7 denotes “not a problem at all” and 1 denotes “a very severe problem.” 
Scores range from 32 to 224; a higher score indicates a better qualit y of life.Patients will 
record their responses to the IBDQ electronically as source data in the tablet device at 
appropriate visit s.
European Quality of Life 5 -
Dimension 5 Level (EQ- 5D 5L):  Awidely used, generic 
questionnaire that assesses healt h status (Herdman et al. 2011; EuroQol Group 2015).  
The quest ionnaire consists of 2 parts.  The first part assesses 5 dimensio ns (mobilit y, self-
care, usual activit ies, pain/disco mfort,and anx iety/depressio n) that have 5 possible levels 
of response (no problems, slight problems, moderate problems, severe problems, extreme 
probl ems).  Thi s part of the EQ -5D can be used to generate a healt h state index score, 
which is often used to compute qualit y-adjusted life y ears (QALY) for utilizat ion in 
healt h econo mic analyses.  The healt h state index score is calculated based on the 
responses to the 5 dimensio ns, providing a single value on a scale fro m less than 0 (where 
zero i s a healt h state equivalent to death; negat ive values are valued as worse than dead) 
to 1 (perfect healt h), wi th higher scores indicat ing better health ut ility(EuroQol  Group 
[WWW]) .  The second part of the questionnaire consists of a visual analog scale (VAS) 
on which the patient ra tes thei r perceived healt h state from 0 (the worst health you can 
imagine) to 100 (the best health you can imagine).  Patients will record their responses to 
the EQ -5D 5L electronically  as source data in the tablet device at appropriate visits.
Medical Out comes Study 36 -Item Short Form Health Survey (SF -36) Version 2:   A
patient-reported, generic, health -related quali ty of life instrument originally published in 
1992, with some item wordings and response options revised in 2000 (Ware and 
Sherbourne 1992; Wa re 2000). It consists of 36 questions measuring 8 healt h dom ains:  
physical funct ioning, bodily pain, role limitat ions due to physical problems, role 
I6T-MC-AMBG(a) Clinical Protocol Page 122
LY3074828limitations due to emotional problems, general healt h perceptions, mental health, social 
funct ion, and vi tality. The pat ient’s responses are solicited using Likert scales that vary  
in length, with 3 –6 response options per item. The SF -36 can be scored into the 8 health 
domains named above and 2overall summary scores:  physical co mponent summary 
(PCS) and mental com ponent summary  (MCS) scores.  The domain and summary scores 
range fro m 0 to 100; higher scores indicate better levels o f function and/or better health. 
The SF -36 versio n 2 (standard versio n) will be used, which utilizes the recall period of 
“the past 4 weeks ” (Ware and Sherbourne 1992; Marui sh 2011).  Pati ents will record 
their responses to the SF -36 Versi on 2 el ectroni cally  as source data in the tablet device at 
appropriate visit s.
Work Productivity and Activity Impairment Questionnaire: Ulcerative Colitis 
(WPAI:UC):   Apatient-reported instrument developed to measure the impact on work 
productivit y and regul ar act ivities attributable to a specific healt h probl em (WPAI:UC). 
It contains 6 items that measure: 1) em ployment status, 2) hours missed fro m work due 
to the specific healt h probl em, 3) hours missed from work for other reasons, 4) hours 
actually worked, 5) degree healt h affected productivit y while working, and 6) degree 
healt h affected productivit y in regular unpaid act ivities. Four scores are calculated fro m 
the responses to these 6 items: absenteeism, presenteeism, work productivit y loss, and 
activit y impairment (Reilly Associates [WWW]) . Scores are calculated as impairment 
percentages (Reilly et al. 1993), with higher numbers i ndicat ing greater impairment and 
less productivit y, that is, worse outcom es(Reilly Associates [WWW]) .  Pati ents will  
record their responses to the WPAI:UC electronically as source data in the tablet device 
at appropriate visits.
I6T-MC-AMBG(a) Clinical Protocol Page 123
LY3074828Appendix 8. Prohibited Medications
I6T-MC-AMBG(a) Clinical Protocol Page 124
LY3074828This sect ion outlines medications that are prohibited during the treatment phase of the study , if 
applicable.  Use of the medicat ions listed in this appendix is allowed at the discretion o f the 
investigator after a patient discont inues study  drug and co mpletes the early terminat ion visit.
Drug Class Comments
Anti- TNF antibodies ( for example , infliximab, adalimumab ,or 
golimumab)Prohibited throughout treatment period
Anti-integrin antibodies ( for example , vedolizumab) Prohibited throughout treatment period
Agents depleting B or T cells ( for example , rituximab, 
alemtuzumab, or visilizumab)Prohibited throughout treatment period
Immunomodulatory medications, including oral cyclosporine, 
IV cy closporine, tacrolimus, mycophenolate mofetil, 
thalidomide o r JAK inhibitors ( for example , tofacitinib) Prohibited throughout treatment period
Rectally  administered 5 -ASAs (enemas or suppositories) Prohibited throughout treatment period
Rectally  administered corticosteroids (enemas or suppositories) Prohibited t hroughout treatment period
Rectally  administered investigational preparations for UC such 
as arsenic preparationsProhibited throughout treatment period
Intravenous corticosteroids for UC A course of I V corticosteroids for UC is 
prohibited
Systemic corticosteroids for no n-UC indications (oral or IV) Patients requiring systemic 
corticosteroids for non -UC conditions 
are excluded.  Exceptions include
corticosteroi ds to treat adrenal 
insufficienc y, premedication for IP 
infusion, or l ocally admi nistered 
corticosteroids (e.g. ,inhaled, intranasal, 
intra-articular, topical) (see Appendix 
10)
Oral budesonide standard formulation (that is, not theoral 
budesonide extended release tablet formulation [budesonide 
MMX])Prohibited throughout treatment period.  
Any investigatio naltherapy  (biologic or nonbiologic) Prohibited throughout treatment period
Interferon therapy Prohibited throughout treatment period
Leukocyte apheresis (leukopheresis, for example , Adacolumn) Prohibited throughout treatment period
Anti-IL12p40 antibodies ( for example, ustekinumab [Stelara®]) 
or anti-IL-23p19 antibodies ( for example , risankizumab 
[BI-655066], brazikumab [MEDI -2070], guselkumab 
[CNTO1959], tildrakizumab [MK -3222]) for any indication, 
including investigational useProhibited throughout treatment period
Bacillus Calmette -Guerin (BCG) vaccine BCG vaccination prohibited throughout the 
duration of the study and for 12 months after 
discontinuation of study drug.
Live attenuated vaccines Live attenuated vaccines are prohibited 
throughout the duration of the study and for 
3months after discontinuation of study drug.
I6T-MC-AMBG(a) Clinical Protocol Page 125
LY3074828Abbreviations:  5 -ASA = 5 -aminosalicyclic; IL = interleukin; IV= intravenous; JAK = Janus Kinase ;TNF =tumor 
necrosis factor; UC = ulcerative colitis .
I6T-MC-AMBG(a) Clinical Protocol Page 126
LY3074828Appendix 9. Permitted Medications with Dose Stabilization
I6T-MC-AMBG(a) Clinical Protocol Page 127
LY3074828Drug Class Comments
Oral 5-ASAs (for example, mesalamine, 
balsalazide, olsalazide) and sulfasalazine 
for UC May continue during study with stable doses encouraged
Oral corticosteroids for UC (prednisone 
≤20mg/day  or equivalent , budesonide 
MMX 9 mg/day , or beclomethasone 
dipropionate [gastro -resistant prolonged -
release tablet] 5 mg/day )Responder patients who are receiving oral corticosteroids at the start of 
Study AMBG will start corticosteroid taper at the beginning of the 
study.  Clinical nonresponders who undergo extended IV induct ion with 
mirikizumab will begin corticosteroid tapering if symptomatic response 
or symptomatic improvement based on investigator discretion is 
achieved at any time after starting extended inductio n (see 
Corticosteroid Taper in Section 7.7).
Corticosteroids for non -UC indications: 
corticosteroids to treat adrenal 
insufficiency, as premedication for IP 
infusion, or locally adminis tered 
corticosteroids (e.g. inhaled, intranasal, 
intra-articular, topical).May continue corticosteroids to treat adrenal insufficiency or locally 
administered corticosteroids during study with stable dose encouraged.  
Single doses of oral or IV corticoste roids as premedication to IP 
administration are allowed in patients with prior IP or other previous 
biologic injection reactions.
Immunomodulators ( for example , AZA, 
6-MP, o r methrotrexatePrescribed dose will remain stable throughout the study unless 
medication is discontinued due to a toxicity related to the medication. 
Antidiarrheals ( for example , loperamide, 
diphenoxylate with atropine)May continue during study with stable doses encouraged
Low-dose or baby  aspirin (75 mg to
162.5 mg)Daily  use for cardiovascular prophylaxis permitted
Non-live (killed, inactivated or subunit) 
vaccinesAllowed during the study.  The efficacy of non -live vaccinations with 
concomitant mirikizumab treatment is unknown.
Abbreviations:  5-ASA = 5 -aminos alicy clicacid; 6 -MP = 6 -mercaptopurine; AZA = azathioprine; IV= intravenous ; 
IP = investigational product; UC = ulcerative colitis.
I6T-MC-AMBG(a) Clinical Protocol Page 128
LY3074828Appendix 10. Additional Information on Sy stemic Drug 
Administration Reactions
I6T-MC-AMBG(a) Clinical Protocol Page 129
LY3074828A systemic drug administration reaction is defined if any of the fo llowing symptom s is present, 
in the absence of other plausible and more likely etio logy, per investi gator j udgment: 
Generalized urticaria or pruritus 
Angioedema at a location other than the inject ion site
Throat ti ghtness
Difficult y swall owing/tal king
Stridor
Chest tightness/dyspnea
Wheeze/bronchospasm
Hypoxemia
“Sense of impending doom ”
Hypotensi on (systolic blood pressure change > 20 mmHg from baseline)
Syncope
Collapse
Vomit ing 
Abdo minal pain
Diarrhea
Bladder/ bowel  incont inence
I6T-MC-AMBG(a) Clinical Protocol Page 130
LY3074828Appendix 11. Additional Information on the Columbia 
Suicide Severity  Rating Scale, and Quick Inventory  of 
Depressive Sy mptomatology  (Self Report)
I6T-MC-AMBG(a) Clinical Protocol Page 131
LY3074828Columbia Suicide Severity Rating Scale
The Columbia Suicide Severi ty Rating Scale (C -SSRS) was developed by the National Inst itute 
of Mental  Heal th Treatment of Adol escent Sui cide Attem pters tri al group for the purpose of 
being a counterpart to the Columbia Classificat ion Algori thm of Suicide Assessment 
categori zation of su icidal events.  For this study , the scale has been adapted (with permission 
from the scale authors) to include only  the porti on of  the scale that captures the occurrence of the 
11preferred ideat ion and behavior categories.  
Quick Inventory of Depressive Symptomatology —Self -Report (16 Items)
For the Qui ck Inventory  of Depressive Symptomatology —Self -Report (16 Items) (QIDS -SR16), 
apatient is asked to consider each statement as it relates to the way  they  have felt for the past 
7days.  There i s a 4-point scale for each item ranging fro m 0 to 3.  The 16 items corresponding 
to 9 depression domains are summed to give a single score ran ging fro m 0 to 27, with higher 
scores denoting greater symptom severit y.  The domains assessed by  the instrum ent include:  
(1)sad mood, (2) concentration, (3) self -criticism, (4) suicidal ideat ion, (5) i nterest, 
(6)energy/fatigue, (7) sleep disturbance ( initial, middle, and late inso mnia or hypersomnia), 
(8)decrease/increase in appetite/weight, and (9) psycho motor agi tation/retardati on. Patients will 
record their responses to the QIDS -SR16 electronically as source data in the tablet device at 
appropriat e visit s.
I6T-MC-AMBG(a) Clinical Protocol Page 132
LY3074828Appendix 12. Protocol A mendment I6T -MC-AMBG(a)
Summary  A Phase 3, Multicenter, Randomized, Double -
Blind, Parallel -Arm, Placebo- Controlled Maintenance 
Study  of Mirikizumab in Patients with Moderately  to 
Severely  Active Ulcerative Colitis
LUCENT 2
Overview
Protocol  I6T-MC-AMBG ,A Phase 3, Mult icenter, Rando mized, Double -Blind, Parallel -Arm, 
Placebo -Controlled Maintenance Study  of Mirikizum ab in Pat ients with Moderately  to Severely 
Active Ulcerat ive Co litis LUCENT 2 has been amended.  The new protocol is indi cated by  
amendment (a) and will be used to conduct the study  in place of any preceding version o f the 
protocol .
The overall changes and rationale for the changes made to this protocol are described in the 
following table:
Amendment Summary for Protocol I6T -MC-AMBG A mendment (a)
Section # and Name Description of Change Brief Rationale
Section 1 Synopsis, Objective(s), 
EndpointsAdded/modified/removed Primary, 
Major secondary and Other 
secondary objectives /endpointsMatch Section 4 Objectives and 
Endpoints
Section 1 Synopsis, Statistical 
Analy sisClarified primary endpoint statistics Match Section 10 Statistical 
Considerations 
Section 2 Table AMBG.2.1
Schedule of Activities, Induction 
Responders,  Informed consentAdded that patients may consent 
between the start of V5 of Study 
AMAN Clarification of consent window
Section 2 Table AMBG.2.1
Schedule of Activities, Induction 
Responders, FSHAdded that FSH is optional in 
women to confirm nonchild-bearing 
potentialClarification of the patient for whom 
FSH should be performed
Section 2 Table AMBG.2.1
Schedule of Activities, Induction 
Responders,  PK Assessment and 
ADA AssessmentClarified that patients with potential 
hypersensitivity or infusion -related 
event should have sample taken as 
soon as possible aft er event occurs 
and at 4 and 12 to 16 weeks after 
the event.Clarification to be consistent with 
management of hypersensitivity and 
infusion related event section 
Section 2 Table AMBG.2.1
Schedule of Activities, Induction 
Responders,  C. Difficile Testin g 
and 
Fecal Calprotectin and Exploratory 
Fecal BiomarkersExpanded the timeframe for C. 
Difficile, Fecal Calprotectin and 
Explo ratory  Fecal Biomarkers 
testing to as early as V3 during the 
loss of response assessment Since loss of response assessment can 
start as early as V3, the window for 
C. Difficile, Fecal Calprotectin and 
Fecal Biomarkers were expanded to 
facilitate this assessment 
Section 2 Table AMBG.2.1
Schedule of Activities, Induction Clarified that loss of response has to 
be confirmed with endoscopy and Clarification of Table AMBG.2.2
Sche dule of Activities comment for 
I6T-MC-AMBG(a) Clinical Protocol Page 133
LY3074828Section # and Name Description of Change Brief Rationale
Responders,  Endoscopy with 
biopsiesadded clarification to refer to 
Section 9.1.1.3 of the protocol for 
specification of what endoscopic 
procedure can be performed whenEndoscopy with biopsies
Section 2 Table AMBG.2.1
Schedule of Activities, Induction 
Responders,  IBDQ, EQ -5D 5L, and 
PGRCAdded that health outcome 
assessments are to be performed for 
patients who have LOR confirmed 
by endosc opy before rescue dosing 
instead of for those with secondary 
LOR at the second of 2 LOR 
assessmentsClarification of when health outcome 
assessments for LOR should be 
performed
Section 2 Table AMBG.2.1
Schedule of Activities, Induction 
Responders,  Abbre viatio nsAdded abbreviation: DNA = 
deoxyribonucleic acidClarification of acronym in Table
Section 2 Table AMBG.2.1
Schedule of Activities, Induction 
Responders,  Footnote section Clarified the options that patients 
have after completing the last visit 
in AMBG or the ETV in AMBGClarification provided since Study
AMBG does not have an open label 
extension period but patients may 
qualify  for the long term extension 
Study I6T-MC -AMAP
Section 2 Table AMBG.2.1
Schedule of Activities, Induction 
Responders,  footnote aChanged that V1 (Week 0) should 
occur no more than 14 days instead 
of 10 day s from the start of the Visit 
5/Week 12 visit of Study AMAN Changes make the transition from 
AMAN to AMBG operationally 
acceptable while enabling AMAN 
Week 12 endoscopy to represent 
baseline status of disease severity in 
AMBG
Section 2 Table AMBG.2.2
Schedule of Activities, Induction 
Non-responders  Footnote letters reordered Editorial change 
Section 2 Table AMBG.2.2 
Schedule of ActivitiesUpdated window for V4 Allow more time for V4
Section 2 Table AMBG.2.2
Schedule of Activities, Induction 
Non-responders, Informed consentAdded that patients may consent 
between the start of V5 of AMAN 
and before any procedures at 
V1/Week 0 are performed instead of 
between the time of induction 
consent and before any procedures 
at V1/Week 0 are performedClarification of consent window
Section 2 Table AMBG.2.2
Schedule of Activities, Induction 
Non-responders, FSHAdded that FSH is optional in 
women to confirm nonchild-bearing 
potent ialClarification of the patient for whom 
FSH should be performed
Section 2 Table AMBG.2.2
Schedule of Activities, Induction 
Non-responders, PK and ADAClarified that patients with potential 
hypersensitivity or infusion -related 
event should have sample ta ken as 
soon as possible after event occurs 
and at 4 and 12 to 16 weeks after 
the eventClarification to be consistent with 
management of hypersensitivity and 
infusion related event section 
I6T-MC-AMBG(a) Clinical Protocol Page 134
LY3074828Section # and Name Description of Change Brief Rationale
Section 2 Table AMBG.2.2
Schedule of Activities, Induction 
Non-responders, C. difficile testingClarified that V1 C. difficile testing 
does not need to be completed 
before the patient can start study 
drug therapyClarification of C. difficile testing 
procedure at V1
Section 2 Table AMBG.2.2
Schedule of Activities, Induction 
Non-responders, Endoscopy with 
biopsiesAdded clarification to refer to 
Section 9.1.1.3 of the protocol for 
specification of what procedure can 
be performed when  Clarification for Endoscopy with 
biopsies 
Section 2 Tab le AMBG.2. 2
Schedule of Activities, Induction 
Non-responders,  Footnote sectionAdded “Notes” section describing 
when study procedures should be 
performed and patient options post 
study completion or early 
termination Information added to be consistent 
with the induction responder path of 
Study AMBG 
Section 2 Table AMBG.2.2
Schedule of Activities, Induction 
Non-responders, footnote aAdded that for patients who cannot 
continue beyond V4 because they 
did not achieve delayed clinical 
response, ETV activit ies that are 
performed as part of V4 do not need 
to be repeated.  Only those ETV 
activities that are not part of V4 
should be completed during the 
ETVClarification to minimize study 
procedures for patients who 
discontinue AMBG soon after 
completing V4
Section 2 Table AMBG.2.2
Schedule of Activities, Induction 
Non-responders, footnote bClarified that V1 (Week 0) should 
occur no more than 14 days instead 
of 10 day s from the start of the Visit 
5/Week 12 visit of Study AMANChanges make the transition from 
AMAN to AMBG operationally 
acceptable while enabling AMAN 
Week 12 endoscopy to represent 
baseline status of disease severity in 
AMBG
Section 4 Objectives and Endpoints, 
Table AMBG.4.1Moved “To test the hypothesis that 
mirikizumab is superior to placebo 
in achieving clinical remission at 
Week 40 amo ng patients induced 
into clinical response with 
mirikizumab in Study AMAN” 
from first Major Secondary 
Objective/Endpoints to Primary 
Objecti ve/EndpointsIn order to align with recent external 
biologic clinical trials in UC, primary 
endpoint changed to clinical 
remission among responders, and 
clinical remission among remitters 
moved to a Major secondary 
Section 4 Objectives and Endpoints, 
Table AMBG.4.1To evaluate the efficacy of 
mirikizumab compared to placebo 
in maintaining clinical remission at 
Week 40 (Week 52 of continuous 
therapy ) among patients induced 
into clinical remission with 
mirikizumab has been moved from 
primary  to first major secondary In order to align with recent external 
biologic clinical trials in UC, primary 
endpoint changed to clinical 
remission among responders, and 
clinical remission among remitters 
moved to a Major secondary. 
Section 4 Objectives and Endpoints, 
Table AMBG.4.1Moved “Clinical remission at Week 
40 in the subgroup of patients in 
whom biologic agents have failed or In order to align with recent external 
biologic clinical trials in UC and 
associated enrollment trends, this 
I6T-MC-AMBG(a) Clinical Protocol Page 135
LY3074828Section # and Name Description of Change Brief Rationale
caused intolerance.” and definition 
of “clinical remission” from Major 
Secondary Objective/Endpoints to 
Other Secondary 
Objectives/Endpointsobjective/endpoints was moved to 
other secondary objective/endpoints 
Section 4 Objectives and Endpoints, 
Table AMBG.4.1Moved “Endoscopic remissi on at 
Week 40 in the subgroup of patients 
in whom biologic agents have failed 
or caused intolerance.” and 
definition of ”endoscopic 
remission” from Major Secondary 
Objective/Endpoints to Other 
Secondary Objectives/EndpointsIn order to align with recent external 
biologic clinical trials in UC and 
associated enrollment trends, this 
objective/endpoints was moved to 
other secondary objective/endpoints
Section 4 Objectives and Endpoints, 
Table AMBG.4.1Added “The proportion of patients 
in sy mptomatic remission defined as 
being in symptomatic remission for 
at least 7 out of 9 visits from Week 
4 to Week 36 and in symptomatic 
remission at Week 40 among 
patients in symptomatic remission at 
Week 12 of AMAN.” and definition 
of “Symptomatic remission” to 
Major Seconda ry 
Objective/EndpointsThis endpoint (and associated 
objective) was added in order to 
assess the stability of efficacy with 
mirikizumab throughout the 
maintenance period 
Section 4 Objectives and Endpoints, 
Table AMBG.4.1Moved and modified “The 
proportion of patients with bowel 
movement urgency improvement at 
Week 40 as defined in the study 
SAP” to Major Secondary 
Objective/EndpointsMoved and modified endpoint to 
assess improvement in urgency.  
Published literature shows that 
improvement in urge ncy is a 
clinically meaningful endpoint and 
supports urgency as one of the most 
bothersome symptoms experienced 
by patients with UC.  Therefore, this 
endpoint has been moved from an 
Other Secondary endpoint to a Major 
secondary endpoint
Section 4 Objectiv es and Endpoints, 
Table AMBG.4.1Deleted from Other Secondary 
Objective/Endpoints: The 
percentage of the total time (in 
weeks) during maintenance study 
treatment that patients achieve: SF = 
0, or SF = 1 with a ≥1-point 
decrease from induction baseline, 
andRB subscore = 0Other Secondary Objective/Endpoints 
for sy mptom free duration removed 
and replaced with new Major 
Secondary Objective/Endpoints of 
stable maintenance of symptomatic 
remission 
Section 4 Objectives and Endpoints, 
Table AMBG.4.1Rem oved red undant text in Other 
Secondary Objective/Endpoints: 
“…among subgroup of patients on 
corticosteroids at induction study 
baseline” from Corticosteroid -free Editorial change 
I6T-MC-AMBG(a) Clinical Protocol Page 136
LY3074828Section # and Name Description of Change Brief Rationale
remission without surgery at Week 
40 endpoint.
Section 4 Objectives and Endpoints, 
Table AMBG.4.1Deleted from Other Secondary 
Objective/Endpoints related to 
patient reported outcomes the 
reference to Urgency NRS score 
following change from induction 
baseline at Week 40 Other Secondary Objective/E ndpoint s
for bowel movement urgency
removed and replaced with new 
Major Secondary 
Objective/Endpoints bowel 
movement urgency improvement
endpoint was added to Major 
secondary endpoints. This 
objective/endpoint now focuses on 
the patient reported outcome of 
abdominal pain only
Section 4 Objecti ves and Endpoints, 
Table AMBG.4.1Added to Other Secondary 
Objective/Endpoints:
The proportion of patients with a 
UCEIS score of ≤1 at Week 40The UCEIS is considered to be an 
important endpoint assessing 
endoscopic disease activity and thus 
has been added as another secondary 
endpoint.  The UCEIS has been 
included in all endoscopy central 
readings f rom the onset of the study  
Section 4 Object ives and Endpoints, 
Table AMBG.4.1Added “The proportion of patients 
with mucosal healing at Week 40, 
defined as achieving both histologic 
remission and endoscopic 
remission” and their definitions to 
Other Secondary 
Objective/EndpointsIn order to align wi th recent UC 
clinical trials and FDA guidance, 
protocol definition of mucosal 
healing was updated to include 
histologic and endoscopic healing. 
This is the same endpoint –note that 
histologic remission is already and 
has always been a secondary 
endpoint .The location of the 
histologic remission/response 
definition has been clarified 
throughout the protocol amendment 
Section 4 Objectives and Endpoints, 
Table AMBG.4.1Other Secondary 
Objectives/Endpoints addedFatigue is a common symptom for 
patients with active disease and 
published literature supports fatigue 
as an impo rtant sy mptom experienced 
by patients with UC. Therefore, this 
endpoint has been added to Other 
Secondary Endpoint
Section 4 Objectives and Endpoints, 
Table AMBG.4.1Abbreviations have be en added 
under the tableEditorial change
Section 5 Study Design Added “baseline” to corticosteroid 
use stratification criteriaClarified that baseline corticosteroid 
use (yes or no) will be used to stratify 
patients 
Section 5 Study Design Clarified definition of “loss of 
response”Clarification that the loss of response  
assessment can start as early as Week 
8/V3 but the endoscopic confirmation 
of loss of response cannot occur any 
I6T-MC-AMBG(a) Clinical Protocol Page 137
LY3074828Section # and Name Description of Change Brief Rationale
earlier than Week 12/V4 
Section 6.0 Study population Changed the du ration for the 
maximum window from the start of 
AMAN Week 12/V5 to the start of 
Week 0/V1 from 10 to 14 days Changes make the transition from 
AMAN to AMBG operationally 
acceptable while enabling AMAN 
Week 12 endoscopy to represent 
baseline status of disea se severity in 
AMBG
Section 6.1 Inclusion Criteria, 
Patient CharacteristicsAdded text to clarify that patients 
require a Visit 5/Week 12 of Study
AMAN MMS, not just an 
endoscopyClarification that not only is an 
endoscopy required but a MMS is 
needed in order to enroll in AMBG 
from AMAN
6.2 Exclusion Criteria, General 
Exclusion CriteriaThe term “malignancy” was added 
to Exclusion Criterion [17]Added to be consistent with exclusion 
criteria in induction study AMAN 
Section 6.4 Screen Failures Changed the duration for the 
maximum window from the start of 
AMAN Week 12/V5 to the start of 
Week 0/V1 from 10 to 14 days Changes make the transition from 
AMAN to AMBG operationally 
acceptable while enabling AMAN 
Week 12 endoscopy to represent 
baseline status o f disease severity in 
AMBG
Section 7.1 Treatments 
Administered, Study Drug 
Administration Added that intravenous infusion of 
mirikizumab (not placebo) will 
occur over at least 30 minutes  Clarification that placebo will not be 
administered IV
Section 7.2 Method of Treatment 
AssignmentAdded “baseline” to corticosteroid 
use stratification criteriaClarified that baseline corticosteroid 
use (y es or no) will be used to stratify 
patients 
Section 7.7 Concomitant Therapy, 
Corticosteroid TaperAdded “or beclomethasone 
dipropionate (gastro -resistant 
prolonged- release tablet) ”including 
tapering schedule Based on wide use of this 
corticosteroid in certain countries, 
tapering instructions were added 
I6T-MC-AMBG(a) Clinical Protocol Page 138
LY3074828Section # and Name Description of Change Brief Rationale
Section 7.8.3.2. Management of 
Hypersensitivity, Infusion R elated 
Events, Infusion Site Reactions and 
Injection Site ReactionsAdded “ These samples will also be 
used for tryptase, complement 
(C3/C4), and cytokine panel 
assay s.”Additional assessments added to 
better understand the possible 
etiology if a drug hyper sensitivity  
event is observed, including markers 
of basophil/mast cell activation (i.e. 
tryptase), immune complex formation 
(i.e. C3/C4 levels) and cytokine 
release (i.e., cytokine panel ). No 
additional blood is required for this 
sample collection.
Section 7.8.3.2. Management of 
Hypersensitivity, Infusion Related 
Events, Infusion Site Reactions and 
Injection Site ReactionsUnder “Other Infusion -Related 
Events and Infusion Site 
Reactions”: added the word “other” 
in sentence describing reaction 
consist ing of headache, rigo rs 
and/o r temperature >38°CClarification of reaction consisting of 
headache, rigors and/or temperature 
>38°C 
Section 8.1.1. Permanent 
Discontinuation from Study 
Treatment, Safety Criteria for Study 
Drug DiscontinuationAdded to safe ty criteria for study 
drug discontinuation:  
“proctocolectomy or partial 
colectomy”.Clarification of safety criteria for 
drug discontinuation
Section 8.1.1. Permanent 
Discontinuation from Study 
Treatment, Safety Criteria for Study 
Drug DiscontinuationAdded to safety criteria for study 
drug discontinuation that the patient 
has an AE or SAE which, in the 
opinio n of the investigator or 
sponsor, would preclude the 
participant from continuing to 
receive study drug.Study drug discontinuation related to 
AEs or SAEs is now consistent with 
wording in AMAN
Section 8.1.1. Permanent 
Discontinuation from Study 
Treatment, Safety Criteria for Study 
Drug DiscontinuationMirikizumab changed to “study 
drug”Clarification since study drug may be 
blinded
Section 9.1 Efficacy Assessments: 
Table AMBG.9.1 Endpoint 
Definitio ns in Study AMBGAdded endpoint, definition ,and 
footnote for corticosteroid-free 
remission without surgery at Week 
40Defined corticosteroid-free remission 
without surgery at Week 40
Section 9.1 Efficacy Assessments: 
Table AMBG.9.1 Endpoint 
Definitio ns in Study AMBGTerm mucosal healing deleted from 
histologic remission endpoint 
definitionClarification of term “histologic 
remission”
Section 9.1 Efficacy Assessments: 
Table AMBG.9.1 Endpoint 
Definitio ns in Study AMBGAdded mucosal healing endpoint 
definition Defined mucosal healing endpoint 
Section 9.1 Efficacy Assessments: 
Table AMBG.9.1 Endpoint 
Definitio ns in Study AMBGAdded stable maintenance of 
symptomatic remission This endpoint was added in order to 
assess the stability of efficacy with 
mirikizumab throughout the 
maintenance period
Section 9.1 Efficacy Assessments: Added bowel movement urgency Now included as a major secondary 
I6T-MC-AMBG(a) Clinical Protocol Page 139
LY3074828Section # and Name Description of Change Brief Rationale
Table AMBG.9.1 Endpoint 
Definitio ns in Study AMBGimprovement endpoint because of unmet patient 
needs and the symptom being one of 
the most meaningful and important 
symptoms from patient perspective
Section 9.1 Efficacy Assessments: 
Table AMBG.9.1 Endpoint 
Definitio ns in Study AMBGAdded footnote: “ aAmong patients 
induced into clinical response with 
mirikizumab during the induction 
study and who were receiving 
corticosteroids at induction 
baseline.”Added footnote clarifying the 
applicable patient population for this 
endpoint
Section 9.1 Efficacy Assessments: 
Table AMBG.9.1 Endpoint 
Definitio ns in Study AMBGAdded footnote: “bAmong patients 
in sy mptomatic remission at Week 
12 of AMAN” Added footnote clarifying the 
applicable patient population for this 
endpoint
Section 9.1.1.1. Primary Endpoint Terminology changed from 
“durable clinical remission” to 
“clinical remission”; “remission ”
changed to “response” with 
mirikizumab induction treatment .Change made due to change in 
primary  endpoint of the study
9.1.1.2. Mayo Score Deleted from SF Subscore and 
expanded to its own sub -section: 
‘Normal SF for that patient is based 
on reported SF when the patient was 
in remission or reported SF before 
initial o nset of signs and symptoms 
of UC. ”  Sentence moved to new description of 
Normal SF and to provide additional 
detail regarding the definition
Section 9.1.1.3. Endoscopy Wording added to clarify when 
colonoscopy can be performed 
instead of flexible sigmoidoscopy in 
the judgement of the investigator 
and after discussion with the 
medical mo nitor as appropriateClarification of importance to discuss 
with medical monitor the need for 
colonoscopy vs. flexible 
sigmoidoscopy to assure appropriate 
consideration for patient safety
Section 9.1.1.3. Endoscopy Added that allowances may be 
made for not performing ETV 
endoscopy if ETV occurs soon after 
a recent study required endoscopy, 
based on approval by the medical 
monitorChange made to assure patient safety 
by not performing unnecessary repeat 
endoscopies soon after a recent 
endoscopy proce dure 
9.1.2.1. Major Secondary 
EndpointsMultiple changes made in major 
secondary endpoints to match 
Section 1 and Section 4 To align with Section 1 Synopsis and 
Section 4 Objectives and Endpoints. 
9.1.2.1.2. Patient Reported Outcome 
InstrumentsDescriptio n of Urgency NRS added 
under major secondary endpoints 
section Moved definition of Urgency NRS to 
major secondary endpoints to be 
consistent with changes in objective 
and endpoint sections ( Section 1 and 
Section 4) 
9.1.2.2.1. Physician Reporte d 
InstrumentAdded description of UCEIS Due to the addition of the 
objective/endpoint, added description 
I 6 T -M C -A M B G( a) Cli ni c al Pr ot o c ol P a g e 1 4 0 
L Y 3 0 7 4 8 2 8 Secti o n # a n d N a me Descri pti o n of C h a n ge Brief R ati o n ale 
of t he i nstr u me nt 
9. 1. 2. 2. 2. P R O I nstr u me nts Use d t o 
Assess Sec o n dar y E n d p oi nts Ur ge nc y N R S delete d fr o m P R O 
i nstr u me nts use d t o assess ot her 
sec o n dar y e n d p oi nts ; Fati g ue N R S 
a d de d M o ve d defi niti o n of Ur ge nc y N R S 
o ut of ot her sec o n dar y e n d p oi nts a n d 
a d de d Fati g ue N R S t o be c o nsiste nt 
wit h c ha n ges i n o bjecti ve s
9. 1. 3. 3. P R O I nstr u me nts Use d t o 
Assess E x pl orat or y E n d p oi nts C ollecti o n c o n diti o ns f or t he 
f oll o wi n g a d de d: 
N oct ur nal St o ol 
Patie nt’s Gl o bal Rati n g of 
Se verit y  
Br ist ol St o ol Scale 
Fati g ue N R S delete d Clarificati o n of data c ollecti o n 
c o n diti o ns 
Secti o n 9. 4. 4. I m m u n o ge nicit y 
Assess me nts A d de d t hat tr y ptase, c o m p le me nt 
( C 3/ C 4), a n d c yt o ki ne pa nel 
sa m ples will be c ollecte d i n t he 
e ve nt of a dr u g h y perse nsiti vit y 
e ve nt, ot her i nf usi o n relate d e ve nts 
a n d i nf usi o n site reacti o ns A d diti o nal assess me nts a d de d t o 
better u n dersta n d t he p ossi ble 
eti ol o g y if a dr u g h y perse nsiti vit y 
e ve nt is o bser ve d, i ncl u di n g mar kers 
of bas o p hil/ mast cell acti vati o n (i.e. 
tr y ptase), i m m u ne c o m ple x f or mati o n 
(i.e. C 3/ C 4 le vels) a n d c yt o ki ne 
release (i.e ., c yt o ki ne pa nel ). N o 
a d diti o nal bl o o d is re q uire d f or  t his 
sa m ple c ollecti o n. 
Secti o n 9. 4. 5. 2. T u berc ul osis, 
Dia g n osis of L T BI d uri n g St u d y F or t he treat me nt of L T BI, a d de d 
t hat C D C g ui deli nes are t o be use d  
f or t he U S A a n d t he W H O 
g ui deli nes  are t o b e f oll o we d  f or 
c o u ntries o utsi de of t he U S A Clarificati o n of g ui da nce f or L T BI 
treat me nt 
Secti o n 9. 5 P har mac o ki netics  
 
 
 
  
 
Secti o n 1 0. 1Sa m ple Size 
Deter mi nati o n Pri mar y  e n d p oi nt statistical c ha n ges Matc h wit h Secti o n 1 S y n o psis a n d 
Secti o n 4 O bjecti ves a n d E n d p oi nts. 
D ue t o c ha n ges i n pri mar y a n d maj or 
sec o n dar y e n d p oi nts, sa m ple size has 
bee n recalc ulate d. 
1 0. 2. P o p ulati o ns f or A nal yses, 
Ta ble A M B G. 1 0. 1 A nal ysis 
P o p ulati o ns i n St u d y A M B G I nte nt -t o -treat (I T T) P o p ulati o n 
c ha n ge d fr o m e nr olle d t o 
ra n d o mize d/assi g ne d Clarificati o n of t he defi niti o n of 
“e nr olle d” i n t he I T T p o p ulati o n 
1 0. 2. P o p ulati o ns f or A nal yses, 
Ta ble A M B G. 1 0. 1 A nal ysis 
P o p ulati o ns i n St u d y A M B G M o difie d I nte nt -t o -treat ( mI T T) 
P o p ulati o n c ha n ge d t o “ All 
ra n d o mize d/assi g ne d patie nts w h o 
recei ve d at least 1 d ose of st u d y 
treat me nt, re gar dless of w het her Defi niti o n clarifie d of t he mI T T 
p o p ulati o nC CI C CI 
I6T-MC-AMBG(a) Clinical Protocol Page 141
LY3074828Section # and Name Description of Change Brief Rationale
correct treatment was administered 
or whether protocol was followed.”
10.3.1. General Statistical 
Consi derationsChanged that induced responders 
instead of induced remitters were 
among those assessed. Induction 
remission status of yes or no was 
added. “Baseline” was added to 
corticosteroid use.Change made due to change in 
primary  endpoint of the study. 
Clarified that baseline corticosteroid 
use (y es or no) will be used to stratify 
patients
10.3.1.1. Missing Data Imputation Deleted “ In addition, the patients 
who require UC surgery, increase 
UC medicatio n dose from baseline , 
or initiate new UC medications will 
be considered as nonresponders ” 
from the description of 
nonresponder imputation .Modifications made to align with 
other recent UC clinical trials and to 
clarify  that patients who require UC 
surgery , require an increase in UC 
medication dose from basel ine, or 
require treatment with new UC 
medications should be discontinued 
from the trial as described in Section 
8.1.1 of the protocol. Therefore, 
imputing such patients as non -
responders will be performed because 
the data will be missing
10.3.2.3 Concomit ant Therapy Changed description of how 
concomitant therapy will be 
presented in frequency table sClarification 
10.3.3.1. Primary  Analy ses Primary  analy sis was changed from 
“durable clinical remission” to 
“clinical remission” and “ remitters” 
to “respond ers.” Change made due to change in 
primary  endpoint of the study.
10.3.3.1. Primary  Analy ses Nonremitter description changed Change made due to clarification of 
NRI 
10.3.7.1 Subgroup Analyses Rem oved “The major subgroup 
analy sis is for the primary and 
major secondary endpoints for 
biologic -failed patients described in 
Section 9.1.2.1.  Multiplicity 
adjustment described in Section 
10.3.1.2. will be used to control type 
I erro r.” Change made due to changes in the 
major secondary endpoints 
Section 11. References References added Editorial change
Appendix 1. Abbreviations and 
Definitio nsTerm added Editorial Change
Appendix 2. Clinical Laboratory 
TestsOther tests along with their 
associated footnote addedClarification of procedures. Updates 
made to align with Section 7.8.3.2 of 
the protocol
Appendix 3.1.7. Final Report 
SignatureDeleted thatthe investigator with 
most enrolled patients will be 
selected by the study team to act as 
the CSR co ordinating investigatorThis change reflects that the selection 
of CSR coordinating investigator is 
not dependent on number of patients 
enrolled
Appendix 6. Mayo Scoring System Note added to table for stoo l Definitio n of no rmal stool frequency 
I6T-MC-AMBG(a) Clinical Protocol Page 142
LY3074828Section # and Name Description of Change Brief Rationale
for the Assessment of Ulcerative 
Colitis Activityfrequency when in remission from UC to align 
with Section 9.1.1.2 of the protocol
Appendix 7. Patient Reported 
Outcome InstrumentsReplaced language in definition of 
Abdominal Pain Numeric Rating 
Scale (NRS) and Fati gue NRS   Clarification of definitions of ranges
Appendix 8. Prohibited Medications Added rectally administered 
investigational preparations for UC 
and restrictions Arsenic and other therapies were 
added because it was recognized that 
there are other tr eatments for UC in 
certain countries that need to be 
consid ered as prohibited medications
Appendix 8. Prohibited Medications Added “for UC” to Intravenous 
corticosteroids categoryClarification of restrictions for IV 
corticosteroid use for U C vs. non UC 
indication
Appendix 8. Prohibited Medications Added that patients requiring 
systemic corticosteroids for non -UC 
indications are “excluded”. Added 
“Exceptions include : premedication 
for IP infusion , or locally ”.  Added allowance for single limited 
dose for study drug administration 
premedication.  This would be a 
single limited dose that would not be 
expected to affect efficacy. Other 
minor editorial changes were made. 
Appendix 9. Permitted Medications 
with Dose StabilizationAdded to Drug Class: oral 5 -ASAs 
“and sulfasalazine for UC” Clarification of drug class
Appendix 9. Permitted Medications 
with Dose StabilizationAdded to Drug Class: oral 
corticosteroids “for UC” indications 
clarificatio nClarified that or al corticosteroid s are 
allowed for UC indication
Appendix 9. Permitted Medications 
with Dose StabilizationAdded beclomethasone dipropionate 
[gastro -resistant prolonged -release 
tablet] 5 mg/dayBased on wide use of this 
corticosteroid in certain countrie s, 
this medication was added as 
permitted medication during the study 
along with prednisone or equivalent 
or budesonide MMX
Appendix 9. Permitted Medications 
with Dose StabilizationAdded to Drug Class: 
“corticosteroids for non -UC 
indications ”that are a llowedAdded clarification to reinforce the 
exception to the prohibited 
concomitant medications
I6T-MC-AMBG(a) Clinical Protocol Page 143
LY3074828Revised Protocol Sections
Note: Deletions have been ident ified by strikethroughs .
Addit ions have been identified by  the use of underscore .
The numbering system  used for inclusio n and exclusion criteria provides a unique number for 
each cri terion and all ows f or efficiency in data collection.
In case an amendment to the protocol adds a criterion, that criterion will receive the next 
available number, regardl ess of whether i t is an inclusio n or excl usion cri terion.
1. Synopsis
Objective(s)/Endpoints:
Objectives Endpoints
Primarya
 To test the hypothesis that mirikizumab is superior 
to placebo in achieving maintaining clinical 
remission at Week 40 (Week 52 of continuous 
therapy ) among patients induced into clinical
response remission with mirikizumab in Study 
AMAN The proportion of patients who were in clinical 
remission at Week 12 in AMAN and are in 
clinical remission at Week 40,that is, with 
durable clinical remission, defined as:
oStool frequency (SF) subscore = 0 or SF = 1 
with a ≥1-point decrease from induction 
baseline, and
oRectal bleeding (RB) subscore = 0, and
oEndoscopic subscore (ES) = 0 or 1 (excluding 
friability )
Major Secondarya,b
 To evaluate the efficacy of mirikizumab compared 
to placebo in achieving maintaining clinical 
remission at Week 40 (Week 52 of continuous 
therapy) among patients induced into clinical 
remission response with mirikizumab  The proportion of patients who were in clinical 
remission at Week 40 among patients in clinical 
remission at Week 12 in Study AMAN (i.e., 
durable clinical remission). C linical remission is
defined as:
oSF subscore = 0 or SF = 1 with a ≥1-point 
decrease from induction baseline, and
oRB subscore = 0, and
oESsubscore = 0 or 1 (excluding friability)
 To evaluate the efficacy of mirikizumab compared 
to placebo on endoscopic remission at Week 40
among patients induced into clinical response with 
mirikizumab The proportion of patients in endoscopic 
remission at Week 40, defined as:
 ES = 0 or 1 (excluding friability)
I6T-MC-AMBG(a) Clinical Protocol Page 144
LY3074828 To evaluate the efficacy of mirikizumab compared 
to placebo in achieving corticosteroid-free remission 
without surgery among patients i nduced into 
clinical response with mirikizumab and receiving 
corticosteroids at induc tion baseline Corticosteroid-free remission without surgery at 
Week 40, defined as:
oClinical remission at Week 40, and 
oSymptomatic remission at Week 28, and 
 No corticosteroid use fo r ≥12 weeks prior to 
Week 40 
 To evaluate, in the subgroup of patients in whom 
biologic agents have failed or caused intolerance, 
clinical remission at Week 40 among patients 
induced into clinical response with mirikizumab Clinical remission at Week 40 in the subgroup of 
patients in whom biologic agents have failed or 
caused intolerance.  Clinical remission is defined 
as:
oSF subscore = 0 or SF = 1 with a ≥1-point 
decrease from induction baseline, and
oRB subscore = 0, and
oES = 0 or 1 (excluding friability)
 To evaluate, in the subgroup of patients in whom 
biologic agents have failed or caused intolerance,
endoscopic remission at Week 40 among patients 
induced into clinical response with mirikizumab Endoscopic remission at Week 40 in the subgroup 
of patients in whom biologic agents have failed or 
caused intolerance.  Endoscopic remission is 
defined as:
oES = 0 or 1 (excluding friability)
 To evaluate the efficacy of mirikizumab compared 
to placebo on histologic remission (mucosal healing) 
at Week 40 among patie nts induced into clinical 
response with mirikizumab Proportio n of patients in histologic remission at 
Week 40, as defined in the histopathology charter
SAP
 To evaluate the efficacy of mirikizumab compared 
to placebo on stable maintenance of symptomatic 
remission among patients who were induced into 
clinical response and symptomatic remission with 
mirikizumab The proportion of patients insymptomatic 
remission defined as being in sympto matic 
remission for at least 7 out of 9 visits from Week 
4 to Week 36 and being in symptomatic remission 
at Week 40 among patients in symptomatic 
remission at Week 12 of Study AMAN.
 Symptomatic remission is defined as:
oSF = 0, or SF = 1 with a ≥1-point dec rease 
from induction baseline and
oRB = 0
 To evaluate the efficacy of mirikizumab compared 
to placebo on bowel movement urgency 
improvement at Week 40, among patients who: (1) 
had bowel urgency symptoms at induction baseline 
and (2) were induced into clini cal response with  
mirikizumab  The proportion of patients with bowel movement 
urgency improvement at Week 40 as defined in 
the study  SAP.
Other Secondary
 To evaluate the efficacy of mirikizumab compared 
to placebo in achieving clinical remission at Week 
40 among patients induced into clinical response 
with mirikizumab, in the subgroup of patients in 
whom biologic agents have failed or caused 
intolerance ,.clinical remi ssion at Week 40 among 
patients induced into clinical remission with  The proportion of patients who were in clinical 
remission at Week 12 in AMAN and are in
cClinical remission at Week 40 , that is, with 
durable clinical remission, in the subgroup of 
patients in whom biologic agents have failed or 
caused intolerance.  Clinical remission is defined 
as:
I6T-MC-AMBG(a) Clinical Protocol Page 145
LY3074828mirikizumab oSF subscore = 0 or SF = 1 with a ≥1-point 
decrease from induction baseline, and
oRB subscore = 0, and
oES = 0 or 1 (excluding friability )
 To evaluate the efficacy of mirikizumab compared 
to placebo in achieving on maintaining endoscopic 
remission at Week 40 among patients induced into 
clinical response endoscopic remission with 
mirikizumab, in the subgroup of patients in whom 
biologic age nts have failed or caused intolerance . The proportion of patients in durable eEndoscopic 
remission at Week 40 in the subgroup of patients 
in whom biologic agents have failed or caused 
intolerance.  Endoscopic remission is defined as: 
ES = 0 or 1 (excluding friability)
 To evaluate the efficacy of mirikizumab as 
compared to placebo in maintaining clinical 
remission at Week 40 (Week 52 of continuous 
therapy ) among patients induced into clinical 
remission with mirikizumab, in the subgroup of 
patients in whom biologic agents have failed or 
caused intolerance. The proportion of patients who were in clinical 
remission at Week 40 among patients in clinical 
remission at Week 12 in Study AMAN (i.e., 
durable clinical remission) in whom biologic 
agents have failed or caused intolerance.  Clinical 
remission is defined as:
oSF subscore = 0 or SF = 1 with a ≥1-point 
decrease from induction baseline, and
oRB subscore = 0, and
oES = 0 or 1 (excluding friability)
 To evaluate the efficacy of mirikizumab compared 
to placebo in a chieving clinical remission (using a 
more stringent ES) at Week 40  among patients 
induced into clinical re sponse mission with  
mirikizumab  The proportion of patients with clinical remission 
(using a more stringent ES) at Week 40, with 
clinical remission defined as:
oSF subscore = 0, or SF = 1 with a ≥1-point 
decrease from induction baseline, and
oRB subscore = 0; and
oES = 0
 To evaluate the efficacy of mirikizumab compared 
to placebo in achieving an endoscopic response at 
Week 40 among patients induced into clinical 
response with mirikizumab The proportion of patients in endoscopic 
response at Week 40 defined as:
oA decrease in ES of ≥1 point from induction 
baseline.
 To evaluate mirikizumab compared with placebo on 
symptom -free duration among patients induced into 
clinical response with mirikizumab  The percentage of the total time (in weeks) 
during maintenance study treatment that patients 
achieve:
SF = 0, or SF = 1 with a ≥1-point decrease 
from induction baseline, and
RB s ubscore = 0
 To evaluate the efficacy of mirikizumab compared 
to placebo in achieving 24 -week corticosteroid -free 
remission without surgery among patients induced 
into clinical response with mirikizumab and 
receiving corticosteroids at induction baseline Corticosteroid-free remission without surgery at 
Week 40, defined as:
oClinical remission at Week 40, and 
oSymptomatic remission at Week 28, and 
oNo corticosteroid use for ≥24 weeks prior to 
Week 40 among subgroup of patients on 
corticosteroids at induction study baseline
I6T-MC-AMBG(a) Clinical Protocol Page 146
LY3074828 To evaluate the effect of mirikizumab compared to 
placebo on changes in patient -reported outcome 
endpoints Abdominal pain at Week 40 Change f rom inductio n baseline at Week 40 in the 
following:
oUrgency NRS score
Abdominal pain NRS score
 To evaluate the efficacy of mirikizumab compared 
to placebo in UCEIS endoscopic remission at Week 
40 among patients induced into clinical response
with  mirikizumab  The proportion of patients with a UCEIS score of 
≤1at Week 40
 To evaluate the efficacy o f mirikizumab compared
to placebo in mucosal healing at Week 40 among 
patients induced into clinical response with 
mirikizumab The proportion of patients with mucosal healing 
at Week 40, defined as achieveing both:  
oHistologic remission, as described in the 
histopathology charter, and
oEndoscopic remission,  defined as ES = 0 or 
1 (excluding friability)
 To evaluate the effect of mirikizumab compared to 
placebo on change in fatigue at Week 40 Change f rom inductio n baseline at Week 40 in the 
Fatigue NRS sco re
Abbreviations:  SAP = statistical analysis plan; UCEIS = Ulcerative Colitis Endoscopic Index of Severity.
Statistical Analysis
It is expected that approximately 459470 of these pati ents will  enter Study  AMBG as clinical 
responders to mirikizumab and then will be randomized 2:1 to 200 mg mirikizumab SC 
(306approximately 313patients) and placebo ( 153approximately 157patients).  Among the 
approximately expected 459470mirikizumab clinical  responders, approximately 169180
mirikizumab clinical remitters will be randomized to 200 mg mirikizumab SC 
(113approximately 120patients) and placebo ( 56approximately 60patients).  Thi s assumes that:
The ind uction study  (AMAN, which has a mixed populat ion with approximately 6050% 
biologic-failed pat ients) is expected to have an overall clinical remissio n rate of 21.623% 
and response rate of 58.660% with mirikizumab.
75% of induct ion pat ients receive treatment with mirikizumab, based on a 3:1 
rando mizat ion rati o for the induct ion study .
10% dropout rate from induct ion to m aintenance .
The primary  endpoint, maintenance of clinical remissio n at Week 40, will be assessed on patients 
who achieved remissio nclinical response to mi rikizum ab induct ion treatment.  Assuming 
mirikizumab and placebo maintenance of clinical remissio n rates of 58.447% and 23.627%, 
respectively (biologic-failed pat ients:  44% and 13%; convent ional-failed patients:  70% and 
32%), this study  based on the 169470mirikizumab induction remitters responders is expected to 
have >9 50%power to demonstrate that mirikizumab is superior to placebo by  using a chi -square 
test wi th a 2-sided0.05 significance level of 0.05 .  This sample size also provides 80% power to 
evaluate clinical remissio n amo ng induct ion remitters in the bio logic-failed subgroup of patients
. In addit ion, 459 mirikizumab induct ion clinical re sponders are the sam ple size i s expected to 
provi de adequate power (>80%) to demonstrate th at mi rikizumab is superior to placebo for the 
I6T-MC-AMBG(a) Clinical Protocol Page 147
LY3074828major secondary  endpoints (clinical remissio n[among pati ents induced into clinical response 
with mirikizumab], endoscopic remissio n, histol ogic remissio n, and or corticosteroi d-free 
remission )at Week 40, among responders to mirikizumab induction treatment by  using a chi -
square test with a 2- sided 0.05 significance level of 0.05 . 
For assessments of the primary en dpoint and other categorical efficacy  endpoints am ong induced 
remitters responders , the Cochran- Mantel -Haenszel (CMH) chi -square test will be used to 
compare mirikizumab and placebo with stratificat ion factors:  (a) previous bio logic therapy  
failure (y es or no), (b) baseline corticosteroi d use (yes or no), and (c) region (North 
America/Europe/Other) , (d) induction remissio n status (y es/no).  The CMH chi -square p- value 
and the relat ive risk along wit h its 95% 2 -sided confidence interval will be provided .
Treatment comparisons of continuous efficacy and healt h outcome variables wit h a single 
post-baseline time po int will be made using analysis of covariance wit h:  (a) treatment group, 
(b)previous bio logic therapy  failure (y es or no ), (c) corticosteroid use (y es or no), (d) regi on 
(North America/Europe/Other), (e) baseline value in the model, and (f) induct ion remissio n 
status (if analysis is amo ng induced responders) .
2. Schedule of A ctivites 
Table AMBG. 2.1. Schedule of A ctivities –Responders from Induction Study
Inform ed Consent Notes: Patients may consent between the start of V5 of Study AMAN time of 
induct ion consent and before any procedures at V1/Week 0 are performed.
Procedure :FSH (optional in women to confirm nonchild -bearing potential )e
PK Assessment: In addition, patients with potential hypersensit ivity or infusi on-related event 
shoul d have sample taken as soon as possible after event occurs,
ADA Assessment: In addit ion, pati ents wi th possib le hypersensit ivity or infusi on-related event 
shoul d have sample taken as soon as possible after event occurs,
C. Difficile Test ing: Table cell expaneded to include V3
Fecal Calprotectin and Exploratory  Fecal  Biomarkers: Tabl e cell expaneded to include V3
Endoscopy  with biopsies: Flexible sigmo idoscopy  is recommended for all pat ients. Col onoscopy  
can be performed instead of flexible sigmo idoscopy for clinically indicated reasons after 
discussio n with the m edical mo nitor(See section 9.1.1.3.)   
Xd:  At least 1 endoscopy  is performed at Week 40/ETV or if LOR is confirmed.  LOR 
assessments confirmat ion based on endoscopy can only  occur at a scheduled or unscheduled visit 
between V4 and V8. Please refer to Secti on 9.1.1.3 for procedure clarificat ion.
I6T-MC-AMBG(a) Clinical Protocol Page 148
LY3074828IBDQ and EQ -5D 5L X d:  To be performed for patients who have LOR confirmed by endoscopy  
before rescue dosingTo be performed for patients with secondary LOR at the second of 2 LOR 
assessments .
PGRC: X d:  To be performed for patients who have LOR confirmed b y endoscopy  before rescue 
dosing To be perform ed for pati ents wi th secondary  LOR at the second of 2 LOR assessments .
Abbreviat ions: DNA = deoxy ribonucleic acid;
Notes:  Last visit or ETV is last visit prior to entering long term  extensi on Study  AMAP open -
label extensio n or post -treatm ent follow-up. 
Footn ote: a V1 (Week 0) should occur no more than 10 14 days from the start of the Visit 
5/Week 12 visit of Study  AMAN.
Table AMBG.2.2. Schedule of A ctivities –Nonresponders from Induction Study
Visit 4:  85 ± 4 7
Inform ed Consent Notes: Patients may consent between the start of V5 of Study AMAN time of 
induct ion consent and before any procedures at V1/Week 0 are performed.
Procedure:  FSH (optional in wo men to confirm nonchild -bearing potential )f
PK Assessment: In addition, patients with potential hypersensit ivity or infusi on-related event 
shoul d have sample taken as soon as possible after event occurs,
ADA Assessment: In addit ion, pati ents wi th possible hypersensit ivity or infusi on-related event 
shoul d have sample taken as soon as possible after event occurs,
C.difficile testing: V1 C. difficile testing does not need to be completed before the patient can 
start study  drug therapy .
Endoscopy  with biopsies: SeePlease refer to Section 9.1. 1.3.for procedure clarificat ion.
Notes: All activities shoul d be co mpleted prior to any study  drug administration unless otherwise 
stated.  Last visit or ETV is last visit prior to entering long term extensio n Study  AMAP or 
post-treatm ent follow-up.  Post -treatment follow -up visi ts shoul d only occur if the pat ient is 
not proceeding to long term extension Study  AMAP or if they  discontinue treatm ent in Study  
AMBG early (i.e. pati ents who do not achieve delayed clinical response) .
Footnote a:For patients who cannot continue beyo nd V4 because they  did not achieve delayed 
clinical response, ETV activites that are performed as part of V4 do not need to be repated. 
Only those ETV activit ies that are not part of V4 should be completed during the E TV.
Footnoteb: V1 (Week 0) should occur no more than 10 14 days from the start of the Visit 5/Week 
12 visit of Study  AMAN.
Various footnotes re -lettered
I6T-MC-AMBG(a) Clinical Protocol Page 149
LY30748284. Objectives and Endpoints 
See Section 1 Synopsis Objective(s)/Endpoints above
5.1. Overall Design
Mirikizumab Responders from Study AMAN
Randomization will be stratified to achieve between -group com parabili ty, based on bio logic-
failed status (yes or no), induct ion remissio n status (y es or no), baseline corticosteroi d use (yes 
or no), and region (North America/Europe/Other).
Loss of Response (LOR) is defined as:
≥2-point increase fro m Study  AMBG baseline in the combined SF + RB scores AND combined 
SF + RB score of ≥4, on 2 consecutive visit s (≥7 days apart, and with confirmat ion of negat ive 
C. difficile testing ) (first assessment can start as early as Week 8/Visi t 3),
AND
Confirmed by centrally read endoscopic subscore (ES) of 2 or 3 not sooner than 
Week 12/Visit 4. 
6. Study Population 
Besides a m aximum  1014-day window between the start of the Visit 5 (Week 12) visit of the 
induct ion study  AMAN and the start of Visit 1 (Week 0) of Study  AMBG, no screening period is 
allowed for Study  AMBG.  Data collected during the last visit of the induct ion study  AMAN, 
including laboratory  evaluati ons, endoscopy , and PRO data, will be used to review enro llment 
criteria for Study  AMBG.  A visit window ( 1014 days) is provided to allow laboratory results 
and central  reading of the endoscopy  to be available for the investigator to appropriately evaluate 
a pati ent and to en sure com pliance wi th enrollment criteria.  Patients who do not meet one or 
more hepatic or hematologic laboratory  enrollment criteria may  have these blood measures 
repeated one time at the invest igator’s discret ion prior to study  entry , as long as all test ing is 
completed wi thin 1014 calendar days fro m the start of the Visit 5 (Week 12) visit of Study  
AMAN.  
6.1.Inclusion Criteria
Patient Characteristics
[2.] Have completed Study  AMAN through the Week 12 visit (Visit 5) and have a 
Visit 5 MMS and have , received at least 1 study  drug administrati on wi thout 
early  terminat ion of study  drug ., and underwent a Visit 5 (Week 12) 
endoscopy .
6.2.Exclusion Criteria
General Exclusion Criteria
I6T-MC-AMBG(a) Clinical Protocol Page 150
LY3074828[17.]  Have an unstable or uncontrolled illness, including, but not limited to, 
cerebro -cardiovascular, respiratory , gastrointestinal (excluding UC), hepat ic, 
renal, endocrine, hematologic or neurological disorder
s or m alignancy that 
woul d potentially affect patient safet y within the study  or confound efficacy  
assessment.
6.4. Screen Failures
As described in Section 6, patients will be entered into Study  AMBG di rectly  from Study  
AMAN, wi th a maximum  1014 day window between start of the Visit 5 (Week 12) visit of the 
induct ion study  AMAN and start of Visit 1 (Week 0) of Study  AMBG.  
Patients who do not meet enrollment criteria may have one or more blood measures repeated one 
time, at the investigator’s discret ion, prior to study entry  as long as all testing is complete d 
within 10 14 calendar days from the start of the last induct ion visit.
7.1.Treatments A dministered
Study Drug Administration
Subcutaneous administration of mirikizumab or placebo will be given in 2 injections (maximum 
volume is 1mL per inject ion).  
Intravenous infusio n of mirikizumab or placebo will occur over at least 30 minutes.  
7.2. Method of Treatment A ssignment
To achieve between -group com parabilit y, pati ents will  be stratified to these arms based upon 
biologic-failed status (y es or no), basel inecorticosteroi d use (y es or no), regi on (North 
America/Europe/Other), and induct ion remissio n status (y es or no).  This stratificat ion will be 
controlled by IWRS.  
7.7. Concomitant Therapy
The recommended tapering schedule for oral corticosteroids (oth er than budesonide extended 
release tabl ets [budesoni de MMX] or beclo methasone dipropionate [gastro -resistant prolonged-
release tabl et]) is asfollows:
The recommended tapering schedule for patients receiving oral beclo methasone dipropionate 
(gastro -resistant prol onged -release tabl et) 5 m g/day  is to reduce tablets to 5 mg every  other day  
for 4 weeks, and then discont inue.
7.8.3.2. Management of Hypersensitivity, Infusion -Related Events, Infusion Site 
Reactions and Injection Site Reactions
After patient’s s tabilizat ion, an ant i-drug antibody  (ADA) andPK sample shoul d be 
collected; addit ional samples should be obtained 4 and 12 -16 weeks after the event.  
I6T-MC-AMBG(a) Clinical Protocol Page 151
LY3074828These samples will also be used for try ptase, com plement (C3/C4), and cy tokine panel 
assays.
Other Infusi on-Related Events and Infusion Site Reactions
If a patient experiences a reaction consist ing o f headache, rigors and/or temperature >38°C (in 
the absence of signs or symptoms o f a systemic hypersensit ivity react ion), or an infusio n site 
reacti on, including urticaria, pruri tus, or angi oedema l ocalized to the IV infusio n site (in the 
absence of other systemic hy persensi tivity signs or symptom s), during or up to 6 hours after an 
infusio n of study  drug, the fo llowing gui dance shoul d be f ollowed:
An ADA and PK s ample shoul d be collected at the time of the event (or as soon as 
possible after the event occurs), and 4 and 12- 16 weeks after the event. These samples 
will also be used for try ptase, com plement (C3/C4), and cy tokine panel assays.
8.1.1. Permanent Discontinuation from Study Treatment
Safety Criteria for Study Drug Discontinuation
The patient requires a colectomy , proctocol ectomy, or parti al colectomy during the study .
The patient experiences an AE or SAE that would preclude him/her fro m participat ing in 
the trial.The participant has an AE or SAE which, in the opinio n of the investigator or 
sponsor, would preclude the participant fro m continuing to receive study  drug.
Systemic hypersensit ivity event or anaphylaxis to mirikizumab study  drug .
9.1. Efficacy A ssessments
Table AMBG.9.1. Endpoint Definitions in Study AMBG
Endpoint Definition 
Corticosteroid -free 
remission without 
surgery at Week 40aClinical remission at Week 40, and
Symptomatic remission at Week 28, and 
No corticosteroid use for ≥12 weeks prior to Week 40
Histologic remission 
(mucosal healing)This definition will be specified in the histopathology charter SAP
Mucosal healingHistologic remission as described in the SAP and
endoscopic remission defined as ES = 0 or 1 (excluding friability)
Stable maintenance of 
symptomatic remissionbSymptomatic remission for at least 7 out of 9 visits from Week 4 to Week 36 
Symptomatic in remission at Week 40
Bowel movement urgency 
improvement The definition will be specified in the study SAP
Abbreviations:  SAP = statistical analysis plan;
Note: The term “mucosal healing” may be used in study reports to describe histologic remission or to describe a 
Mayo ES of 0 -1, and the definition will be clarified in the study report.
aAmo ng patients induced into clinical response with mirikizumab during the induction study and who were 
receiving corticosteroids at induction baseline.
bAmong patients in symptomatic remission at Week 12 of Study  AMAN .
I6T-MC-AMBG(a) Clinical Protocol Page 152
LY30748289.1.1.1. Primary Endpoint
The primary  endpo int is durable clinical remission at Week 40, among patients induced into 
clinical remissio nresponse with mirikizumab induction treatment (Study  AMAN).  
9.1.1.2. Mayo Score
SF Subscore :  The reference “normal” SF for that patient will be recorded electronically  
at the induct ion study  screening visit.  Normal SF for that pati ent is based on reported SF 
when the patient was in remissio n or reported SF before init ial onset of signs and 
sympto ms of UC.   Study  software will use the patient -reported daily SF and the reference 
norm al SF to autom atically calculate the Mayo SF subscore.  
Normal SF: The Normal SF is a patient -reported measure. This item reports the number 
of stools in a 24- hour pe riod when the pati ent was in remissio n or, if the patient has never 
achieved remissio n, the reported SF before init ial onset of signs and symptoms of UC.  
Remissio n refers to a period of time since being diagnosed with UC when the patient is 
not experienci ng any signs or symptoms relat ing to UC. This peri od of  time may  last a 
few weeks or a few months or may even last several years. The patient will record this 
electroni cally as source data in the tablet device at the screening study  visitof Study  
AMAN .
9.1.1.3. Endoscopy
However, colonoscopy  can be perform ed instead of flexible sigmo idoscopy  within this study  in 
order to surveille for dy splasia, screen for colorectal cancer (see Inclusio n Cri terion [5]), or for 
other clinically indicated reasons, in the judgement of the invest igator ., and after discussio n with 
the medical mo nitor as appropri ate.  
If a patient becomes pregnant during the study , no addi tional endoscopi es will be performed. 
If a patient undergoes early terminat ion soon after baseline, loss of response, or at the end of 
extended induct ion endoscopy , the need for ETV endoscopy  shoul d be discussed wit h the 
medical mo nitor.
9.1.2.1. Major Secondary Endpoints
Clinical remission at Week 40, among pat ients induced into clinical response remission
(that i s, dem onstrati ng clinical response or clinical remission) with mirikizumab at Week 
12 of induction study  (Study  AMAN)
Corti costeroi d-free remissio n without surgery  at Week 40, am ong patients induced into 
clinical response with mirikizumab at Week 12 of the induction study during the
induct ion study and who were receiving corticosteroids at induct ion baseline.  For Week 
40, thi s endpo int is defined as:
Clinical remissio n at Week 40, and
Symptom atic remissio n at Week 28, and 
I6T-MC-AMBG(a) Clinical Protocol Page 153
LY3074828No corticosteroi d use for ≥12 weeks prior to Week 40
Evaluate, in the subgroup of pat ients in who m biologic agents have failed or caused 
intolerance, clinical remission at Week 40 am ong pati ents induced into clinical response
with mirikizumab
Evaluate, in the subgroup of patients in who m biologic agents have failed or caused 
intolerance, endoscopic remissio n at Week 40 among patients induced into clinical 
response with mirikizumab
Histologic remissio n at Week 40, among pat ients induced into clinical response with 
mirikizumab at Week 12 of induct ion study
Stabl e maintenance of symptomat ic remissio n, among patients induced into clinical 
response with mirikizumab and were in symptomatic remissio n at Week 12 of induction 
study
Bowel  movement urgency  improvement a mong pati ents induced into clinical response
with mirikizumab at Week 12 of induction study

9.1.2.1.2. Patient Reported Outcome Instruments
The Urgency NRS (see Appendix 7 for descript ion) is a PRO instrum ent used to collect bowel 
movement urgency  data in the patient eDiary . The Urgency  NRS will  be used to determine the 
secondary  endpoint for bowel  movement urgency  improvement (see Tabl e AMBG.4.1 for 
definit ion).
9.1.2.2.1. Physician Reported Instrument
The Ul cerative Co litis Endoscopic Index of Severity  (UCEIS) i s a physician reported instrument 
for measuring the endoscopic disease act ivity of UC on flexible sigmo idoscopy  or col onoscopy , 
that includes 3 descriptors of vascular pattern, bleeding ,and erosi ons/ulcerat ions(Arai et al . 
2016; Ikey a et al . 201 6; Tontini et al. 2014) .  Only blinded central reading of endoscopies will be 
used to determine the UCEIS score for each endoscopy .
9.1.2.2.2. PRO Instruments Used to A ssess Secondary Endpoints
The fo llowing are addi tional PRO instrum ents collected using a patient el ectroni c diary (eDiary ).  
Abdo minal Pain Numeric Rat ing Scale (NRS)
Fatigue NRS (collected at site visits unt il Visit 10 when collected via electronic diary ) 
Urgency NRS
9.1.3.3. PRO Instruments Used to A ssess Exploratory Endpoints
The following exploratory  endpo ints will be assessed via the electronic diary tool and/or at 
applicable study  visits using the tabl et device:
Nocturnal  Stool  (collected at site visits until Visit 10 when collected via electronic diary)
Fatigue NRS 
Patient’s Global Rating of Severit y (PGRS) (collected via electronic diary )
I 6 T -M C -A M B G( a) Cli ni c al Pr ot o c ol P a g e 1 5 4 
L Y 3 0 7 4 8 2 8 Bri st ol  St o ol  Scale (c ollecte d at site visits u ntil Visit 1 0 w he n c o llecte d via electr o nic 
di ar y )
9. 4. 4. I m m u n o g e ni cit y A s s e s s m e nt s 
I n t he e ve nt of a dr u g h y perse nsi ti vi t y  e ve nt (i m me di ate o r n o ni m me diate), a d diti o nal sa m ples 
f o r A D A a n d P K will be c ollecte d as cl ose t o t he o nset of t he e ve nt as p ossi ble, a n d at 4 a n d 
1 2- 1 6 wee ks after t he e ve nt.  T hese sa m ples will als o be use d f or tr y ptase, c o m ple me nt ( C 3/ C 4), 
a n d c y t o ki ne pa nel  assa ys. 
9. 4 . 5. 2. T u b er c ul o si s 
Di a g n osis of L T BI d uri n g St u d y 
P ati e nts di a g n ose d wi t h  L T BI d uri n g t he st u d y  m ust ha ve st u d y  dr u g i nterr u pte d.  If treat me nt 
f o r L T BI is c o nsi dere d t o be a p pr o priate, t he patie nt m ust c o m plete at least 4 wee ks of 
a p pr o priate t hera p y  f or L T BI, base d o n nat i o nal or i nter nat i o nal g ui deli ne s (f or e xa m ple, t h e 
U nite d States Ce nters f or Disease C o ntr ol a n d Pre ve nt i o n g ui da nce ( C D C [ W W W]) f o r t he 
U nite d States ;or t he W orl d Heal t h  Or ga nizat i o n g ui da nce f or t he treat me nt of L T BI f or all 
c o u ntri es o utsi de of t he U nite d States ( W H Oa [ W W W]), a n d ha v e n o e vi de nce of he pat ot o xicit y 
( A L T a n d A S T le vels m ust re mai n ≤ 2 x U L N) u p o n retesti n g of ser u m A L T a n d A S T le vels after 
at l east 4 wee ks of L T BI treat me nt.  
9. 5. P h ar m a c o ki n eti c s 
 
 
 
 
 
 
1 0. 1. S a m pl e Si z e D et er mi n ati o n 
It i s e x pecte d t hat a p pr o xi matel y 4 5 9 4 7 0 of  t hese pati e nts will  e nter St u d y  A M B G as cli nical 
res p o n ders t o miri kiz u ma b a n d t he n will be ra n d o mize d 2: 1 t o 2 0 0 m g miri kiz u ma b S C 
(a p pr o xi matel y 3 1 3 0 6 patie nts) a n d place b o ( a p pr o xi mat el y 1 5 73pat ie nt s).  A m o n g t he 
a p pr o xi matel y e x pecte d 4 7 0 4 5 9 mir i kiz u ma b cli nical res p o n ders, a p pr o xi matel y 1 6 9 
1 8 0 mir i kiz u ma b cli nical re mitters will be ra n d o mize d t o 2 0 0 m g miri kiz u ma b S C 
(a p pr o xi matel y 1 1 3 1 2 0 patie nts) a n d place b o ( a p pr o xi matel y 5 6 6 0 pat ie nt s).  T hi s ass u mes t hat: 
T he i n d uct i o n st u d y  ( A M A N, w hic h has a mi xe d p o p ulat i o n wi t h  a p pr o xi matel y 6 0 5 0 % 
bi o l o gic -fa ile d pat ie nt s) is e x pecte d t o ha ve a n o verall cli nical re missi o n rate of 2 3 2 1. 6 % 
a n d res p o nse rate of 6 0 5 8. 6 % wit h miri kiz u ma b. 
T he pri mar y  e n d p oi nt, ma i nt e na nce of cli nical re missi o n at Wee k 4 0 , will be assesse d o n patie nts 
w h o ac hie ve d cli nical re missi o n  res p o nse t o mi ri ki z u m a b i n d uct i o n treat me nt.  Ass u mi n g C CI 
I6T-MC-AMBG(a) Clinical Protocol Page 155
LY3074828mirikizumab and placebo maintenance of clinical remissio n rates of 58.447% and 23.627%, 
respectively (biologic-failed pat ients:  44% and 13%; convent ional-failed patients:  70% and 
32%) , this study based on the 169 470 mirikizumab induction remitters responders is expected to 
have >9 50%power to demonstrate that mirikizumab is su perior to pl acebo by  using a chi -square 
test wi th a 2-sided 0.05 significance level of 0.05 .  This sample size also provides 80% power to 
evaluate clinical remissio n amo ng induct ion remitters in the subgroup of bio logic-failed patients.   
In addit ion, 459 m irikizumab induct ion clinical responders are the sam ple size is expected to 
provi de adequate power (>80%) to demonstrate th at mi rikizumab is superior to placebo for the 
major secondary  endpoints (clinical remissio n,endoscopi c remissio n, histol ogic remissi on,and
or corticosteroi d-free remissio n)at Week 40, among responders to mirikizumab induct ion 
treatm ent by  using a chi -square test wi th a 2-sided 0.05 significan cetlevelof 0.05 .
10.2. Populations for Analyses
Table AMBG.10.1 .Analysis Populations in Study AMBG
Population Description
Intent -to-treat (ITT) Population All enrolled randomized/assigned patients.  Patients will be analyzed according 
to the treatment to which they were assigned
Modified Intent -to-treat (mITT) 
PopulationAll enrolled patients w ho received at least 1 dose of study treatment, does not 
receive the correct treatment, or otherwise does not follow the protocol. All 
randomized/assigned patients who received at least 1 dose of study treatment, 
regardless of whether correct trea tment was administered or whether protocol 
was followed ,.Patients will be analyzed according to the treatment to which they 
were assigned
10.3.1. General Statistical Considerations
For assessments of the primary endpo int and other categorical efficacy endpo ints among induced 
remitters responders, the Cochran -Mantel -Haenszel ( CMH )chi-square test will be used to 
compare mirikizumab and placebo with stratificat ion factors:  (a) previous biologic therapy  
failure (y es or no), (b) baseline corticosteroi d use (yes or no), and(c) regi on (North 
America/Europe/Other) ,. and (d) induct ion remission status (y es/no). For other major secondary 
endpo ints and categorical efficacy endpo ints among indu ced responders, similar CHM chi -
square test will be used.  Another stratificat ion factor of induct ion remissio n status will be added 
in the analysis.   
Treatment comparisons of continuous efficacy and healt h outcome variables wit h a single 
post-baseline ti me po int will be made using analysis of covariance wit h:  (a) treatment group, 
(b)previous bio logic therapy  failure (y es or no), (c) corti costeroi d use (y es or no), (d) regi on 
(North America/Europe/Other), (e) baseline value in the model, and (f) induct ion remissio n 
status (if analysis is amo ng induced responders) .  Type III sum s of squares for LS means will be 
used for statistical co mpar ison between treatment groups.  The LS mean difference, standard 
error, p -value, and 95% CI, unless otherwise specified, will also be reported.  
I6T-MC-AMBG(a) Clinical Protocol Page 156
LY307482810.3.1.1. Missing Data Imputation:
Nonresponder imputation (NRI):  For analysis of categorical efficacy  and heal th 
outcom es variables, missing data will be imputed using an NRI method .  Patients will be 
considered a nonresponder for the NRI analysis if they do not meet the categorical 
response criteria, have missing clinical response data at a time point of interest , or take 
rescue dosi ng wit h mirikizumab prior to the time point of int erest . In addit ion, the 
patients who requi re UC surgery , take rescue dosing with mirikizumab, increase UC 
medicat ion dose fro m baseline , or ini tiatenew UC medicat ions will be considered as 
nonresponders .  
10.3.2.3. Concomitant Therapy
Concomitant therap y will be collected at each visit , and the reported term will be classified by  
the World Healt h Organizat ion drug dict ionary.  Medi cations started pri or to randomizat ion and 
medicat ions started on study  after randomizat ionPrevious conco mitant therapy  (rep orted before 
rando mizat ion) and current concomitant therapy  (reported after randomizat ion)will be presented 
separately  in frequency tables by  drug name and by  cohort f or all  enrolled pati ents.  
10.3.3.1. Primary Analyses
The primary  endpoint is the propo rtion of  patients wi th durable clinical remissio n at Week 40 
(Week 52 of continuous therapy ) among the patients who are remitters responders to 300 m g 
mirikizumab IV at 12 weeks of induct ion dosing.
Rates of clinical remissio n at Week 40 among induction responders remitters will be analyzed.  
Patients who do not achieve clinical remission or who do not reach the Week 40 assessment will 
be considered to be nonremitters.  In addit ion,patients who undergo UC surgery ,take rescue 
dosing wit h mirikizumab , increase their concomitant UC medication, or init iate new UC 
medicat ionswill be considered nonremitters.
10.3.7.1. Subgroup A nalyses 
The m ajor subgroup analysis is for the primary  and maj or secondary  endpoints for biologic-
failed patients described in Sect ion 9.1.2.1.  Mult iplicity adjust ment described in Sect ion 
10.3.1.2. will be used to control ty pe I error.
Addit ional sSubgroup analyses will be conducted for the primary  endpoint and selected major 
secondary  endpoints.  
11. References
Arai M, Naganuma M, Sugimoto S, Kiy ohara H, Ono K, Mori  K, Sai gusa K, Nanki  K, 
Mutaguchi M, Mizuno S, Bessho R, Nakazato Y, Hosoe N, Matsuoka K, Inoue N, Ogata H, 
Iwao Y, Kanai T. The Ulcerative Co litis Endoscopic Index o f Severit y is useful to predict 
medium -to long-term prognosis in ulcerative co litis pat ients with clinical remissio n. J Crohns 
Colitis. 2016;10:1303 -1309.
I6T-MC-AMBG(a) Clinical Protocol Page 157
LY3074828Ikeya K, Hanai H, Sugimoto K, Osawa S, Kawasaki S, Iida T, Maruy ama Y, Watanabe F. The 
ulcerat ive co litis endoscopic index of severit y more accurately re ﬂects clinica l outcom es and 
long-term prognosi s than the May o endoscopi c score. J Crohns Colitis . 2016;10:286- 295.
Tontini GE, Bi sschops R, Neumann H. Endoscopic scoring systems for in ﬂammatory  bowel  
disease: Pros and cons. Expert Rev Gastroenterol Hepatol. 2014;8:543 -554. 
Appendix 1. Abbreviations and Definitions
UCEIS   Ulcerative Colitis Endoscopic Index of Severity
Appendix 2. Clinical Laboratory Tests
Other tests a
Tryptaseh
Complement (C3/C4)h
Cytokine panelh
Abbreviations:  ADA = anti -drug antibody
hPerformed only in the event of systemic allergic/hypersensitivity events, along with ADA and PK.
Appendix 3.1.7. Final Report Signature
Theinvest igator with the most enrolled pat ients will serve as the CSR coordinat inginvestigator
will be selected by  thestudy  team .  If this invest igator is unable to fulfill this funct ion, another 
investigator will be chosen by  Lilly to serve as the CSR coordinat ing investigator.
Appendix 6. Mayo Scoring System for the Assessment of Ulcerative Colitis A ctivity
Stool frequency reports the number of stools in a 24 -hour period, relative to the normal number of stools for that 
patient. The reference “normal” stool frequency for that patient will be recorded electronically at the screening visit
in Study AMAN .  The Normal SF refers to when the patient was in remission or, if the patient has never achieved 
remission, the reported SF before initial onset of signs and symptoms of ulcerative colitis .  Remission refers to a 
period of time since being diagnosed with ulcera tive colitis when the patient is not experiencing any signs or 
symptoms relating to ulcerative colitis.  This period of time may last a few weeks or a few months or may even last 
several years. The patient will record this electronically as source data in the tablet device at the screening study 
visit in Study AMAN .
Appendix 7. Patient -Reported Outcome Instruments
Abdominal Pain NRS: A single item that measures the “worst abdo minal pain in the past 24 
hours” using an 11 -point NRS ranging from 0 (no pain ) to 10 ( pain as bad as can imagine worst 
possible pain ).  
Fatigue NRS :  The Fatigue NRS is a single item that measures the “worst fat igue (weariness, 
tiredness) in the past 24 hours” using an 11- point NRS ranging fro m 0 (no fat igue) to 10 (fatigue 
as bad as youcan imagine).
I6T-MC-AMBG(a) Clinical Protocol Page 158
LY3074828Appendix 8. Prohibited Medications
Drug Class Comments
Rectally  administered investigational preparations for UC such 
as arsenic preparationsProhibited throughout treatment period
Intravenous corticosteroids for UC A course of IV corticosteroids for UC is 
prohibited
Systemic corticosteroids for non -UC indications (oral or IV) Patients requiring systemic 
corticosteroids for non -UC conditions 
are excluded.  Exceptions
(except include corticosteroids to treat 
adrenal i nsufficiency , premedication for 
IP infusion, or l are excluded.  L ocally  
administered corticosteroids (e.g., 
inhaled, intranasal, intra -articular, 
topical) (see Appendix 10) .are allowed.
Appendix 9. Permitted Medications with Dose Stabilization
Drug Class Comments
Oral 5-ASAs (for example, mesalamine, 
balsalazide, olsalazide) and sulfasalazine 
for UC (for example, mesalamine, 
balsalazide, olsalazide)May continue during study with stable doses encouraged
Oral corticosteroids for UC (prednisone 
≤20mg/day or equivalent , orbudesonide 
MMX 9 mg/day , or beclomethasone 
dipropionate [gastro -resistant prolonged -
release tablet] 5 mg/day )Responder patients w ho are receiving oral corticosteroids at the start of 
Study AMBG will start corticosteroid taper at the beg inning of the 
study.  Clinical nonresponders who undergo extended IV induction with 
mirikizumab will begin corticosteroid tapering if symptomatic response 
or symptomatic improvement based on investigator discretion is 
achieved at any time after starting ex tended induction (see 
Corticosteroid Taper in Section 7.7).
Corticosteroids for non -UC indications: 
corticosteroids to treat adrenal 
insufficiency, as premedication for IP 
infusion, or locally administered 
corticosteroids (e.g. inhaled, intranasal, 
intra-articular, topical).May continue corticosteroids to treat adrenal insufficiency or locally 
administered corticosteroids during study with stable dose encouraged.  
Single doses of oral or IV corticosteroids as premedication to IP 
administration are allowed in patients with prior IP or other previous 
biologic injection reactions.
Abbreviations:  IP = investigational product; UC = ulcerative colitis
Leo Document ID = 8776699c-01e8-4a66-b52c-c63190ba695e
Approver: 
Approval Date & Time: 12-Sep-2019 20:08:01 GMT
Signature meaning: Approved
Approver: 
Approval Date & Time: 12-Sep-2019 20:48:02 GMT
Signature meaning: Approved
PPD
PPD